{"68ed7fcee486b3e869c0088252cd8956d5872efa": [["80,397-408.", [["80,397-408", "CHEMICAL", 0, 10]]], ["Interaction of a single dose (36 mg/kg body wt) of the organochlorine pesticide dieldrin with mouse peritoneal macrophages was examined in C57Bl/6, (C57Bl/6 x A/J)F,, and A/J strains of different genetic resistance to mouse hepatitis virus 3 (MHV3) infection.", [["peritoneal macrophages", "ANATOMY", 100, 122], ["organochlorine", "CHEMICAL", 55, 69], ["dieldrin", "CHEMICAL", 80, 88], ["mouse hepatitis virus", "DISEASE", 218, 239], ["infection", "DISEASE", 249, 258], ["organochlorine", "CHEMICAL", 55, 69], ["dieldrin", "CHEMICAL", 80, 88], ["body", "ORGANISM_SUBDIVISION", 39, 43], ["organochlorine", "SIMPLE_CHEMICAL", 55, 69], ["dieldrin", "SIMPLE_CHEMICAL", 80, 88], ["mouse", "ORGANISM", 94, 99], ["peritoneal macrophages", "CELL", 100, 122], ["C57Bl/6", "ORGANISM", 139, 146], ["C57Bl/6 x A/J)F", "GENE_OR_GENE_PRODUCT", 149, 164], ["A/J strains", "ORGANISM", 171, 182], ["mouse hepatitis virus 3", "ORGANISM", 218, 241], ["MHV3", "ORGANISM", 243, 247], ["mouse peritoneal macrophages", "CELL_TYPE", 94, 122], ["mouse", "SPECIES", 94, 99], ["mouse", "SPECIES", 218, 223], ["hepatitis virus", "SPECIES", 224, 239], ["mouse", "SPECIES", 94, 99], ["mouse hepatitis virus", "SPECIES", 218, 239], ["MHV3", "SPECIES", 243, 247], ["the organochlorine pesticide dieldrin", "TREATMENT", 51, 88], ["mouse peritoneal macrophages", "TREATMENT", 94, 122], ["A/J strains", "TREATMENT", 171, 182], ["mouse hepatitis virus", "PROBLEM", 218, 239], ["infection", "PROBLEM", 249, 258], ["peritoneal", "ANATOMY", 100, 110], ["macrophages", "OBSERVATION", 111, 122], ["genetic resistance", "OBSERVATION", 196, 214], ["hepatitis virus", "OBSERVATION", 224, 239], ["infection", "OBSERVATION", 249, 258]]], ["In vivo studies showed increased susceptibility to MHV3 acute disease of C57Bl/6 and (C57B1/6 X A/J)F, animals challenged with the pesticide.", [["C57Bl/6", "ORGANISM", 73, 80], ["MHV3", "SPECIES", 51, 55], ["vivo studies", "TEST", 3, 15], ["increased susceptibility to MHV3 acute disease", "PROBLEM", 23, 69], ["increased", "OBSERVATION_MODIFIER", 23, 32], ["acute", "OBSERVATION_MODIFIER", 56, 61], ["disease", "OBSERVATION", 62, 69]]], ["Significant decrease of mean time of death in dieldrin-exposed, MHV3-infected susceptible C57Bl/6 mice was observed similarly upon po or ip administration of a single, sublethal dose of dieldrin.", [["death", "DISEASE", 37, 42], ["dieldrin", "CHEMICAL", 46, 54], ["dieldrin", "CHEMICAL", 186, 194], ["dieldrin", "CHEMICAL", 46, 54], ["dieldrin", "CHEMICAL", 186, 194], ["dieldrin", "SIMPLE_CHEMICAL", 46, 54], ["MHV3", "ORGANISM", 64, 68], ["C57Bl/6 mice", "ORGANISM", 90, 102], ["ip", "SIMPLE_CHEMICAL", 137, 139], ["dieldrin", "SIMPLE_CHEMICAL", 186, 194], ["mice", "SPECIES", 98, 102], ["mice", "SPECIES", 98, 102], ["death", "PROBLEM", 37, 42], ["dieldrin", "TREATMENT", 46, 54], ["a single, sublethal dose of dieldrin", "TREATMENT", 158, 194], ["decrease", "OBSERVATION_MODIFIER", 12, 20], ["mean time", "OBSERVATION_MODIFIER", 24, 33]]], ["In addition, decrease of humoral response to the virus was quantified by determination of anti-MHV3 IgG antibodies in spleen cell supematant fractions and in blood sera of dieldrin-exposed C57Bl/6 mice.", [["spleen cell supematant fractions", "ANATOMY", 118, 150], ["blood sera", "ANATOMY", 158, 168], ["dieldrin", "CHEMICAL", 172, 180], ["dieldrin", "CHEMICAL", 172, 180], ["spleen cell supematant fractions", "ORGANISM_SUBSTANCE", 118, 150], ["blood sera", "ORGANISM_SUBSTANCE", 158, 168], ["dieldrin", "SIMPLE_CHEMICAL", 172, 180], ["C57Bl/6 mice", "ORGANISM", 189, 201], ["anti-MHV3 IgG antibodies", "PROTEIN", 90, 114], ["mice", "SPECIES", 197, 201], ["anti-MHV3", "SPECIES", 90, 99], ["mice", "SPECIES", 197, 201], ["humoral response", "PROBLEM", 25, 41], ["the virus", "PROBLEM", 45, 54], ["anti-MHV3 IgG antibodies", "TEST", 90, 114], ["blood sera", "TEST", 158, 168], ["dieldrin", "TREATMENT", 172, 180], ["decrease", "OBSERVATION_MODIFIER", 13, 21], ["humoral response", "OBSERVATION", 25, 41], ["spleen", "ANATOMY", 118, 124], ["cell", "OBSERVATION", 125, 129], ["supematant fractions", "OBSERVATION", 130, 150]]], ["A single dose of dieldrin did not alter the in vivo resistance of A/J animals to acute MHV3 disease.", [["dieldrin", "CHEMICAL", 17, 25], ["acute MHV3 disease", "DISEASE", 81, 99], ["dieldrin", "CHEMICAL", 17, 25], ["dieldrin", "SIMPLE_CHEMICAL", 17, 25], ["A/J animals", "ORGANISM", 66, 77], ["dieldrin", "TREATMENT", 17, 25], ["A/J animals", "TREATMENT", 66, 77], ["acute MHV3 disease", "PROBLEM", 81, 99], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["MHV3 disease", "OBSERVATION", 87, 99]]], ["The resistant A/J mice, however, showed increased mortality upon two subsequent exposures to dieldtin followed by infection with high lethal doses of MHV3.", [["dieldtin", "CHEMICAL", 93, 101], ["infection", "DISEASE", 114, 123], ["MHV3", "CHEMICAL", 150, 154], ["dieldtin", "CHEMICAL", 93, 101], ["A/J mice", "ORGANISM", 14, 22], ["dieldtin", "SIMPLE_CHEMICAL", 93, 101], ["mice", "SPECIES", 18, 22], ["A/J mice", "SPECIES", 14, 22], ["The resistant A/J mice", "TREATMENT", 0, 22], ["increased mortality", "PROBLEM", 40, 59], ["dieldtin", "TREATMENT", 93, 101], ["infection", "PROBLEM", 114, 123], ["high lethal doses of MHV3", "TREATMENT", 129, 154], ["resistant", "OBSERVATION_MODIFIER", 4, 13], ["increased", "OBSERVATION_MODIFIER", 40, 49], ["mortality", "OBSERVATION", 50, 59], ["infection", "OBSERVATION", 114, 123]]], ["Phagocytic activity, cell adherence capacity, and attachment and uptake of 3H-radiolabeled MHV3 by C57Bl/6 peritoneal macrophages were determined by in vitro studies.", [["cell", "ANATOMY", 21, 25], ["C57Bl/6 peritoneal macrophages", "ANATOMY", 99, 129], ["3H", "CHEMICAL", 75, 77], ["3H", "CHEMICAL", 75, 77], ["cell", "CELL", 21, 25], ["3H", "SIMPLE_CHEMICAL", 75, 77], ["MHV3", "SIMPLE_CHEMICAL", 91, 95], ["C57Bl/6 peritoneal macrophages", "CELL", 99, 129], ["C57Bl/6 peritoneal macrophages", "CELL_LINE", 99, 129], ["Phagocytic activity", "PROBLEM", 0, 19], ["cell adherence capacity", "PROBLEM", 21, 44], ["3H", "TEST", 75, 77], ["radiolabeled MHV3", "TEST", 78, 95], ["C57Bl/6 peritoneal macrophages", "PROBLEM", 99, 129], ["cell adherence", "OBSERVATION", 21, 35], ["peritoneal", "ANATOMY", 107, 117], ["macrophages", "OBSERVATION", 118, 129]]], ["These affector activities of peritoneal macrophages were slightly decreased or unchanged in cells originating from animals exposed to the pesticide.", [["peritoneal macrophages", "ANATOMY", 29, 51], ["cells", "ANATOMY", 92, 97], ["peritoneal macrophages", "CELL", 29, 51], ["cells", "CELL", 92, 97], ["peritoneal macrophages", "CELL_TYPE", 29, 51], ["peritoneal macrophages", "PROBLEM", 29, 51], ["peritoneal", "ANATOMY", 29, 39], ["macrophages", "OBSERVATION", 40, 51], ["slightly", "OBSERVATION_MODIFIER", 57, 65], ["decreased", "OBSERVATION_MODIFIER", 66, 75], ["unchanged", "OBSERVATION_MODIFIER", 79, 88]]], ["However, the intrinsic activity of MHV3 restriction appeared to be affected in macrophages derived from dieldrin-treated animals: (i) peritoneal C57Bl/6 macrophages collected from the early phase of acute MHV3 disease contained increased MHV3 antigen and (ii) increased cytolysis was observed after in vitro MHV3 infection of macrophages originating from dieldrin-exposed C57Bl/6 mice. o 1985 Academic PRSS, IX.", [["macrophages", "ANATOMY", 79, 90], ["peritoneal C57Bl/6 macrophages", "ANATOMY", 134, 164], ["macrophages", "ANATOMY", 326, 337], ["dieldrin", "CHEMICAL", 104, 112], ["infection", "DISEASE", 313, 322], ["dieldrin", "CHEMICAL", 355, 363], ["dieldrin", "CHEMICAL", 104, 112], ["dieldrin", "CHEMICAL", 355, 363], ["MHV3", "GENE_OR_GENE_PRODUCT", 35, 39], ["macrophages", "CELL", 79, 90], ["dieldrin", "SIMPLE_CHEMICAL", 104, 112], ["peritoneal C57Bl/6 macrophages", "CELL", 134, 164], ["MHV3 antigen", "GENE_OR_GENE_PRODUCT", 238, 250], ["MHV3", "ORGANISM", 308, 312], ["macrophages", "CELL", 326, 337], ["dieldrin", "SIMPLE_CHEMICAL", 355, 363], ["C57Bl/6 mice", "ORGANISM", 372, 384], ["MHV3", "PROTEIN", 35, 39], ["macrophages", "CELL_TYPE", 79, 90], ["peritoneal C57Bl/6 macrophages", "CELL_TYPE", 134, 164], ["MHV3 antigen", "PROTEIN", 238, 250], ["macrophages", "CELL_TYPE", 326, 337], ["IX", "PROTEIN", 408, 410], ["mice", "SPECIES", 380, 384], ["MHV3", "SPECIES", 308, 312], ["mice", "SPECIES", 380, 384], ["MHV3 restriction", "TREATMENT", 35, 51], ["peritoneal C57Bl/6 macrophages", "TEST", 134, 164], ["acute MHV3 disease", "PROBLEM", 199, 217], ["increased MHV3 antigen", "PROBLEM", 228, 250], ["increased cytolysis", "PROBLEM", 260, 279], ["macrophages", "PROBLEM", 326, 337], ["dieldrin", "TREATMENT", 355, 363], ["peritoneal", "ANATOMY", 134, 144], ["early phase", "OBSERVATION_MODIFIER", 184, 195], ["acute", "OBSERVATION_MODIFIER", 199, 204], ["MHV3 disease", "OBSERVATION", 205, 217], ["increased", "OBSERVATION_MODIFIER", 228, 237]]], ["Exposure to certain environmental pollutants or drugs may perturb immune responsiveness and alter susceptibility of animals and humans to infectious agents, including viral infections (Cracker et al., 1976; Bradley and Morahan, 1982; Kern, 1982; Howett et al., 1979; Casto et al., 1974) .", [["viral infections", "DISEASE", 167, 183], ["humans", "ORGANISM", 128, 134], ["humans", "SPECIES", 128, 134], ["humans", "SPECIES", 128, 134], ["drugs", "TREATMENT", 48, 53], ["perturb immune responsiveness", "PROBLEM", 58, 87], ["infectious agents", "TREATMENT", 138, 155], ["viral infections", "PROBLEM", 167, 183]]], ["The interaction of xenobiotics with host antiviral defense mech-' Supported by Natural Sciences and Engineering Research Council of Canada.", [["xenobiotics", "CHEMICAL", 19, 30], ["xenobiotics", "TREATMENT", 19, 30], ["host antiviral defense mech", "TREATMENT", 36, 63]]]], "PMC7004370": [["IntroductionViruses cause respiratory tract infections (RTIs), which if severe, can lead to a visit to the Emergency Department (ED) and hospitalization.", [["respiratory tract", "ANATOMY", 26, 43], ["respiratory tract infections", "DISEASE", 26, 54], ["RTIs", "DISEASE", 56, 60], ["respiratory tract", "ORGANISM_SUBDIVISION", 26, 43], ["IntroductionViruses", "TREATMENT", 0, 19], ["respiratory tract infections", "PROBLEM", 26, 54], ["respiratory tract", "ANATOMY", 26, 43]]], ["This places a large burden on healthcare services in primary and secondary care but also puts patients with chronic lung diseases such as chronic obstructive pulmonary disease (COPD)[1] and asthma at risk of an exacerbation[2, 3].", [["lung", "ANATOMY", 116, 120], ["pulmonary", "ANATOMY", 158, 167], ["chronic lung diseases", "DISEASE", 108, 129], ["chronic obstructive pulmonary disease", "DISEASE", 138, 175], ["COPD", "DISEASE", 177, 181], ["asthma", "DISEASE", 190, 196], ["patients", "ORGANISM", 94, 102], ["lung", "ORGAN", 116, 120], ["pulmonary", "ORGAN", 158, 167], ["patients", "SPECIES", 94, 102], ["chronic lung diseases", "PROBLEM", 108, 129], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 138, 182], ["asthma", "PROBLEM", 190, 196], ["an exacerbation", "PROBLEM", 208, 223], ["large", "OBSERVATION_MODIFIER", 14, 19], ["burden", "OBSERVATION_MODIFIER", 20, 26], ["lung", "ANATOMY", 116, 120], ["diseases", "OBSERVATION", 121, 129], ["chronic", "OBSERVATION_MODIFIER", 138, 145], ["obstructive", "OBSERVATION_MODIFIER", 146, 157], ["pulmonary", "ANATOMY", 158, 167], ["disease", "OBSERVATION", 168, 175], ["COPD", "OBSERVATION", 177, 181], ["asthma", "OBSERVATION", 190, 196], ["exacerbation", "OBSERVATION", 211, 223]]], ["During epidemics, viruses can also lead to death as has been demonstrated with influenza, respiratory syncytial virus (RSV) [4, 5], particularly in the young and elderly[6\u20138].", [["death", "DISEASE", 43, 48], ["influenza", "DISEASE", 79, 88], ["respiratory syncytial virus", "DISEASE", 90, 117], ["RSV", "DISEASE", 119, 122], ["respiratory syncytial virus", "ORGANISM", 90, 117], ["RSV", "ORGANISM", 119, 122], ["respiratory syncytial virus", "SPECIES", 90, 117], ["respiratory syncytial virus", "SPECIES", 90, 117], ["RSV", "SPECIES", 119, 122], ["epidemics", "PROBLEM", 7, 16], ["viruses", "PROBLEM", 18, 25], ["death", "PROBLEM", 43, 48], ["influenza", "PROBLEM", 79, 88], ["respiratory syncytial virus", "PROBLEM", 90, 117], ["viruses", "OBSERVATION", 18, 25], ["syncytial virus", "OBSERVATION", 102, 117]]], ["Therefore, identifying viruses and monitoring the severity of their effects will always remain a major scientific and clinical endeavor.IntroductionThe Canadian Respiratory Virus Detection Surveillance program consists of a network of laboratories, hospitals, physician offices and provincial and territorial ministries of health.", [["Respiratory Virus", "DISEASE", 161, 178], ["viruses", "PROBLEM", 23, 30], ["viruses", "OBSERVATION", 23, 30], ["territorial", "OBSERVATION_MODIFIER", 297, 308]]], ["The aim of the program is to detect and respond to outbreaks, use data on viruses to improve and inform health programs and policies, and to ensure information gathered in Canada supports international monitoring and is ready in case of any global threats and outbreaks.", [["viruses", "TREATMENT", 74, 81], ["international monitoring", "TEST", 188, 212]]], ["The surveillance system was setup in 2003 using multiplex polymerase chain reaction (PCR) to detect 5 viruses: Influenza A and B, RSV, parainfluenza and adenovirus and 3 viruses were added in 2010: human metapneumovirus (hMPV), human rhinovirus (hRV) and coronavirus.", [["Influenza A and B", "DISEASE", 111, 128], ["parainfluenza and adenovirus and 3 viruses", "DISEASE", 135, 177], ["human metapneumovirus (hMPV), human rhinovirus (hRV) and coronavirus", "DISEASE", 198, 266], ["Influenza A", "ORGANISM", 111, 122], ["B", "GENE_OR_GENE_PRODUCT", 127, 128], ["RSV", "ORGANISM", 130, 133], ["parainfluenza", "ORGANISM", 135, 148], ["adenovirus", "ORGANISM", 153, 163], ["human", "ORGANISM", 198, 203], ["metapneumovirus", "ORGANISM", 204, 219], ["hMPV", "ORGANISM", 221, 225], ["human", "ORGANISM", 228, 233], ["rhinovirus", "ORGANISM", 234, 244], ["hRV", "CANCER", 246, 249], ["coronavirus", "ORGANISM", 255, 266], ["Influenza", "SPECIES", 111, 120], ["RSV", "SPECIES", 130, 133], ["parainfluenza", "SPECIES", 135, 148], ["human", "SPECIES", 198, 203], ["metapneumovirus", "SPECIES", 204, 219], ["hMPV", "SPECIES", 221, 225], ["human", "SPECIES", 228, 233], ["rhinovirus", "SPECIES", 234, 244], ["coronavirus", "SPECIES", 255, 266], ["Influenza A", "SPECIES", 111, 122], ["RSV", "SPECIES", 130, 133], ["adenovirus", "SPECIES", 153, 163], ["human metapneumovirus", "SPECIES", 198, 219], ["hMPV", "SPECIES", 221, 225], ["human rhinovirus", "SPECIES", 228, 244], ["hRV", "SPECIES", 246, 249], ["The surveillance system", "TEST", 0, 23], ["multiplex polymerase chain reaction", "PROBLEM", 48, 83], ["PCR", "TEST", 85, 88], ["5 viruses", "PROBLEM", 100, 109], ["Influenza", "PROBLEM", 111, 120], ["RSV", "PROBLEM", 130, 133], ["parainfluenza", "PROBLEM", 135, 148], ["adenovirus", "PROBLEM", 153, 163], ["3 viruses", "PROBLEM", 168, 177], ["human metapneumovirus", "PROBLEM", 198, 219], ["hMPV", "PROBLEM", 221, 225], ["human rhinovirus", "PROBLEM", 228, 244], ["coronavirus", "PROBLEM", 255, 266]]], ["Data is available to the public on a weekly basis up until the present time.IntroductionThe Canadian surveillance program thus provides a unique opportunity to investigate the prevalence of multiple viruses in a real-world setting where the test is routinely performed as part of free universal healthcare.", [["multiple viruses", "PROBLEM", 190, 206], ["the test", "TEST", 237, 245], ["multiple", "OBSERVATION_MODIFIER", 190, 198], ["viruses", "OBSERVATION", 199, 206]]], ["Furthermore, the Canadian Institute of Health Information also report the daily numbers of visits to the emergency department (ED) and number hospitalized for asthma, chronic obstructive pulmonary disease (COPD) and respiratory tract infections (RTI).IntroductionTherefore, the objective of this study was to retrospectively investigate the prevalence and contribution of respiratory viruses on daily ED visits and hospitalizations with RTIs, COPD and asthma in an unselected population in Ontario, Canada over a period of 11 years.", [["pulmonary", "ANATOMY", 187, 196], ["respiratory tract", "ANATOMY", 216, 233], ["asthma", "DISEASE", 159, 165], ["chronic obstructive pulmonary disease", "DISEASE", 167, 204], ["COPD", "DISEASE", 206, 210], ["respiratory tract infections", "DISEASE", 216, 244], ["RTI", "DISEASE", 246, 249], ["respiratory viruses", "DISEASE", 372, 391], ["RTIs", "DISEASE", 437, 441], ["COPD", "DISEASE", 443, 447], ["asthma", "DISEASE", 452, 458], ["pulmonary", "ORGAN", 187, 196], ["tract", "ORGANISM_SUBDIVISION", 228, 233], ["asthma", "PROBLEM", 159, 165], ["chronic obstructive pulmonary disease", "PROBLEM", 167, 204], ["COPD)", "PROBLEM", 206, 211], ["respiratory tract infections", "PROBLEM", 216, 244], ["this study", "TEST", 291, 301], ["respiratory viruses", "PROBLEM", 372, 391], ["RTIs", "PROBLEM", 437, 441], ["COPD", "PROBLEM", 443, 447], ["asthma", "PROBLEM", 452, 458], ["chronic", "OBSERVATION_MODIFIER", 167, 174], ["obstructive", "OBSERVATION_MODIFIER", 175, 186], ["pulmonary", "ANATOMY", 187, 196], ["disease", "OBSERVATION", 197, 204], ["COPD", "OBSERVATION", 206, 210], ["respiratory tract", "ANATOMY", 216, 233], ["infections", "OBSERVATION", 234, 244], ["respiratory viruses", "OBSERVATION", 372, 391], ["COPD", "OBSERVATION", 443, 447], ["asthma", "OBSERVATION", 452, 458]]], ["The yearly and seasonal trend was also explored over the study period.Data acquisition ::: Materials and methods\u201cThe Respiratory Virus Detection Surveillance System\u201d collects and reports to the Centre for Immunization and Respiratory Infectious Diseases (CIRID) the number of daily tests performed and the number of tests positive for respiratory viruses using multi-plex PCR from laboratories across Canada.", [["Respiratory Virus", "DISEASE", 117, 134], ["Respiratory Infectious Diseases", "DISEASE", 222, 253], ["respiratory viruses", "DISEASE", 335, 354], ["Immunization", "TREATMENT", 205, 217], ["daily tests", "TEST", 276, 287], ["tests", "TEST", 316, 321], ["respiratory viruses", "PROBLEM", 335, 354], ["multi-plex PCR", "TEST", 361, 375], ["Respiratory Virus", "OBSERVATION", 117, 134], ["Respiratory", "ANATOMY", 222, 233], ["Infectious", "OBSERVATION", 234, 244], ["respiratory viruses", "OBSERVATION", 335, 354]]], ["The data is reported on a weekly basis for respiratory viruses and were obtained for the province of Ontario.", [["respiratory viruses", "PROBLEM", 43, 62]]], ["Data were available for Influenza A and B, RSV, parainfluenza and adenovirus for the full study period, hMPV, hRV and coronavirus were added to the testing program in 2010.Data acquisition ::: Materials and methodsDaily ED visits and hospitalizations for asthma (ICD-10 J45), COPD (J40-44, J47) and RTI (J00-J06, J09-J18, J20-22) as a primary diagnosis were obtained from the Canadian Institute for Health Information for the calendar years 2003 to 2013 by date (11 years).", [["Influenza A and B", "DISEASE", 24, 41], ["parainfluenza", "DISEASE", 48, 61], ["asthma", "DISEASE", 255, 261], ["COPD", "DISEASE", 276, 280], ["RTI", "DISEASE", 299, 302], ["Influenza A", "ORGANISM", 24, 35], ["B", "GENE_OR_GENE_PRODUCT", 40, 41], ["RSV", "ORGANISM", 43, 46], ["parainfluenza", "ORGANISM", 48, 61], ["adenovirus", "ORGANISM", 66, 76], ["hMPV", "ORGANISM", 104, 108], ["coronavirus", "ORGANISM", 118, 129], ["parainfluenza", "SPECIES", 48, 61], ["Influenza A", "SPECIES", 24, 35], ["RSV", "SPECIES", 43, 46], ["adenovirus", "SPECIES", 66, 76], ["hMPV", "SPECIES", 104, 108], ["hRV", "SPECIES", 110, 113], ["Influenza", "PROBLEM", 24, 33], ["RSV", "PROBLEM", 43, 46], ["parainfluenza", "PROBLEM", 48, 61], ["adenovirus", "PROBLEM", 66, 76], ["the full study", "TEST", 81, 95], ["hMPV", "PROBLEM", 104, 108], ["hRV", "TEST", 110, 113], ["coronavirus", "PROBLEM", 118, 129], ["asthma", "PROBLEM", 255, 261], ["ICD", "TEST", 263, 266], ["COPD", "PROBLEM", 276, 280], ["J40", "TEST", 282, 285], ["RTI", "TEST", 299, 302], ["J00", "TEST", 304, 307], ["J09", "TEST", 313, 316], ["COPD", "OBSERVATION", 276, 280], ["RTI", "ANATOMY", 299, 302]]], ["Population data were obtained from Statistics Canada.", [["Population data", "TEST", 0, 15]]], ["Data for asthma prevalence in Ontario were obtained from Statistics Canada and The Ontario Asthma Surveillance Information System (OASIS).Virus detection ::: Materials and methodsNasopharyngeal swabs were performed on individuals presenting in the community to a health care practitioner in Ontario.", [["Nasopharyngeal swabs", "ANATOMY", 179, 199], ["asthma", "DISEASE", 9, 15], ["Asthma", "DISEASE", 91, 97], ["Virus", "ORGANISM", 138, 143], ["Nasopharyngeal swabs", "CANCER", 179, 199], ["asthma", "PROBLEM", 9, 15], ["methodsNasopharyngeal swabs", "TEST", 172, 199], ["Nasopharyngeal", "ANATOMY", 179, 193]]], ["Multiplex PCR was performed for the viruses described above.", [["Multiplex PCR", "TEST", 0, 13], ["the viruses", "PROBLEM", 32, 43], ["viruses", "OBSERVATION", 36, 43]]], ["The number of positive tests to each virus was expressed as a percentage of the total number of tests performed and the value obtained for each week was assumed to apply for each day of the previous week.Statistical analysis ::: Materials and methodsThe population of Ontario increased from 12,251,405 in 2003 to 13,606,541 in 2013.", [["positive tests to each virus", "PROBLEM", 14, 42], ["tests", "TEST", 96, 101], ["positive", "OBSERVATION", 14, 22], ["population", "OBSERVATION_MODIFIER", 254, 264], ["Ontario", "OBSERVATION_MODIFIER", 268, 275], ["increased", "OBSERVATION_MODIFIER", 276, 285]]], ["The daily rates for ED visits and hospitalizations with RTI, COPD and Asthma were transformed using the natural log (e) of the rates to achieve normal distribution and subsequently used in all analyses.", [["RTI", "DISEASE", 56, 59], ["COPD", "DISEASE", 61, 65], ["Asthma", "DISEASE", 70, 76], ["RTI", "PROBLEM", 56, 59], ["COPD", "PROBLEM", 61, 65], ["Asthma", "PROBLEM", 70, 76], ["COPD", "OBSERVATION", 61, 65], ["Asthma", "OBSERVATION", 70, 76], ["normal", "OBSERVATION", 144, 150]]], ["Influenza A & B, RSV, parainfluenza, adenovirus was studied over 11 years (Period A) and Influenza A & B, RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus over the final 3 years (Period B).", [["Influenza A & B", "DISEASE", 0, 15], ["parainfluenza", "DISEASE", 22, 35], ["Influenza A & B", "DISEASE", 89, 104], ["RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus", "DISEASE", 106, 163], ["Influenza A & B", "ORGANISM", 0, 15], ["RSV", "ORGANISM", 17, 20], ["parainfluenza", "ORGANISM", 22, 35], ["adenovirus", "ORGANISM", 37, 47], ["Influenza A & B", "ORGANISM", 89, 104], ["RSV", "ORGANISM", 106, 109], ["parainfluenza", "ORGANISM", 111, 124], ["adenovirus", "ORGANISM", 126, 136], ["hMPV", "ORGANISM", 138, 142], ["hRV", "CANCER", 144, 147], ["Influenza", "SPECIES", 0, 9], ["RSV", "SPECIES", 17, 20], ["parainfluenza", "SPECIES", 22, 35], ["RSV", "SPECIES", 106, 109], ["parainfluenza", "SPECIES", 111, 124], ["hMPV", "SPECIES", 138, 142], ["Influenza A & B", "SPECIES", 0, 15], ["RSV", "SPECIES", 17, 20], ["adenovirus", "SPECIES", 37, 47], ["Influenza A & B", "SPECIES", 89, 104], ["RSV", "SPECIES", 106, 109], ["adenovirus", "SPECIES", 126, 136], ["hMPV", "SPECIES", 138, 142], ["hRV", "SPECIES", 144, 147], ["Influenza", "PROBLEM", 0, 9], ["RSV", "PROBLEM", 17, 20], ["parainfluenza", "PROBLEM", 22, 35], ["adenovirus", "PROBLEM", 37, 47], ["Influenza A & B", "PROBLEM", 89, 104], ["RSV", "PROBLEM", 106, 109], ["parainfluenza", "PROBLEM", 111, 124], ["adenovirus", "PROBLEM", 126, 136], ["hMPV", "PROBLEM", 138, 142], ["hRV", "PROBLEM", 144, 147], ["coronavirus", "PROBLEM", 152, 163], ["parainfluenza", "OBSERVATION", 111, 124]]], ["The contribution of individual viruses was performed using the Pearson correlation co-efficient.", [["individual viruses", "PROBLEM", 20, 38], ["viruses", "OBSERVATION", 31, 38]]], ["The collective contribution of influenza A & B, RSV, parainfluenza, adenovirus, human metapneumovirus (hMPV), human rhinovirus (hRV) and coronavirus was addressed using multiple regression analysis and the relative strength of each virus to the total variability as the standardized beta value.", [["influenza A & B", "DISEASE", 31, 46], ["parainfluenza, adenovirus, human metapneumovirus (hMPV), human rhinovirus (hRV) and coronavirus", "DISEASE", 53, 148], ["influenza A & B", "ORGANISM", 31, 46], ["RSV", "ORGANISM", 48, 51], ["parainfluenza", "ORGANISM", 53, 66], ["adenovirus", "ORGANISM", 68, 78], ["human metapneumovirus", "ORGANISM", 80, 101], ["hMPV", "ORGANISM", 103, 107], ["human", "ORGANISM", 110, 115], ["rhinovirus", "ORGANISM", 116, 126], ["hRV", "CANCER", 128, 131], ["coronavirus", "ORGANISM", 137, 148], ["beta", "GENE_OR_GENE_PRODUCT", 283, 287], ["RSV", "SPECIES", 48, 51], ["parainfluenza", "SPECIES", 53, 66], ["human", "SPECIES", 80, 85], ["metapneumovirus", "SPECIES", 86, 101], ["hMPV", "SPECIES", 103, 107], ["human", "SPECIES", 110, 115], ["rhinovirus", "SPECIES", 116, 126], ["RSV", "SPECIES", 48, 51], ["adenovirus", "SPECIES", 68, 78], ["human metapneumovirus", "SPECIES", 80, 101], ["hMPV", "SPECIES", 103, 107], ["human rhinovirus", "SPECIES", 110, 126], ["hRV", "SPECIES", 128, 131], ["influenza A & B", "PROBLEM", 31, 46], ["RSV", "PROBLEM", 48, 51], ["parainfluenza", "PROBLEM", 53, 66], ["adenovirus", "PROBLEM", 68, 78], ["human metapneumovirus", "PROBLEM", 80, 101], ["hMPV", "PROBLEM", 103, 107], ["human rhinovirus", "PROBLEM", 110, 126], ["coronavirus", "PROBLEM", 137, 148], ["multiple regression analysis", "TEST", 169, 197], ["the standardized beta value", "TEST", 266, 293], ["influenza", "OBSERVATION", 31, 40]]], ["All analyses were performed in TIBCO Statistica (Academic Package v13.2).Daily ED visits and hospitalizations ::: ResultsThe mean number of ED visits and hospitalizations was highest for RTIs, followed by COPD and asthma, however, the % of hospitalized was highest for COPD, followed by asthma and RTIs (Table 1).", [["RTIs", "DISEASE", 187, 191], ["COPD", "DISEASE", 205, 209], ["asthma", "DISEASE", 214, 220], ["COPD", "DISEASE", 269, 273], ["asthma", "DISEASE", 287, 293], ["RTIs", "DISEASE", 298, 302], ["All analyses", "TEST", 0, 12], ["RTIs", "PROBLEM", 187, 191], ["COPD", "PROBLEM", 205, 209], ["asthma", "PROBLEM", 214, 220], ["COPD", "PROBLEM", 269, 273], ["asthma", "PROBLEM", 287, 293], ["COPD", "OBSERVATION", 205, 209], ["asthma", "OBSERVATION", 214, 220], ["COPD", "OBSERVATION", 269, 273]]], ["The daily trends over the entire study period is shown in Fig 1.", [["the entire study", "TEST", 22, 38]]], ["The prevalence of % positive tests to viruses in the community are shown in Fig 2.Contribution of individual viruses to ED visits and hospitalizations ::: ResultsThe daily % positive response of each virus was correlated with ED visits and hospitalizations for 5 viruses over 11 years (Table 2) and 8 viruses over 3 years (Table 3).", [["% positive tests to viruses", "PROBLEM", 18, 45], ["each virus", "PROBLEM", 195, 205], ["5 viruses", "PROBLEM", 261, 270], ["individual viruses", "OBSERVATION", 98, 116]]], ["ED visits and hospitalizations for RTIs and COPD were strongly and similarly influenced by influenza A, followed by RSV, coronavirus, hMPV and then influenza B. ED visits and hospitalizations for asthma were not influenced by any of the viruses with a minor contribution from hRV (r = 0.21, and r = 0.14 respectively).Contribution of all viruses combined to ED Visits and Hospitalization with RTIs ::: ResultsThe combination of % positive tests to influenza A & B, RSV, parainfluenza and adenovirus to the daily rates of ED visits and hospitalizations with RTI explained 57.4% of the daily variance in ED visits with RTI and explained 63.8% of the daily variance in RTI hospitalizations in period A. Influenza A & B, RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus explained 66.7% of the daily variance in ED visits with RTI and 74.4% of the daily variance in hospital hospitalizations over the final 3 years, period B. The relative influence of individual viruses contributing to the variability is shown in Figs 3A and 4A for the 5 viruses over the 11-year period and the 8 viruses over 3 years, respectively.", [["RTIs", "DISEASE", 35, 39], ["COPD", "DISEASE", 44, 48], ["RSV, coronavirus, hMPV", "DISEASE", 116, 138], ["asthma", "DISEASE", 196, 202], ["RTIs", "DISEASE", 393, 397], ["parainfluenza", "DISEASE", 470, 483], ["RTI", "DISEASE", 557, 560], ["RTI", "DISEASE", 617, 620], ["RTI", "DISEASE", 666, 669], ["Influenza A & B", "DISEASE", 700, 715], ["RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus", "DISEASE", 717, 774], ["RTI", "DISEASE", 831, 834], ["influenza A", "ORGANISM", 91, 102], ["RSV", "ORGANISM", 116, 119], ["coronavirus", "ORGANISM", 121, 132], ["hMPV", "ORGANISM", 134, 138], ["influenza A & B", "ORGANISM", 448, 463], ["RSV", "ORGANISM", 465, 468], ["parainfluenza", "ORGANISM", 470, 483], ["adenovirus", "ORGANISM", 488, 498], ["Influenza A & B", "ORGANISM", 700, 715], ["RSV", "ORGANISM", 717, 720], ["parainfluenza", "ORGANISM", 722, 735], ["adenovirus", "ORGANISM", 737, 747], ["hMPV", "ORGANISM", 749, 753], ["hRV", "GENE_OR_GENE_PRODUCT", 755, 758], ["coronavirus", "ORGANISM", 763, 774], ["parainfluenza", "SPECIES", 470, 483], ["RSV", "SPECIES", 717, 720], ["parainfluenza", "SPECIES", 722, 735], ["hMPV", "SPECIES", 749, 753], ["influenza A", "SPECIES", 91, 102], ["RSV", "SPECIES", 116, 119], ["hMPV", "SPECIES", 134, 138], ["RSV", "SPECIES", 465, 468], ["adenovirus", "SPECIES", 488, 498], ["Influenza A & B", "SPECIES", 700, 715], ["RSV", "SPECIES", 717, 720], ["adenovirus", "SPECIES", 737, 747], ["hMPV", "SPECIES", 749, 753], ["hRV", "SPECIES", 755, 758], ["RTIs", "PROBLEM", 35, 39], ["COPD", "PROBLEM", 44, 48], ["influenza A", "PROBLEM", 91, 102], ["RSV", "PROBLEM", 116, 119], ["coronavirus", "PROBLEM", 121, 132], ["hMPV", "PROBLEM", 134, 138], ["influenza", "PROBLEM", 148, 157], ["asthma", "PROBLEM", 196, 202], ["hRV", "TEST", 276, 279], ["all viruses", "PROBLEM", 334, 345], ["% positive tests", "PROBLEM", 428, 444], ["influenza", "PROBLEM", 448, 457], ["RSV", "PROBLEM", 465, 468], ["parainfluenza", "PROBLEM", 470, 483], ["adenovirus", "PROBLEM", 488, 498], ["RTI", "TEST", 557, 560], ["RTI", "TEST", 617, 620], ["Influenza", "PROBLEM", 700, 709], ["RSV", "PROBLEM", 717, 720], ["parainfluenza", "PROBLEM", 722, 735], ["adenovirus", "PROBLEM", 737, 747], ["hMPV", "PROBLEM", 749, 753], ["hRV", "PROBLEM", 755, 758], ["coronavirus", "PROBLEM", 763, 774], ["RTI", "TEST", 831, 834], ["individual viruses", "PROBLEM", 956, 974], ["the 5 viruses", "PROBLEM", 1038, 1051], ["COPD", "OBSERVATION", 44, 48], ["viruses", "OBSERVATION", 237, 244], ["all viruses", "OBSERVATION", 334, 345]]], ["Most of the variance in RTIs was explained by Influenza A, RSV, and hRV.Contribution of all viruses combined to ED Visits and Hospitalization with COPD ::: ResultsThe combination of % positive tests to Influenza A & B, RSV, paraInfluenza and adenovirus to the daily rates ED visits and hospitalizations with COPD explained 41.4% of the daily variance in ED visits with COPD and explained 39.2% of the daily variance in COPD hospitalizations over the total 11 years (period A).", [["RTIs", "DISEASE", 24, 28], ["COPD", "DISEASE", 147, 151], ["Influenza A & B", "DISEASE", 202, 217], ["COPD", "DISEASE", 308, 312], ["COPD", "DISEASE", 369, 373], ["COPD", "DISEASE", 419, 423], ["Influenza A", "ORGANISM", 46, 57], ["RSV", "ORGANISM", 59, 62], ["Influenza A & B", "ORGANISM", 202, 217], ["RSV", "ORGANISM", 219, 222], ["paraInfluenza", "GENE_OR_GENE_PRODUCT", 224, 237], ["adenovirus", "ORGANISM", 242, 252], ["Influenza A", "SPECIES", 46, 57], ["RSV", "SPECIES", 59, 62], ["hRV", "SPECIES", 68, 71], ["Influenza A & B", "SPECIES", 202, 217], ["RSV", "SPECIES", 219, 222], ["adenovirus", "SPECIES", 242, 252], ["RTIs", "PROBLEM", 24, 28], ["Influenza A", "PROBLEM", 46, 57], ["RSV", "PROBLEM", 59, 62], ["hRV", "PROBLEM", 68, 71], ["all viruses", "PROBLEM", 88, 99], ["COPD", "PROBLEM", 147, 151], ["% positive tests", "PROBLEM", 182, 198], ["Influenza A & B", "PROBLEM", 202, 217], ["RSV", "PROBLEM", 219, 222], ["paraInfluenza", "PROBLEM", 224, 237], ["adenovirus", "PROBLEM", 242, 252], ["COPD", "PROBLEM", 308, 312], ["COPD", "PROBLEM", 369, 373], ["COPD hospitalizations", "PROBLEM", 419, 440], ["all viruses", "OBSERVATION", 88, 99], ["COPD", "OBSERVATION", 147, 151], ["paraInfluenza", "OBSERVATION", 224, 237], ["COPD", "OBSERVATION", 419, 423]]], ["Influenza A & B, RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus explained 52.5% of the daily variance in ED visits with COPD and 48.2% of the daily variance in hospitalizations over the final 3 years (period B).", [["Influenza A & B", "DISEASE", 0, 15], ["RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus", "DISEASE", 17, 74], ["COPD", "DISEASE", 131, 135], ["Influenza A & B", "ORGANISM", 0, 15], ["RSV", "ORGANISM", 17, 20], ["parainfluenza", "ORGANISM", 22, 35], ["adenovirus", "ORGANISM", 37, 47], ["hMPV", "ORGANISM", 49, 53], ["hRV", "GENE_OR_GENE_PRODUCT", 55, 58], ["coronavirus", "ORGANISM", 63, 74], ["Influenza", "SPECIES", 0, 9], ["RSV", "SPECIES", 17, 20], ["parainfluenza", "SPECIES", 22, 35], ["hMPV", "SPECIES", 49, 53], ["RSV", "SPECIES", 17, 20], ["adenovirus", "SPECIES", 37, 47], ["hMPV", "SPECIES", 49, 53], ["hRV", "SPECIES", 55, 58], ["Influenza", "TEST", 0, 9], ["RSV", "PROBLEM", 17, 20], ["parainfluenza", "PROBLEM", 22, 35], ["adenovirus", "PROBLEM", 37, 47], ["hMPV", "PROBLEM", 49, 53], ["hRV", "PROBLEM", 55, 58], ["coronavirus", "PROBLEM", 63, 74], ["COPD", "PROBLEM", 131, 135], ["COPD", "OBSERVATION", 131, 135]]], ["The relative influence of individual viruses contributing to the variability is shown in Figs 3B and 4B for the 5 viruses over the 11-year period (period A) and the 8 viruses over 3 years (period B).", [["individual viruses", "PROBLEM", 26, 44], ["the 5 viruses", "PROBLEM", 108, 121], ["the 8 viruses", "PROBLEM", 161, 174], ["viruses", "OBSERVATION", 37, 44]]], ["Similar to RTIs, most of the variance explained was due to influenza A, RSV, and hRV.Contribution of all viruses combined to ED visits and hospitalization with asthma ::: ResultsThe combination of % positive tests to influenza A & B, RSV, paraInfluenza and adenovirus to the daily rates ED visits and hospitalizations with asthma explained 1.5% of the daily variance in ED visits with Asthma and explained 2.7% of the daily variance in asthma hospitalizations over the 11 years.", [["RTIs", "DISEASE", 11, 15], ["asthma", "DISEASE", 160, 166], ["asthma", "DISEASE", 323, 329], ["Asthma", "DISEASE", 385, 391], ["asthma", "DISEASE", 436, 442], ["RSV", "ORGANISM", 72, 75], ["influenza A & B", "ORGANISM", 217, 232], ["RSV", "ORGANISM", 234, 237], ["paraInfluenza", "GENE_OR_GENE_PRODUCT", 239, 252], ["adenovirus", "ORGANISM", 257, 267], ["RSV", "SPECIES", 72, 75], ["hRV", "SPECIES", 81, 84], ["RSV", "SPECIES", 234, 237], ["adenovirus", "SPECIES", 257, 267], ["RTIs", "PROBLEM", 11, 15], ["influenza A", "PROBLEM", 59, 70], ["RSV", "PROBLEM", 72, 75], ["hRV", "PROBLEM", 81, 84], ["all viruses", "PROBLEM", 101, 112], ["asthma", "PROBLEM", 160, 166], ["% positive tests", "PROBLEM", 197, 213], ["influenza A & B", "PROBLEM", 217, 232], ["RSV", "PROBLEM", 234, 237], ["paraInfluenza", "PROBLEM", 239, 252], ["adenovirus", "PROBLEM", 257, 267], ["asthma", "PROBLEM", 323, 329], ["Asthma", "PROBLEM", 385, 391], ["asthma hospitalizations", "PROBLEM", 436, 459], ["RTIs", "OBSERVATION", 11, 15], ["influenza", "OBSERVATION", 59, 68], ["all viruses", "OBSERVATION", 101, 112], ["paraInfluenza", "OBSERVATION", 239, 252]]], ["Influenza A & B, RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus explained 13.3% of the daily variance in ED visits with asthma and 10.4% of the daily variance in hospital hospitalizations over the final 3 years.", [["Influenza A & B", "DISEASE", 0, 15], ["RSV, parainfluenza, adenovirus, hMPV, hRV and coronavirus", "DISEASE", 17, 74], ["asthma", "DISEASE", 131, 137], ["Influenza A & B", "ORGANISM", 0, 15], ["RSV", "ORGANISM", 17, 20], ["parainfluenza", "ORGANISM", 22, 35], ["adenovirus", "ORGANISM", 37, 47], ["hMPV", "ORGANISM", 49, 53], ["hRV", "GENE_OR_GENE_PRODUCT", 55, 58], ["coronavirus", "ORGANISM", 63, 74], ["Influenza", "SPECIES", 0, 9], ["RSV", "SPECIES", 17, 20], ["parainfluenza", "SPECIES", 22, 35], ["hMPV", "SPECIES", 49, 53], ["RSV", "SPECIES", 17, 20], ["adenovirus", "SPECIES", 37, 47], ["hMPV", "SPECIES", 49, 53], ["hRV", "SPECIES", 55, 58], ["Influenza", "TEST", 0, 9], ["RSV", "PROBLEM", 17, 20], ["parainfluenza", "PROBLEM", 22, 35], ["adenovirus", "PROBLEM", 37, 47], ["hMPV", "PROBLEM", 49, 53], ["hRV", "PROBLEM", 55, 58], ["coronavirus", "PROBLEM", 63, 74], ["asthma", "PROBLEM", 131, 137]]], ["The relative influence of individual viruses contributing to the variability is shown in Figs 3C and 4C for the 5 viruses over the 11-year period and the 8 viruses over3 years.", [["individual viruses", "PROBLEM", 26, 44], ["the 5 viruses", "PROBLEM", 108, 121], ["viruses", "OBSERVATION", 37, 44]]], ["Most of the variance remained unexplained by the prevalence of viruses in the community, except for a modest contribution from hRV and hMPV.Yearly and seasonal variations in ED visits and hospitalizations for RTIs, asthma and COPD ::: ResultsThe daily rates of ED visits and hospitalizations with asthma declined by almost 45% between 2003 and 2013 [1.51 per 105 (95% C.I. 1.47\u20131.55) to 0.86 per 105 (0.84\u20130.88), 0.17 per 105 (0.16\u20130.18) to 0.09 per 105 (0.08\u20130.09), respectively, Fig 5].", [["hMPV", "DISEASE", 135, 139], ["RTIs", "DISEASE", 209, 213], ["asthma", "DISEASE", 215, 221], ["COPD", "DISEASE", 226, 230], ["asthma", "DISEASE", 297, 303], ["hRV", "CANCER", 127, 130], ["hMPV", "ORGANISM", 135, 139], ["hRV", "SPECIES", 127, 130], ["hMPV", "SPECIES", 135, 139], ["viruses", "PROBLEM", 63, 70], ["hMPV", "PROBLEM", 135, 139], ["RTIs", "PROBLEM", 209, 213], ["asthma", "PROBLEM", 215, 221], ["COPD", "PROBLEM", 226, 230], ["asthma", "PROBLEM", 297, 303], ["C.I.", "TEST", 368, 372], ["viruses", "OBSERVATION", 63, 70], ["hMPV", "OBSERVATION", 135, 139], ["asthma", "OBSERVATION", 215, 221], ["COPD", "OBSERVATION", 226, 230]]], ["There were no substantial yearly trends for the daily rates of ED visits and hospitalizations for RTIs [8.00 per 105 (7.72\u20138.29) to 7.62 per 105 (7.37\u20137.87), 0.67 per 105 (0.64\u20130.70) to 0.58 per 105 (0.56\u20130.61, respectively, Fig 5].", [["RTIs", "DISEASE", 98, 102], ["RTIs", "TEST", 98, 102], ["no", "UNCERTAINTY", 11, 13], ["substantial", "OBSERVATION_MODIFIER", 14, 25]]], ["There was a 19% increase in the daily rates of ED visits and 16% increase in hospitalizations for COPD over 11 years [1.35 per 105 (1.31\u20131.39) to 1.60 (1.56\u20131.65), 0.44 per 105 (0.43\u20130.45) to 0.51 per 105 (0.49\u20130.52) respectively, Fig 5].Yearly and seasonal variations in ED visits and hospitalizations for RTIs, asthma and COPD ::: ResultsThe daily rates of ED visits for RTIs and COPD were substantially seasonal with highest rates in the winter [10.7 per 105 (95% C.I. 10.55\u201310.87) and 1.84 per 105 (1.81\u20131.87) respectively, Fig 6] and lowest in the summer [5.72 per 105 (5.66\u20135.79) and 0.59 per 105 (0.58\u20130.60), respectively].", [["COPD", "DISEASE", 98, 102], ["RTIs", "DISEASE", 307, 311], ["asthma", "DISEASE", 313, 319], ["COPD", "DISEASE", 324, 328], ["RTIs", "DISEASE", 373, 377], ["COPD", "DISEASE", 382, 386], ["COPD", "PROBLEM", 98, 102], ["RTIs", "PROBLEM", 307, 311], ["asthma", "PROBLEM", 313, 319], ["COPD", "PROBLEM", 324, 328], ["RTIs", "PROBLEM", 373, 377], ["COPD", "PROBLEM", 382, 386], ["highest rates", "TEST", 420, 433], ["C.I.", "TEST", 467, 471], ["Fig", "TEST", 528, 531], ["increase", "OBSERVATION_MODIFIER", 16, 24], ["asthma", "OBSERVATION", 313, 319], ["COPD", "OBSERVATION", 324, 328], ["COPD", "OBSERVATION", 382, 386]]], ["The rates in the other seasons are also shown in Fig 6.", [["The rates", "TEST", 0, 9]]], ["The daily rates for ED visits and hospitalizations for asthma were highest in the fall [1.39 per 105 (1.37\u20131.72), and 0.15 per 105 (0.146\u20130.154), respectively] and the lowest in the summer (1.05 per 105 (1.03\u20131.08), and 0.095 per 105 (0.091\u20130.096) respectively].DiscussionThe approach adopted in this study is novel in that we begin with the prevalence of positive tests for a particular respiratory virus (or viruses) in the community on any given day and its contribution to ED visits and hospitalizations with RTI, COPD and asthma over an 11-year period using a multiplex PCR technique.", [["asthma", "DISEASE", 55, 61], ["respiratory virus", "DISEASE", 388, 405], ["RTI", "DISEASE", 513, 516], ["COPD", "DISEASE", 518, 522], ["asthma", "DISEASE", 527, 533], ["respiratory virus", "ORGANISM", 388, 405], ["asthma", "PROBLEM", 55, 61], ["this study", "TEST", 296, 306], ["positive tests", "PROBLEM", 356, 370], ["a particular respiratory virus", "PROBLEM", 375, 405], ["viruses", "PROBLEM", 410, 417], ["RTI", "PROBLEM", 513, 516], ["COPD", "PROBLEM", 518, 522], ["asthma", "PROBLEM", 527, 533], ["a multiplex PCR technique", "TREATMENT", 563, 588], ["COPD", "OBSERVATION", 518, 522], ["asthma", "OBSERVATION", 527, 533]]], ["The key findings of this study were: i) ED visits and hospitalizations were highest for RTIs and COPD and follow similar daily patterns, ii) between 41% and 74% of RTIs and COPD related ED visits and hospitalizations can be attributed to respiratory viruses, iii) asthma related visits and hospitalizations were the lowest, with a 45% reduction over the 11 year period and, iv) only human rhinovirus had a minor contribution to asthma.DiscussionThe case for a causative role for viral respiratory infections in causing exacerbations of COPD and RTIs is strong and explains the concordant temporal relationship with the prevalence of the common respiratory viruses in the community.", [["respiratory", "ANATOMY", 485, 496], ["RTIs", "DISEASE", 88, 92], ["COPD", "DISEASE", 97, 101], ["RTIs", "DISEASE", 164, 168], ["COPD", "DISEASE", 173, 177], ["respiratory viruses", "DISEASE", 238, 257], ["asthma", "DISEASE", 264, 270], ["asthma", "DISEASE", 428, 434], ["viral respiratory infections", "DISEASE", 479, 507], ["COPD", "DISEASE", 536, 540], ["RTIs", "DISEASE", 545, 549], ["respiratory viruses", "DISEASE", 644, 663], ["human", "ORGANISM", 383, 388], ["rhinovirus", "ORGANISM", 389, 399], ["human", "SPECIES", 383, 388], ["human rhinovirus", "SPECIES", 383, 399], ["this study", "TEST", 20, 30], ["RTIs", "PROBLEM", 88, 92], ["COPD", "PROBLEM", 97, 101], ["RTIs", "PROBLEM", 164, 168], ["COPD", "PROBLEM", 173, 177], ["respiratory viruses", "PROBLEM", 238, 257], ["asthma", "PROBLEM", 264, 270], ["a 45% reduction", "TREATMENT", 329, 344], ["human rhinovirus", "PROBLEM", 383, 399], ["asthma", "PROBLEM", 428, 434], ["viral respiratory infections", "PROBLEM", 479, 507], ["COPD", "PROBLEM", 536, 540], ["RTIs", "PROBLEM", 545, 549], ["the common respiratory viruses", "PROBLEM", 633, 663], ["COPD", "OBSERVATION", 97, 101], ["rhinovirus", "OBSERVATION", 389, 399], ["asthma", "OBSERVATION", 428, 434], ["respiratory", "ANATOMY", 485, 496], ["infections", "OBSERVATION", 497, 507], ["COPD", "OBSERVATION", 536, 540], ["respiratory viruses", "OBSERVATION", 644, 663]]], ["Our data is in keeping with other studies demonstrating COPD exacerbations coincide with the prevalence of respiratory viruses[9, 10] and subjects who were serially monitored in the community, respiratory viruses are detected in 40% of exacerbations[11, 12] and as high as 60% in a hospital inpatient setting[10, 13].", [["COPD", "DISEASE", 56, 60], ["respiratory viruses", "DISEASE", 107, 126], ["respiratory viruses", "DISEASE", 193, 212], ["exacerbations", "DISEASE", 236, 249], ["Our data", "TEST", 0, 8], ["other studies", "TEST", 28, 41], ["COPD exacerbations", "PROBLEM", 56, 74], ["respiratory viruses", "PROBLEM", 107, 126], ["respiratory viruses", "PROBLEM", 193, 212], ["exacerbations", "PROBLEM", 236, 249], ["COPD", "OBSERVATION", 56, 60], ["respiratory viruses", "OBSERVATION", 107, 126], ["respiratory", "ANATOMY", 193, 204], ["viruses", "OBSERVATION", 205, 212]]], ["The higher proportion of patients hospitalized with COPD compared to with RTIs in our study is likely due to a number of disease processes and risk factors such as the presence of chronic airflow limitation, emphysema, smoking, ageing, and associated co-morbidities such as heart failure.DiscussionIn contrast, viral epidemics and ED visits and hospitalizations with asthma were not synchronous and, except for hRV, did not contribute much to ED visits and hospitalization.DiscussionNumerous studies have previously shown 50\u201385% of asthma exacerbations are reported to coincide with the detection of respiratory viruses[14\u201316], however they were mainly in cohort studies of children with asthma and often with intensive community monitoring longitudinally[17].", [["heart", "ANATOMY", 274, 279], ["COPD", "DISEASE", 52, 56], ["RTIs", "DISEASE", 74, 78], ["chronic airflow limitation", "DISEASE", 180, 206], ["emphysema", "DISEASE", 208, 217], ["heart failure", "DISEASE", 274, 287], ["asthma", "DISEASE", 367, 373], ["asthma", "DISEASE", 532, 538], ["respiratory viruses", "DISEASE", 600, 619], ["asthma", "DISEASE", 688, 694], ["patients", "ORGANISM", 25, 33], ["heart", "ORGAN", 274, 279], ["children", "ORGANISM", 674, 682], ["patients", "SPECIES", 25, 33], ["children", "SPECIES", 674, 682], ["COPD", "PROBLEM", 52, 56], ["RTIs", "PROBLEM", 74, 78], ["our study", "TEST", 82, 91], ["disease processes", "PROBLEM", 121, 138], ["risk factors", "PROBLEM", 143, 155], ["chronic airflow limitation", "PROBLEM", 180, 206], ["emphysema", "PROBLEM", 208, 217], ["associated co-morbidities", "PROBLEM", 240, 265], ["heart failure", "PROBLEM", 274, 287], ["asthma", "PROBLEM", 367, 373], ["Numerous studies", "TEST", 483, 499], ["asthma exacerbations", "PROBLEM", 532, 552], ["respiratory viruses", "PROBLEM", 600, 619], ["asthma", "PROBLEM", 688, 694], ["higher", "OBSERVATION_MODIFIER", 4, 10], ["COPD", "OBSERVATION", 52, 56], ["likely due to", "UNCERTAINTY", 95, 108], ["disease", "OBSERVATION", 121, 128], ["chronic", "OBSERVATION_MODIFIER", 180, 187], ["airflow limitation", "OBSERVATION", 188, 206], ["emphysema", "OBSERVATION", 208, 217], ["heart", "ANATOMY", 274, 279], ["failure", "OBSERVATION", 280, 287], ["asthma", "OBSERVATION", 532, 538], ["respiratory viruses", "OBSERVATION", 600, 619]]], ["The average detection rates of viruses in incidental studies during exacerbations of asthma were much lower at 24%, with 32% in children and only 13% in adults[18].", [["asthma", "DISEASE", 85, 91], ["children", "ORGANISM", 128, 136], ["children", "SPECIES", 128, 136], ["viruses", "PROBLEM", 31, 38], ["incidental studies", "TEST", 42, 60], ["asthma", "PROBLEM", 85, 91], ["average", "OBSERVATION_MODIFIER", 4, 11], ["viruses", "OBSERVATION", 31, 38], ["asthma", "OBSERVATION", 85, 91]]], ["Furthermore, virus detection was more prevalent when asthmatics were more symptomatic with wheeze, likely due to a more severe acute illness[18].", [["wheeze", "DISEASE", 91, 97], ["illness", "DISEASE", 133, 140], ["virus detection", "TEST", 13, 28], ["asthmatics", "PROBLEM", 53, 63], ["wheeze", "PROBLEM", 91, 97], ["a more severe acute illness", "PROBLEM", 113, 140], ["severe", "OBSERVATION_MODIFIER", 120, 126], ["acute", "OBSERVATION_MODIFIER", 127, 132], ["illness", "OBSERVATION", 133, 140]]], ["Therefore, the low rates of % positive viruses in our study could be explained by the fact that this was an unselected population of the whole of Ontario with children and adults, ED visits likely represent less severe illness in asthma compared with COPD.DiscussionOur finding that hRV is the dominant virus in asthma is in keeping with previous data that showed hRV is detected in 33% of adults with exacerbations[19] and two-thirds of children presenting to the ED with an asthma attack were due to hRV[20].", [["illness", "DISEASE", 219, 226], ["asthma", "DISEASE", 230, 236], ["COPD", "DISEASE", 251, 255], ["asthma", "DISEASE", 312, 318], ["exacerbations", "DISEASE", 402, 415], ["asthma", "DISEASE", 476, 482], ["children", "ORGANISM", 159, 167], ["hRV", "GENE_OR_GENE_PRODUCT", 283, 286], ["hRV", "CANCER", 364, 367], ["children", "ORGANISM", 438, 446], ["children", "SPECIES", 159, 167], ["children", "SPECIES", 438, 446], ["hRV", "SPECIES", 283, 286], ["hRV", "SPECIES", 364, 367], ["the low rates of % positive viruses", "PROBLEM", 11, 46], ["our study", "TEST", 50, 59], ["less severe illness", "PROBLEM", 207, 226], ["asthma", "PROBLEM", 230, 236], ["COPD", "PROBLEM", 251, 255], ["hRV", "PROBLEM", 283, 286], ["the dominant virus", "PROBLEM", 290, 308], ["asthma", "PROBLEM", 312, 318], ["previous data", "TEST", 338, 351], ["hRV", "PROBLEM", 364, 367], ["exacerbations", "PROBLEM", 402, 415], ["an asthma attack", "PROBLEM", 473, 489], ["low", "OBSERVATION_MODIFIER", 15, 18], ["viruses", "OBSERVATION", 39, 46], ["likely represent", "UNCERTAINTY", 190, 206], ["less", "OBSERVATION_MODIFIER", 207, 211], ["severe", "OBSERVATION_MODIFIER", 212, 218], ["illness", "OBSERVATION", 219, 226], ["asthma", "OBSERVATION", 230, 236], ["COPD", "OBSERVATION", 251, 255], ["dominant", "OBSERVATION_MODIFIER", 294, 302], ["virus", "OBSERVATION", 303, 308], ["asthma", "OBSERVATION", 476, 482]]], ["A recent pooled meta-analysis of 60 studies across all ages and continents found the prevalence of respiratory viruses associated with asthma exacerbations was <15%, except hRV which was 42%[21].", [["respiratory viruses", "DISEASE", 99, 118], ["asthma", "DISEASE", 135, 141], ["hRV", "SPECIES", 173, 176], ["A recent pooled meta-analysis", "TEST", 0, 29], ["respiratory viruses", "PROBLEM", 99, 118], ["asthma exacerbations", "PROBLEM", 135, 155], ["hRV", "TEST", 173, 176], ["respiratory viruses", "OBSERVATION", 99, 118], ["asthma", "OBSERVATION", 135, 141]]], ["Although hRV had the highest prevalence in both children and adults, there were some notable difference: children were more positive for RSV and hRV, whilst adults were more positive for influenza, coronavirus and parainfluenza.", [["influenza, coronavirus and parainfluenza", "DISEASE", 187, 227], ["hRV", "CANCER", 9, 12], ["children", "ORGANISM", 48, 56], ["children", "ORGANISM", 105, 113], ["RSV", "ORGANISM", 137, 140], ["hRV", "CANCER", 145, 148], ["adults", "ORGANISM", 157, 163], ["coronavirus", "ORGANISM", 198, 209], ["parainfluenza", "ORGANISM", 214, 227], ["children", "SPECIES", 48, 56], ["children", "SPECIES", 105, 113], ["coronavirus", "SPECIES", 198, 209], ["parainfluenza", "SPECIES", 214, 227], ["RSV", "SPECIES", 137, 140], ["hRV", "SPECIES", 145, 148], ["RSV", "PROBLEM", 137, 140], ["hRV", "PROBLEM", 145, 148], ["influenza", "PROBLEM", 187, 196], ["coronavirus", "PROBLEM", 198, 209], ["parainfluenza", "PROBLEM", 214, 227]]], ["These age-related changes in viral detection rates was also evident during the yearly cycle, where children <3 month were mainly positive between the months of Jan-March, whilst those aged between 3\u201318 were positive in Sept-Nov[22].", [["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["changes in viral detection rates", "PROBLEM", 18, 50], ["viral detection", "OBSERVATION", 29, 44]]], ["Human rhinovirus also occurs in seasonal epidemics in our data, particularly in seasons where influenza and RSV epidemics are much lower.", [["influenza", "DISEASE", 94, 103], ["RSV", "DISEASE", 108, 111], ["Human", "ORGANISM", 0, 5], ["rhinovirus", "ORGANISM", 6, 16], ["RSV", "ORGANISM", 108, 111], ["Human", "SPECIES", 0, 5], ["Human rhinovirus", "SPECIES", 0, 16], ["RSV", "SPECIES", 108, 111], ["Human rhinovirus", "PROBLEM", 0, 16], ["influenza", "PROBLEM", 94, 103], ["RSV epidemics", "PROBLEM", 108, 121], ["rhinovirus", "OBSERVATION", 6, 16], ["RSV", "OBSERVATION", 108, 111]]], ["Previously 20% of all hospital admissions of school aged children in Canada were shown to occur in September, attributed predominantly to hRV[23, 24].", [["children", "ORGANISM", 57, 65], ["children", "SPECIES", 57, 65]]], ["Importantly, hRV has recently also been linked with mortality in asthmatics, elderly and in those in long term care facilities [25\u201327].", [["hRV", "GENE_OR_GENE_PRODUCT", 13, 16], ["hRV", "PROTEIN", 13, 16], ["hRV", "SPECIES", 13, 16], ["asthmatics", "PROBLEM", 65, 75]]], ["It is likely that factors related to hRV species and type [28], along with age, host risk factors determine the severity of symptoms on presentation to the ED may explain the lack of overall relationship to viral epidemics in our data.", [["hRV species", "PROBLEM", 37, 48], ["host risk factors", "PROBLEM", 80, 97], ["symptoms", "PROBLEM", 124, 132]]], ["Data relating to the effects of age and gender in our dataset is not yet to be fully available but will add an important dimension to the current data.DiscussionPossible explanations for the low rates of ED visits and hospitalizations for asthma and the 45% fall over 11 years is that i) treatment for asthma with inhaled corticosteroids with or without long acting \u03b22 agonists has improved or ii) the prevalence of asthma has decreased or iii) active cases have decreased across Canada.", [["asthma", "DISEASE", 239, 245], ["asthma", "DISEASE", 302, 308], ["corticosteroids", "CHEMICAL", 322, 337], ["asthma", "DISEASE", 416, 422], ["corticosteroids", "CHEMICAL", 322, 337], ["long acting \u03b22 agonists", "GENE_OR_GENE_PRODUCT", 354, 377], ["asthma", "PROBLEM", 239, 245], ["asthma", "PROBLEM", 302, 308], ["inhaled corticosteroids", "TREATMENT", 314, 337], ["long acting \u03b22 agonists", "TREATMENT", 354, 377], ["asthma", "PROBLEM", 416, 422], ["active cases", "PROBLEM", 445, 457], ["asthma", "OBSERVATION", 416, 422], ["decreased", "OBSERVATION_MODIFIER", 463, 472]]], ["The Ontario Asthma Surveillance Information System (OASIS) estimated the actual prevalence of asthma at 12.6% in 2003 and 15.3% in 2013, an increase of 22%[29].", [["Asthma", "DISEASE", 12, 18], ["asthma", "DISEASE", 94, 100], ["asthma", "PROBLEM", 94, 100], ["asthma", "OBSERVATION", 94, 100]]], ["This is calculated using a health administrative data case definition of \u2265 2 outpatient claims in 2 consecutive years or \u2265 1 hospitalization(s) for asthma.", [["asthma", "DISEASE", 148, 154], ["asthma", "PROBLEM", 148, 154], ["asthma", "OBSERVATION", 148, 154]]], ["The Public Health Agency of Canada (PHAC) estimates that the age-standardized prevalence rates of \u2018active\u2019 cases, defined as at least one physician claim or \u2265 1 hospitalizations(s) among Canadian in 2003 was 3.3% and this decreased to 2.8%, representing a fall in incidence rates from 723 per 105 to 499 per 105 [30] This suggests that although prevalence of asthma is increasing, the healthcare utilization is decreasing, likely due to improved care and treatment.DiscussionThere are some important limitations worth noting.", [["asthma", "DISEASE", 359, 365], ["a fall in incidence rates", "PROBLEM", 254, 279], ["asthma", "PROBLEM", 359, 365], ["treatment", "TREATMENT", 455, 464], ["asthma", "OBSERVATION", 359, 365], ["increasing", "OBSERVATION_MODIFIER", 369, 379]]], ["First, this analysis was done on 2 separate databases which are unlinked and hence a positive virus detection is not linked with the individual attending the ED.", [["this analysis", "TEST", 7, 20], ["a positive virus detection", "PROBLEM", 83, 109]]], ["However, the accuracy and validity of the database can be corroborated by the peak in ED visits and hospitalizations with RTIs but not COPD seen in 2009 due to the H1N1 epidemic.", [["RTIs", "DISEASE", 122, 126], ["COPD", "DISEASE", 135, 139], ["the accuracy", "TEST", 9, 21], ["the database", "TEST", 38, 50], ["RTIs", "PROBLEM", 122, 126], ["COPD", "PROBLEM", 135, 139], ["the H1N1 epidemic", "PROBLEM", 160, 177], ["H1N1", "OBSERVATION", 164, 168]]], ["Third, the study was not designed to investigate co-infection with multiple viruses.", [["the study", "TEST", 7, 16], ["co-infection", "PROBLEM", 49, 61], ["multiple viruses", "PROBLEM", 67, 83], ["viruses", "OBSERVATION", 76, 83]]], ["Fourth, as this is a population-based database, we do not have access to additional potentially confounding variables such as medical co-morbidities, allergy status, and medication usage, however, we are currently in the process of acquiring the data for age and gender.", [["allergy", "DISEASE", 150, 157], ["medical co-morbidities", "PROBLEM", 126, 148], ["allergy status", "PROBLEM", 150, 164]]], ["Fifth, we do not have information about the day the clinical sample for virus testing was taken in relation to the start of the symptoms.", [["virus testing", "TEST", 72, 85], ["the symptoms", "PROBLEM", 124, 136]]], ["It is possible that virus detection rates may be able altered depending on the day the test was done.", [["virus detection rates", "PROBLEM", 20, 41], ["the test", "TEST", 83, 91]]], ["Sixth, we do have quantitative PCR data for viral loads, which may be useful at investigating the strength of relationship between virus, severity of illness and hospitalizations.", [["illness", "DISEASE", 150, 157], ["quantitative PCR data", "TEST", 18, 39], ["viral loads", "PROBLEM", 44, 55], ["illness", "PROBLEM", 150, 157]]], ["Seventh, each hospital performs nasopharyngeal swabs on the individual patients at their respective sites and different multiplex PCR panels and assays are used for virus testing as universal use of a single multiplex panel is unlikely to be achieved.", [["nasopharyngeal swabs", "ANATOMY", 32, 52], ["nasopharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 32, 52], ["patients", "ORGANISM", 71, 79], ["patients", "SPECIES", 71, 79], ["nasopharyngeal swabs", "TEST", 32, 52], ["different multiplex PCR panels", "TEST", 110, 140], ["assays", "TEST", 145, 151], ["virus testing", "TEST", 165, 178], ["a single multiplex panel", "TEST", 199, 223]]], ["Each laboratory is licensed in Ontario and are required to undergo quality assurance, auditing and proficiency testing conducted by The Institute for Quality Management in Healthcare.ConclusionsInfluenza A, RSV and hRV viruses can explain the majority of variability in ED visits and hospitalizations due to RTIs and COPD.", [["RTIs", "DISEASE", 308, 312], ["COPD", "DISEASE", 317, 321], ["Influenza A", "ORGANISM", 194, 205], ["RSV", "ORGANISM", 207, 210], ["hRV viruses", "ORGANISM", 215, 226], ["Influenza A", "SPECIES", 194, 205], ["RSV", "SPECIES", 207, 210], ["hRV", "SPECIES", 215, 218], ["proficiency testing", "TEST", 99, 118], ["Influenza", "PROBLEM", 194, 203], ["RSV", "PROBLEM", 207, 210], ["hRV viruses", "PROBLEM", 215, 226], ["RTIs", "PROBLEM", 308, 312], ["COPD", "PROBLEM", 317, 321], ["COPD", "OBSERVATION", 317, 321]]], ["Human RV, hMPV and influenza only has a modest contribution to asthma visits and hospitalizations.", [["influenza", "DISEASE", 19, 28], ["asthma", "DISEASE", 63, 69], ["Human", "ORGANISM", 0, 5], ["hMPV", "ORGANISM", 10, 14], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["hMPV", "SPECIES", 10, 14], ["hMPV", "PROBLEM", 10, 14], ["influenza", "PROBLEM", 19, 28], ["asthma visits", "PROBLEM", 63, 76], ["RV", "ANATOMY", 6, 8], ["hMPV", "OBSERVATION", 10, 14], ["asthma", "OBSERVATION", 63, 69]]]], "ee51022145917b342046e9bfd9d86d2e40733c17": [["mulatta), the infants displayed a range of neurodevelopmental phenotypes and pathologies, from seizure activity and motor delay (Steinbach et al., 2020) .", [["neurodevelopmental phenotypes", "DISEASE", 43, 72], ["seizure", "DISEASE", 95, 102], ["mulatta", "ORGANISM", 0, 7], ["infants", "ORGANISM", 14, 21], ["mulatta", "SPECIES", 0, 7], ["infants", "SPECIES", 14, 21], ["mulatta", "SPECIES", 0, 7], ["neurodevelopmental phenotypes", "PROBLEM", 43, 72], ["pathologies", "PROBLEM", 77, 88], ["seizure activity", "PROBLEM", 95, 111], ["motor delay", "PROBLEM", 116, 127]]]], "PMC3840891": [["The StudyDuring 2008, more than 500 bats associated with possible human exposure were submitted to the Maryland Department of Health and Mental Hygiene State Laboratory for postmortem diagnosis of rabies by direct fluorescent antibody assay (Technical Appendix).", [["rabies", "DISEASE", 197, 203], ["human", "ORGANISM", 66, 71], ["rabies", "ORGANISM", 197, 203], ["human", "SPECIES", 66, 71], ["human", "SPECIES", 66, 71], ["rabies", "SPECIES", 197, 203], ["rabies", "PROBLEM", 197, 203], ["direct fluorescent antibody assay", "TEST", 207, 240]]], ["For this study, virus particles were purified from the lungs and livers of 120 rabies-negative bats with good carcass condition, and viral nucleic acids were extracted, randomly amplified, and sequenced by using 454 pyrosequencing (Roche, Mannheim, Germany) and Solexa Illumina sequencing (Illumina, San Diego, CA, USA).", [["lungs", "ANATOMY", 55, 60], ["livers", "ANATOMY", 65, 71], ["nucleic acids", "CHEMICAL", 139, 152], ["lungs", "ORGAN", 55, 60], ["livers", "ORGAN", 65, 71], ["rabies", "ORGANISM", 79, 85], ["bats", "ORGANISM", 95, 99], ["this study", "TEST", 4, 14], ["virus particles", "PROBLEM", 16, 31], ["viral nucleic acids", "TEST", 133, 152], ["lungs", "ANATOMY", 55, 60], ["livers", "ANATOMY", 65, 71]]], ["A total of \u2248100,000 pyrosequences and 13.5 million Solexa Illumina sequences were generated and then assembled to form contigs.", [["Solexa Illumina sequences", "TEST", 51, 76]]], ["More than 30 contigs showed low protein identities to known vesiculoviruses (BLASTx; http://blast.ncbi.nlm.nih.gov/Blast.cgi), indicating a possible novel virus.", [["vesiculoviruses", "PROTEIN", 60, 75], ["BLASTx", "PROTEIN", 77, 83], ["30 contigs", "TEST", 10, 20], ["low protein identities", "PROBLEM", 28, 50], ["known vesiculoviruses", "PROBLEM", 54, 75], ["BLASTx", "TEST", 77, 83], ["novel virus", "PROBLEM", 149, 160], ["low protein", "OBSERVATION_MODIFIER", 28, 39], ["possible", "UNCERTAINTY", 140, 148], ["virus", "OBSERVATION", 155, 160]]], ["PCR and rapid amplification of cDNA ends were performed to obtain the complete genome of this virus (primers shown in Technical Appendix Figures 1, 2).", [["cDNA ends", "DNA", 31, 40], ["PCR", "TEST", 0, 3], ["rapid amplification of cDNA ends", "TEST", 8, 40], ["this virus", "PROBLEM", 89, 99], ["Appendix", "ANATOMY", 128, 136]]], ["We proposed the name American bat vesiculovirus (ABVV) for this virus.The StudyThe full-length ABVV genome (GenBank accession no. JX569193) consists of 10,692 nt of negative-sense, single-stranded RNA beginning with a 103-nt 5\u2032 untranslated region, followed by open reading frames encoding for the nucleoprotein, phosphoprotein, matrix protein, glycoprotein, and polymerase protein genes (Figure, panel A).", [["American bat vesiculovirus", "ORGANISM", 21, 47], ["ABVV", "ORGANISM", 49, 53], ["ABVV", "GENE_OR_GENE_PRODUCT", 95, 99], ["matrix", "CELLULAR_COMPONENT", 329, 335], ["ABVV genome", "DNA", 95, 106], ["103-nt 5\u2032 untranslated region", "DNA", 218, 247], ["open reading frames", "DNA", 261, 280], ["nucleoprotein, phosphoprotein, matrix protein", "PROTEIN", 298, 343], ["glycoprotein", "PROTEIN", 345, 357], ["polymerase protein genes", "DNA", 363, 387], ["bat vesiculovirus", "SPECIES", 30, 47], ["American bat vesiculovirus", "SPECIES", 21, 47], ["ABVV", "SPECIES", 49, 53], ["GenBank accession no. JX569193", "SPECIES", 108, 138], ["this virus", "PROBLEM", 59, 69], ["The Study", "TEST", 70, 79], ["nt", "TEST", 159, 161], ["single-stranded RNA", "PROBLEM", 181, 200], ["a 103-nt 5\u2032 untranslated region", "PROBLEM", 216, 247], ["the nucleoprotein, phosphoprotein, matrix protein", "TEST", 294, 343], ["glycoprotein", "TREATMENT", 345, 357], ["polymerase protein genes", "TEST", 363, 387], ["negative", "OBSERVATION", 165, 173]]], ["Phylogenetic analyses showed that ABVV is related to vesiculoviruses including Chandipura virus and Isfahan virus, both of which are associated with encephalitic illness in humans.", [["encephalitic illness", "DISEASE", 149, 169], ["ABVV", "GENE_OR_GENE_PRODUCT", 34, 38], ["vesiculoviruses", "GENE_OR_GENE_PRODUCT", 53, 68], ["Chandipura virus", "ORGANISM", 79, 95], ["Isfahan virus", "ORGANISM", 100, 113], ["humans", "ORGANISM", 173, 179], ["ABVV", "DNA", 34, 38], ["Chandipura virus", "SPECIES", 79, 95], ["Isfahan virus", "SPECIES", 100, 113], ["humans", "SPECIES", 173, 179], ["ABVV", "SPECIES", 34, 38], ["Chandipura virus", "SPECIES", 79, 95], ["Isfahan virus", "SPECIES", 100, 113], ["humans", "SPECIES", 173, 179], ["Phylogenetic analyses", "TEST", 0, 21], ["ABVV", "PROBLEM", 34, 38], ["vesiculoviruses", "PROBLEM", 53, 68], ["Chandipura virus", "PROBLEM", 79, 95], ["Isfahan virus", "PROBLEM", 100, 113], ["encephalitic illness in humans", "PROBLEM", 149, 179], ["associated with", "UNCERTAINTY", 133, 148], ["encephalitic", "OBSERVATION_MODIFIER", 149, 161], ["illness", "OBSERVATION", 162, 169]]], ["ABVV is located close to the root of vesiculoviruses in the Bayesian analysis of the nucleoprotein gene (Figure, panel B) and shares 41%\u201349% aa identity with known vesiculoviruses, similar to the vesiculovirus interspecies identities reported (47.9%\u201372.5%) and higher than the intergenera identities between vesiculoviruses, lyssaviruses, and ephemeroviruses (17.0%\u201333.1%) (14).", [["root", "ANATOMY", 29, 33], ["vesiculoviruses", "ANATOMY", 164, 179], ["vesiculoviruses", "ANATOMY", 308, 323], ["lyssaviruses", "ANATOMY", 325, 337], ["ABVV", "CHEMICAL", 0, 4], ["lyssaviruses", "DISEASE", 325, 337], ["ABVV", "GENE_OR_GENE_PRODUCT", 0, 4], ["vesiculoviruses", "CANCER", 164, 179], ["lyssaviruses", "CANCER", 325, 337], ["ABVV", "PROTEIN", 0, 4], ["vesiculoviruses", "DNA", 37, 52], ["nucleoprotein gene", "DNA", 85, 103], ["ABVV", "SPECIES", 0, 4], ["aa identity", "TEST", 141, 152], ["known vesiculoviruses", "PROBLEM", 158, 179], ["vesiculoviruses", "TEST", 308, 323], ["lyssaviruses", "TEST", 325, 337], ["ephemeroviruses", "TEST", 343, 358], ["root", "ANATOMY_MODIFIER", 29, 33], ["vesiculoviruses", "OBSERVATION", 164, 179]]], ["Analyses of the polymerase gene alone (Technical Appendix Figure 3) and of a concatenation of all 5 genes (Figure, panel C) suggested that ABVV lies within the vesiculovirus clade, more closely related to mammalian than fish vesiculoviruses.", [["ABVV", "GENE_OR_GENE_PRODUCT", 139, 143], ["vesiculovirus", "GENE_OR_GENE_PRODUCT", 160, 173], ["fish", "ORGANISM", 220, 224], ["polymerase gene", "DNA", 16, 31], ["5 genes", "DNA", 98, 105], ["ABVV", "DNA", 139, 143], ["ABVV", "SPECIES", 139, 143], ["the polymerase gene", "TREATMENT", 12, 31], ["ABVV lies within the vesiculovirus clade", "PROBLEM", 139, 179]]], ["Combined, these analyses indicate that ABVV is likely to belong to the Vesiculovirus genus, rather than representing a novel genus.", [["ABVV", "CHEMICAL", 39, 43], ["ABVV", "GENE_OR_GENE_PRODUCT", 39, 43], ["ABVV", "SPECIES", 39, 43], ["these analyses", "TEST", 10, 24], ["ABVV", "PROBLEM", 39, 43], ["a novel genus", "PROBLEM", 117, 130], ["Vesiculovirus genus", "ANATOMY", 71, 90], ["novel genus", "OBSERVATION", 119, 130]]], ["The basal phylogenetic position of ABVV suggests early divergence from other mammalian vesiculovirus species.The StudyLung and liver tissues from 60 of the bats used for the pooled metagenomic analyses were screened individually for ABVV by using reverse transcription PCR targeting the polymerase gene (Technical Appendix).", [["StudyLung", "ANATOMY", 113, 122], ["liver tissues", "ANATOMY", 127, 140], ["ABVV", "GENE_OR_GENE_PRODUCT", 35, 39], ["mammalian vesiculovirus species", "ORGANISM", 77, 108], ["liver tissues", "TISSUE", 127, 140], ["bats", "ORGANISM", 156, 160], ["polymerase gene", "DNA", 287, 302], ["ABVV", "SPECIES", 233, 237], ["early divergence", "PROBLEM", 49, 65], ["other mammalian vesiculovirus species", "PROBLEM", 71, 108], ["The StudyLung and liver tissues", "TEST", 109, 140], ["the pooled metagenomic analyses", "TEST", 170, 201], ["reverse transcription PCR", "TEST", 247, 272], ["basal", "ANATOMY_MODIFIER", 4, 9], ["phylogenetic position", "OBSERVATION", 10, 31], ["early divergence", "OBSERVATION", 49, 65], ["mammalian vesiculovirus species", "OBSERVATION", 77, 108], ["liver", "ANATOMY", 127, 132]]], ["Three (5%) bats tested positive for ABVV: 1 adult female, 1 adult male, and 1 juvenile male.", [["bats", "ORGANISM", 11, 15], ["ABVV", "SPECIES", 36, 40]]], ["Viral RNA was found in liver tissue from the 2 male bats and in lung and liver tissues from the female adult bat.The StudyConsidering the extensive lyssavirus diversity in bats, we hypothesize that bat vesiculoviruses are similarly diverse.", [["liver tissue", "ANATOMY", 23, 35], ["lung", "ANATOMY", 64, 68], ["liver tissues", "ANATOMY", 73, 86], ["Viral", "ORGANISM", 0, 5], ["liver tissue", "TISSUE", 23, 35], ["bats", "ORGANISM", 52, 56], ["lung", "ORGAN", 64, 68], ["liver tissues", "TISSUE", 73, 86], ["bat", "ORGANISM", 109, 112], ["bat vesiculoviruses", "ORGANISM", 198, 217], ["Viral RNA", "RNA", 0, 9], ["Viral RNA", "PROBLEM", 0, 9], ["liver tissue", "PROBLEM", 23, 35], ["RNA", "OBSERVATION", 6, 9], ["liver", "ANATOMY", 23, 28], ["tissue", "ANATOMY_MODIFIER", 29, 35], ["lung", "ANATOMY", 64, 68], ["liver", "ANATOMY", 73, 78], ["tissues", "ANATOMY_MODIFIER", 79, 86], ["adult bat", "OBSERVATION", 103, 112], ["extensive", "OBSERVATION_MODIFIER", 138, 147], ["lyssavirus diversity", "OBSERVATION", 148, 168]]], ["To facilitate characterization of diverse vesiculoviruses in bats, we designed 2 pairs of degenerate PCR primers (VesiConAF-KCDGAYAARAGYCAYTCVATGA; VesiConAR-TGNGCNACDGTNARDGCATT; VesiConBF-GGNMGRTTYTTYTCHYTDATGTC; VesiConBR-TCHGCNGAYTGCATNGTYTCA) on the basis of a sequence alignment of the polymerase gene of ABVV and the formally classified mammalian vesiculoviruses.", [["vesiculoviruses", "ANATOMY", 354, 369], ["vesiculoviruses", "CANCER", 42, 57], ["ABVV", "GENE_OR_GENE_PRODUCT", 311, 315], ["vesiculoviruses", "CANCER", 354, 369], ["degenerate PCR primers", "DNA", 90, 112], ["VesiConAR", "DNA", 148, 157], ["VesiConBF-GGNMGRTTYTTYTCHYTDATGTC", "DNA", 180, 213], ["VesiConBR", "DNA", 215, 224], ["TCHGCNGAYTGCATNGTYTCA", "DNA", 225, 246], ["polymerase gene", "DNA", 292, 307], ["ABVV", "DNA", 311, 315], ["ABVV", "SPECIES", 311, 315], ["diverse vesiculoviruses in bats", "PROBLEM", 34, 65], ["degenerate PCR primers", "PROBLEM", 90, 112], ["VesiConAF-KCDGAYAARAGYCAYTCVATGA", "TEST", 114, 146], ["VesiConAR", "TEST", 148, 157], ["mammalian vesiculoviruses", "OBSERVATION", 344, 369]]], ["When the ABVV-positive bat liver cDNA was used as a control, the nested PCR yielded an amplicon of 704 bases, and its sequence was confirmed by cloning and Sanger sequencing.", [["liver", "ANATOMY", 27, 32], ["ABVV", "GENE_OR_GENE_PRODUCT", 9, 13], ["bat", "ORGANISM", 23, 26], ["liver", "ORGAN", 27, 32], ["ABVV-positive bat liver cDNA", "DNA", 9, 37], ["ABVV", "SPECIES", 9, 13], ["the ABVV", "TEST", 5, 13], ["the nested PCR", "TEST", 61, 75], ["its sequence", "TEST", 114, 126], ["Sanger sequencing", "TEST", 156, 173], ["liver", "ANATOMY", 27, 32]]], ["Future studies may use these pan-vesiculovirus PCR primers to investigate vesiculovirus diversity in other bat species and in other regions.ConclusionsBig brown bats are prevalent in North America, where their geographic range overlaps extensively with that of humans, and considerable interactions occur between big brown bats and humans and their pets.", [["Big brown bats", "ORGANISM", 151, 165], ["humans", "ORGANISM", 261, 267], ["brown bats", "ORGANISM", 317, 327], ["humans", "ORGANISM", 332, 338], ["pan-vesiculovirus PCR primers", "DNA", 29, 58], ["humans", "SPECIES", 261, 267], ["humans", "SPECIES", 332, 338], ["brown bats", "SPECIES", 155, 165], ["humans", "SPECIES", 261, 267], ["brown bats", "SPECIES", 317, 327], ["humans", "SPECIES", 332, 338], ["Future studies", "TEST", 0, 14], ["these pan-vesiculovirus PCR primers", "TEST", 23, 58], ["vesiculovirus diversity in other bat species", "PROBLEM", 74, 118], ["Big brown bats", "PROBLEM", 151, 165], ["brown bats", "OBSERVATION", 155, 165]]], ["Big brown bats from this region are a known reservoir of rabies virus; our analysis shows that these bats also constitute a sylvatic mammalian reservoir of vesiculoviruses.ConclusionsThe characterization of ABVV sheds light on vesiculovirus diversity in bats.", [["vesiculoviruses", "ANATOMY", 156, 171], ["rabies virus", "DISEASE", 57, 69], ["brown bats", "ORGANISM", 4, 14], ["rabies virus", "ORGANISM", 57, 69], ["bats", "ORGANISM", 101, 105], ["vesiculoviruses", "CANCER", 156, 171], ["ABVV", "ORGANISM", 207, 211], ["vesiculovirus", "GENE_OR_GENE_PRODUCT", 227, 240], ["bats", "ORGANISM", 254, 258], ["ABVV", "PROTEIN", 207, 211], ["rabies virus", "SPECIES", 57, 69], ["Big brown bats", "SPECIES", 0, 14], ["rabies virus", "SPECIES", 57, 69], ["ABVV", "SPECIES", 207, 211], ["Big brown bats from this region", "PROBLEM", 0, 31], ["rabies virus", "PROBLEM", 57, 69], ["our analysis", "TEST", 71, 83], ["a sylvatic mammalian reservoir of vesiculoviruses", "PROBLEM", 122, 171], ["brown bats", "OBSERVATION", 4, 14], ["reservoir", "OBSERVATION_MODIFIER", 44, 53], ["rabies virus", "OBSERVATION", 57, 69], ["sylvatic mammalian reservoir", "OBSERVATION", 124, 152]]], ["The other bat rhabdoviruses\u2014Mount Elgon bat virus, Oita rhabdovirus, and Kern Canyon virus\u2014do not belong to the vesiculovirus clade but cluster together in a separate clade (14) (Figure, panel B).", [["Elgon bat virus", "ORGANISM", 34, 49], ["Oita rhabdovirus", "ORGANISM", 51, 67], ["Elgon bat virus", "SPECIES", 34, 49], ["Elgon bat virus", "SPECIES", 34, 49], ["Oita rhabdovirus", "SPECIES", 51, 67], ["Kern Canyon virus\u2014do", "SPECIES", 73, 93], ["Mount Elgon bat virus", "PROBLEM", 28, 49], ["Oita rhabdovirus", "PROBLEM", 51, 67], ["rhabdoviruses", "OBSERVATION", 14, 27]]], ["A recent report described several rhabdoviruses in oropharyngeal swab specimens from Spanish bats, but the short reads (100 bases) precluded a detailed phylogenetic analysis (15).", [["oropharyngeal swab specimens", "ANATOMY", 51, 79], ["oropharyngeal swab specimens", "CANCER", 51, 79], ["several rhabdoviruses", "PROBLEM", 26, 47], ["oropharyngeal swab specimens", "TEST", 51, 79], ["a detailed phylogenetic analysis", "TEST", 141, 173], ["several", "OBSERVATION_MODIFIER", 26, 33], ["rhabdoviruses", "OBSERVATION", 34, 47], ["oropharyngeal", "ANATOMY", 51, 64]]], ["Of the bats tested in our study, 5% were infected with ABVV, a finding that suggests vesiculoviruses are prevalent in bats.", [["ABVV", "GENE_OR_GENE_PRODUCT", 55, 59], ["vesiculoviruses", "GENE_OR_GENE_PRODUCT", 85, 100], ["bats", "ORGANISM", 118, 122], ["ABVV", "SPECIES", 55, 59], ["our study", "TEST", 22, 31], ["vesiculoviruses", "PROBLEM", 85, 100]]], ["The characterization of a novel rhabdovirus in bats with a history of human contact raises questions for further research, including health effects on the virus\u2019 hosts, seroprevalence, possible transmission by insect vectors, and the extent of zoonotic exposure in humans.", [["rhabdovirus", "CANCER", 32, 43], ["bats", "ORGANISM", 47, 51], ["human", "ORGANISM", 70, 75], ["humans", "ORGANISM", 265, 271], ["human", "SPECIES", 70, 75], ["humans", "SPECIES", 265, 271], ["human", "SPECIES", 70, 75], ["humans", "SPECIES", 265, 271], ["a novel rhabdovirus", "PROBLEM", 24, 43], ["the virus\u2019 hosts", "TREATMENT", 151, 167], ["zoonotic exposure in humans", "PROBLEM", 244, 271], ["rhabdovirus", "OBSERVATION", 32, 43], ["zoonotic exposure", "OBSERVATION", 244, 261]]], ["ABVV-specific and vesiculovirus-consensus PCRs, as well as future endeavors to culture this virus, will help address these questions.", [["ABVV", "GENE_OR_GENE_PRODUCT", 0, 4], ["vesiculovirus", "GENE_OR_GENE_PRODUCT", 18, 31], ["ABVV-specific and vesiculovirus-consensus PCRs", "DNA", 0, 46], ["ABVV", "SPECIES", 0, 4], ["ABVV", "TEST", 0, 4], ["vesiculovirus", "TEST", 18, 31], ["consensus PCRs", "TEST", 32, 46]]]], "PMC3325917": [["IntroductionThe caliciviruses are a family of small non-enveloped viruses, and can be classified into five genera: Vesivirus, Lagovirus, Norovirus, Sapovirus and Nebovirus.", [["Norovirus", "DISEASE", 137, 146], ["caliciviruses", "GENE_OR_GENE_PRODUCT", 16, 29], ["Vesivirus", "GENE_OR_GENE_PRODUCT", 115, 124], ["Norovirus", "ORGANISM", 137, 146], ["small non-enveloped viruses", "PROBLEM", 46, 73], ["Vesivirus", "TREATMENT", 115, 124], ["Lagovirus", "TREATMENT", 126, 135], ["Norovirus", "PROBLEM", 137, 146], ["Sapovirus", "PROBLEM", 148, 157], ["Nebovirus", "TREATMENT", 162, 171], ["caliciviruses", "OBSERVATION", 16, 29], ["small", "OBSERVATION_MODIFIER", 46, 51], ["non-enveloped", "OBSERVATION_MODIFIER", 52, 65], ["viruses", "OBSERVATION", 66, 73], ["Sapovirus", "OBSERVATION", 148, 157]]], ["They possess a non-segmented, polyadenylated, positive-sense ssRNA genome of about 7.5 to 8.5 kb in length, enclosed in an icosahedral capsid of 27 to 40 nm in diameter.", [["ssRNA genome", "DNA", 61, 73], ["a non-segmented, polyadenylated, positive-sense ssRNA genome", "PROBLEM", 13, 73], ["length", "TEST", 100, 106], ["an icosahedral capsid", "TREATMENT", 120, 141], ["ssRNA genome", "OBSERVATION", 61, 73], ["length", "OBSERVATION_MODIFIER", 100, 106], ["icosahedral", "ANATOMY_MODIFIER", 123, 134], ["capsid", "ANATOMY_MODIFIER", 135, 141], ["27 to 40 nm", "OBSERVATION_MODIFIER", 145, 156], ["diameter", "OBSERVATION_MODIFIER", 160, 168]]], ["Among them, noroviruses and sapoviruses (SaVs) are well known to cause enteric disease in a range of mammals, including humans, while vesiviruses and lagoviruses cause systemic diseases in specific animal hosts.", [["enteric disease", "DISEASE", 71, 86], ["lagoviruses", "DISEASE", 150, 161], ["systemic diseases", "DISEASE", 168, 185], ["noroviruses", "ORGANISM", 12, 23], ["sapoviruses", "GENE_OR_GENE_PRODUCT", 28, 39], ["SaVs", "GENE_OR_GENE_PRODUCT", 41, 45], ["humans", "ORGANISM", 120, 126], ["humans", "SPECIES", 120, 126], ["humans", "SPECIES", 120, 126], ["noroviruses", "PROBLEM", 12, 23], ["sapoviruses", "PROBLEM", 28, 39], ["enteric disease", "PROBLEM", 71, 86], ["vesiviruses", "TREATMENT", 134, 145], ["lagoviruses", "TREATMENT", 150, 161], ["systemic diseases", "PROBLEM", 168, 185], ["noroviruses", "OBSERVATION", 12, 23], ["disease", "OBSERVATION", 79, 86], ["systemic", "OBSERVATION_MODIFIER", 168, 176], ["diseases", "OBSERVATION", 177, 185]]], ["Nebovirus is the most recently established genus in the family Caliciviridae[1], and its members are associated with enteric diseases in cattle [2], [3].", [["Nebovirus", "CHEMICAL", 0, 9], ["enteric diseases", "DISEASE", 117, 133], ["cattle", "SPECIES", 137, 143], ["Nebovirus", "SPECIES", 0, 9], ["cattle", "SPECIES", 137, 143], ["Nebovirus", "TREATMENT", 0, 9], ["enteric diseases", "PROBLEM", 117, 133]]], ["A putative sixth genus, Recovirus, has been proposed for a novel calicivirus detected in stool specimens from rhesus monkeys [4], [5].", [["stool specimens", "ANATOMY", 89, 104], ["calicivirus", "DISEASE", 65, 76], ["calicivirus", "ORGANISM", 65, 76], ["stool specimens", "ORGANISM_SUBSTANCE", 89, 104], ["rhesus monkeys", "ORGANISM", 110, 124], ["rhesus monkeys", "SPECIES", 110, 124], ["rhesus monkeys", "SPECIES", 110, 124], ["a novel calicivirus", "PROBLEM", 57, 76], ["stool specimens", "TEST", 89, 104], ["sixth genus", "ANATOMY", 11, 22]]], ["Another new genus, Valovirus, has been proposed for a novel group of swine caliciviruses known as the St-Val\u00e9rien-like viruses [6].", [["swine caliciviruses", "DISEASE", 69, 88], ["swine caliciviruses", "ORGANISM", 69, 88], ["St-Val\u00e9rien-like viruses", "ORGANISM", 102, 126], ["swine", "SPECIES", 69, 74], ["swine caliciviruses", "SPECIES", 69, 88], ["Another new genus, Valovirus", "PROBLEM", 0, 28], ["swine caliciviruses", "PROBLEM", 69, 88], ["new", "OBSERVATION_MODIFIER", 8, 11], ["genus", "OBSERVATION", 12, 17], ["viruses", "OBSERVATION", 119, 126]]], ["In addition, there exist other unclassified caliciviruses, such as the recently described chicken calicivirus [7].IntroductionThe genus Sapovirus currently contains only one recognized species, the Sapporo virus, which was discovered in 1977 in Sapporo, Japan [8].", [["chicken calicivirus", "DISEASE", 90, 109], ["caliciviruses", "CANCER", 44, 57], ["chicken calicivirus", "ORGANISM", 90, 109], ["Sapporo virus", "ORGANISM", 198, 211], ["chicken calicivirus", "SPECIES", 90, 109], ["chicken calicivirus", "SPECIES", 90, 109], ["Sapporo virus", "SPECIES", 198, 211], ["other unclassified caliciviruses", "PROBLEM", 25, 57], ["the recently described chicken calicivirus", "PROBLEM", 67, 109], ["The genus Sapovirus", "PROBLEM", 126, 145], ["the Sapporo virus", "PROBLEM", 194, 211], ["unclassified", "OBSERVATION_MODIFIER", 31, 43], ["caliciviruses", "OBSERVATION", 44, 57], ["calicivirus", "OBSERVATION", 98, 109], ["genus Sapovirus", "OBSERVATION", 130, 145]]], ["The SaV genome is approximately 7.1 to 7.5 kb in length, and may have two or three ORFs.", [["SaV", "GENE_OR_GENE_PRODUCT", 4, 7], ["SaV genome", "DNA", 4, 14], ["ORFs", "DNA", 83, 87], ["length", "TEST", 49, 55], ["SaV genome", "OBSERVATION", 4, 14], ["approximately", "OBSERVATION_MODIFIER", 18, 31], ["7.1 to 7.5 kb", "OBSERVATION_MODIFIER", 32, 45]]], ["ORF1 encodes a polyprotein that undergoes proteolytic cleavage to form the non-structural proteins and the major capsid protein VP1.", [["ORF1", "GENE_OR_GENE_PRODUCT", 0, 4], ["VP1", "GENE_OR_GENE_PRODUCT", 128, 131], ["ORF1", "DNA", 0, 4], ["non-structural proteins", "PROTEIN", 75, 98], ["major capsid protein VP1", "PROTEIN", 107, 131], ["a polyprotein", "PROBLEM", 13, 26], ["proteolytic cleavage", "TREATMENT", 42, 62], ["the non-structural proteins", "PROBLEM", 71, 98], ["the major capsid protein VP1", "PROBLEM", 103, 131], ["protein VP1", "OBSERVATION", 120, 131]]], ["ORF2 encodes the minor structural protein VP2.", [["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["VP2", "GENE_OR_GENE_PRODUCT", 42, 45], ["ORF2", "DNA", 0, 4], ["minor structural protein VP2", "PROTEIN", 17, 45], ["protein VP2", "OBSERVATION", 34, 45]]], ["ORF3 encodes a small basic protein of unknown function [9], [10].", [["ORF3", "GENE_OR_GENE_PRODUCT", 0, 4], ["ORF3", "DNA", 0, 4], ["small basic protein", "PROTEIN", 15, 34], ["a small basic protein", "TEST", 13, 34], ["small", "OBSERVATION_MODIFIER", 15, 20]]], ["Interestingly, it is located in an overlapping reading frame within ORF1, and is present only in SaVs from selected genogroups.", [["ORF1", "GENE_OR_GENE_PRODUCT", 68, 72], ["SaVs", "GENE_OR_GENE_PRODUCT", 97, 101], ["overlapping reading frame", "DNA", 35, 60], ["ORF1", "DNA", 68, 72], ["SaVs", "DNA", 97, 101], ["ORF1", "OBSERVATION_MODIFIER", 68, 72]]], ["At present, SaVs are classified formally into 5 genogroups based on phylogenetic analysis of the full-length VP1 sequence, though additional genogroups have been proposed to accommodate some novel SaVs discovered in recent years.", [["SaVs", "GENE_OR_GENE_PRODUCT", 12, 16], ["VP1", "ORGANISM", 109, 112], ["SaVs", "CANCER", 197, 201], ["SaVs", "PROTEIN", 12, 16], ["full-length VP1 sequence", "DNA", 97, 121], ["SaVs", "PROTEIN", 197, 201], ["phylogenetic analysis", "TEST", 68, 89], ["the full-length VP1 sequence", "TEST", 93, 121], ["additional genogroups", "PROBLEM", 130, 151]]], ["Further classification of SaVs into genotypes has also been undertaken, though taxonomic assignment at the genotype level appears to be less well-defined than at the genogroup level [11].IntroductionAs mentioned above, both noroviruses and SaVs generally cause mild to asymptomatic enteric infections in human and animal hosts [12].", [["noroviruses", "DISEASE", 224, 235], ["enteric infections", "DISEASE", 282, 300], ["SaVs", "GENE_OR_GENE_PRODUCT", 26, 30], ["SaVs", "GENE_OR_GENE_PRODUCT", 240, 244], ["human", "ORGANISM", 304, 309], ["SaVs", "DNA", 26, 30], ["human", "SPECIES", 304, 309], ["human", "SPECIES", 304, 309], ["SaVs into genotypes", "PROBLEM", 26, 45], ["taxonomic assignment", "TEST", 79, 99], ["IntroductionAs", "TREATMENT", 187, 201], ["mild to asymptomatic enteric infections in human", "PROBLEM", 261, 309], ["appears to be", "UNCERTAINTY", 122, 135], ["less", "OBSERVATION_MODIFIER", 136, 140], ["noroviruses", "OBSERVATION", 224, 235], ["mild", "OBSERVATION_MODIFIER", 261, 265], ["asymptomatic", "OBSERVATION_MODIFIER", 269, 281], ["enteric", "OBSERVATION_MODIFIER", 282, 289], ["infections", "OBSERVATION", 290, 300]]], ["Human SaV infections are reported to be similar to or milder than human norovirus infections, but SaV infections have a shorter duration of viral shedding and are less associated with projectile vomiting [13]\u2013[16].", [["SaV infections", "DISEASE", 6, 20], ["norovirus infections", "DISEASE", 72, 92], ["infections", "DISEASE", 102, 112], ["vomiting", "DISEASE", 195, 203], ["Human", "ORGANISM", 0, 5], ["SaV", "GENE_OR_GENE_PRODUCT", 6, 9], ["human", "ORGANISM", 66, 71], ["SaV infections", "ORGANISM", 98, 112], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 66, 71], ["Human SaV", "SPECIES", 0, 9], ["human norovirus", "SPECIES", 66, 81], ["SaV", "SPECIES", 98, 101], ["Human SaV infections", "PROBLEM", 0, 20], ["human norovirus infections", "PROBLEM", 66, 92], ["SaV infections", "PROBLEM", 98, 112], ["viral shedding", "PROBLEM", 140, 154], ["projectile vomiting", "PROBLEM", 184, 203], ["infections", "OBSERVATION", 10, 20], ["norovirus", "OBSERVATION", 72, 81]]], ["Incidence of SaV-associated gastroenteritis infections remains less than norovirus-associated infections for both sporadic and outbreak settings, though various studies have reported increasing rates of SaV infections around the world [17]\u2013[21].", [["SaV", "CHEMICAL", 13, 16], ["gastroenteritis infections", "DISEASE", 28, 54], ["norovirus", "DISEASE", 73, 82], ["infections", "DISEASE", 94, 104], ["infections", "DISEASE", 207, 217], ["SaV", "ORGANISM", 13, 16], ["SaV", "SPECIES", 203, 206], ["SaV-associated gastroenteritis infections", "PROBLEM", 13, 54], ["norovirus", "PROBLEM", 73, 82], ["associated infections", "PROBLEM", 83, 104], ["various studies", "TEST", 153, 168], ["SaV infections", "PROBLEM", 203, 217], ["SaV", "OBSERVATION", 13, 16], ["gastroenteritis", "OBSERVATION_MODIFIER", 28, 43], ["infections", "OBSERVATION", 44, 54], ["infections", "OBSERVATION", 94, 104], ["SaV infections", "OBSERVATION", 203, 217]]], ["The genetic diversity of SaVs is comparable to that of noroviruses, and the diversity of reported animal hosts is also similar.", [["noroviruses", "DISEASE", 55, 66], ["SaVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["SaVs", "PROTEIN", 25, 29], ["noroviruses", "PROBLEM", 55, 66], ["diversity", "OBSERVATION_MODIFIER", 12, 21], ["noroviruses", "OBSERVATION", 55, 66], ["animal hosts", "OBSERVATION", 98, 110], ["similar", "OBSERVATION_MODIFIER", 119, 126]]], ["Noroviruses have been discovered in specimens from humans, pigs, cattle, dogs, sea lions, African lion, and mice [22]\u2013[25].", [["specimens", "ANATOMY", 36, 45], ["Noroviruses", "GENE_OR_GENE_PRODUCT", 0, 11], ["specimens", "CANCER", 36, 45], ["humans", "ORGANISM", 51, 57], ["pigs", "ORGANISM", 59, 63], ["cattle", "ORGANISM", 65, 71], ["dogs", "ORGANISM", 73, 77], ["sea lions", "ORGANISM", 79, 88], ["African lion", "ORGANISM", 90, 102], ["mice", "ORGANISM", 108, 112], ["humans", "SPECIES", 51, 57], ["pigs", "SPECIES", 59, 63], ["cattle", "SPECIES", 65, 71], ["dogs", "SPECIES", 73, 77], ["mice", "SPECIES", 108, 112], ["humans", "SPECIES", 51, 57], ["pigs", "SPECIES", 59, 63], ["cattle", "SPECIES", 65, 71], ["mice", "SPECIES", 108, 112], ["Noroviruses", "PROBLEM", 0, 11]]], ["In comparison, SaVs have been found in specimens from humans, pigs, dogs, minks and California sea lions [23], [25]\u2013[27].IntroductionBats (order Chiroptera of class Mammalia) constitute a significant portion of biological diversity in many ecosystems and have a wide geographical distribution [28].", [["specimens", "ANATOMY", 39, 48], ["SaVs", "GENE_OR_GENE_PRODUCT", 15, 19], ["specimens", "CANCER", 39, 48], ["humans", "ORGANISM", 54, 60], ["pigs", "ORGANISM", 62, 66], ["dogs", "ORGANISM", 68, 72], ["[25]\u2013[27]", "SIMPLE_CHEMICAL", 111, 120], ["SaVs", "PROTEIN", 15, 19], ["humans", "SPECIES", 54, 60], ["pigs", "SPECIES", 62, 66], ["dogs", "SPECIES", 68, 72], ["humans", "SPECIES", 54, 60], ["pigs", "SPECIES", 62, 66], ["significant", "OBSERVATION_MODIFIER", 188, 199], ["biological diversity", "OBSERVATION", 211, 231]]], ["We have previously discovered novel viruses in several local bat species [29]\u2013[35], and there were many similar discoveries of novel bat viruses by researchers in other parts of the world.", [["bat viruses", "ORGANISM", 133, 144], ["novel viruses", "PROBLEM", 30, 43], ["novel bat viruses", "PROBLEM", 127, 144], ["viruses", "OBSERVATION", 36, 43], ["novel bat viruses", "OBSERVATION", 127, 144]]], ["In particular, important human viral pathogens like the SARS virus, Nipah virus and Ebola virus were found to have originated from bats and contributed to substantial human morbidity and mortality in recent outbreaks.", [["SARS", "DISEASE", 56, 60], ["Nipah virus", "DISEASE", 68, 79], ["Ebola virus", "DISEASE", 84, 95], ["human", "ORGANISM", 25, 30], ["SARS virus", "ORGANISM", 56, 66], ["Nipah virus", "ORGANISM", 68, 79], ["Ebola virus", "ORGANISM", 84, 95], ["human", "ORGANISM", 167, 172], ["human", "SPECIES", 25, 30], ["Nipah virus", "SPECIES", 68, 79], ["Ebola virus", "SPECIES", 84, 95], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 25, 30], ["SARS virus", "SPECIES", 56, 66], ["Nipah virus", "SPECIES", 68, 79], ["Ebola virus", "SPECIES", 84, 95], ["human", "SPECIES", 167, 172], ["important human viral pathogens", "PROBLEM", 15, 46], ["the SARS virus", "PROBLEM", 52, 66], ["Nipah virus", "PROBLEM", 68, 79], ["Ebola virus", "PROBLEM", 84, 95], ["substantial human morbidity", "PROBLEM", 155, 182], ["substantial", "OBSERVATION_MODIFIER", 155, 166], ["human", "OBSERVATION_MODIFIER", 167, 172], ["morbidity", "OBSERVATION", 173, 182]]], ["Taken together, these discoveries hint that these small mammals are important reservoirs of diverse and undiscovered animal viruses, with significant risk of zoonotic transmission to humans [36].IntroductionIn the present study, we investigated the presence of unknown calicivirus diversity in bats by targeted RT-PCR screening.", [["small mammals", "ORGANISM", 50, 63], ["humans", "ORGANISM", 183, 189], ["calicivirus", "ORGANISM", 269, 280], ["humans", "SPECIES", 183, 189], ["humans", "SPECIES", 183, 189], ["undiscovered animal viruses", "PROBLEM", 104, 131], ["the present study", "TEST", 210, 227], ["unknown calicivirus diversity", "PROBLEM", 261, 290], ["PCR screening", "TEST", 314, 327], ["small", "OBSERVATION_MODIFIER", 50, 55], ["diverse", "OBSERVATION_MODIFIER", 92, 99], ["animal viruses", "OBSERVATION", 117, 131], ["calicivirus diversity", "OBSERVATION", 269, 290]]], ["Novel SaV sequences were amplified from several faecal samples of the bat species Hipposideros pomona, and genome sequences were obtained for three strains of the bat SaV.", [["faecal samples", "ANATOMY", 48, 62], ["SaV", "GENE_OR_GENE_PRODUCT", 6, 9], ["Hipposideros pomona", "ORGANISM", 82, 101], ["SaV sequences", "DNA", 6, 19], ["Hipposideros pomona", "SPECIES", 82, 101], ["Hipposideros pomona", "SPECIES", 82, 101], ["Novel SaV sequences", "TEST", 0, 19], ["several faecal samples", "TEST", 40, 62], ["the bat species", "TEST", 66, 81], ["genome sequences", "TEST", 107, 123]]], ["Sequence analysis indicated that the novel virus possesses several genomic features atypical of SaVs, and phylogenetic analysis revealed that it descended from a lineage that had diverged early from other SaV.Surveillance and detection of novel SaVs in bats ::: ResultsA total of 728 anal swabs from different bat species in Hong Kong were obtained.", [["anal swabs", "ANATOMY", 284, 294], ["SaVs", "GENE_OR_GENE_PRODUCT", 96, 100], ["SaVs", "CANCER", 245, 249], ["anal swabs", "MULTI-TISSUE_STRUCTURE", 284, 294], ["SaVs", "DNA", 96, 100], ["Sequence analysis", "TEST", 0, 17], ["the novel virus", "PROBLEM", 33, 48], ["SaVs", "TEST", 96, 100], ["phylogenetic analysis", "TEST", 106, 127], ["Surveillance", "TEST", 209, 221], ["anal swabs", "TEST", 284, 294], ["lineage", "OBSERVATION_MODIFIER", 162, 169]]], ["No obvious signs of enteric disease, like anorexia and diarrhoea, were observed in the bats during the brief period of captivity needed for sampling.Surveillance and detection of novel SaVs in bats ::: ResultsRT-PCR using broadly reactive degenerate primers for a 185 nt fragment in the 3D-like RNA-dependent RNA polymerase (RdRp) region of the calicivirus ORF1 gene was positive in two specimens.", [["specimens", "ANATOMY", 387, 396], ["enteric disease", "DISEASE", 20, 35], ["anorexia", "DISEASE", 42, 50], ["diarrhoea", "DISEASE", 55, 64], ["SaVs", "CANCER", 185, 189], ["calicivirus", "ORGANISM", 345, 356], ["ORF1", "GENE_OR_GENE_PRODUCT", 357, 361], ["185 nt fragment", "DNA", 264, 279], ["3D-like RNA-dependent RNA polymerase (RdRp) region", "DNA", 287, 337], ["calicivirus ORF1 gene", "DNA", 345, 366], ["enteric disease", "PROBLEM", 20, 35], ["anorexia", "PROBLEM", 42, 50], ["diarrhoea", "PROBLEM", 55, 64], ["sampling", "TEST", 140, 148], ["Surveillance", "TEST", 149, 161], ["ResultsRT", "TEST", 202, 211], ["PCR", "TEST", 212, 215], ["broadly reactive degenerate primers", "PROBLEM", 222, 257], ["a 185 nt fragment", "PROBLEM", 262, 279], ["the 3D", "TEST", 283, 289], ["dependent RNA polymerase", "PROBLEM", 299, 323], ["the calicivirus ORF1 gene", "TEST", 341, 366], ["obvious signs of", "UNCERTAINTY", 3, 19], ["enteric disease", "OBSERVATION", 20, 35], ["anorexia", "OBSERVATION", 42, 50], ["diarrhoea", "OBSERVATION", 55, 64], ["reactive degenerate primers", "OBSERVATION", 230, 257], ["RNA polymerase", "OBSERVATION", 309, 323], ["calicivirus ORF1", "OBSERVATION", 345, 361]]], ["Repeated screening using more sensitive specific primers revealed three additional positive specimens.", [["specimens", "ANATOMY", 92, 101], ["Repeated screening", "TEST", 0, 18], ["three additional positive specimens", "PROBLEM", 66, 101], ["positive specimens", "OBSERVATION", 83, 101]]], ["Further information on the species and RT-PCR screening results are presented in Table 1, Table S1 and Figure S1.", [["the species", "TEST", 23, 34], ["RT-PCR screening", "TEST", 39, 55], ["S1", "ANATOMY", 96, 98], ["S1", "ANATOMY", 110, 112]]], ["Sequence similarity search using BLASTN against the NCBI non-redundant nucleotide database did not reveal significant similarity to known SaV sequences.", [["SaV", "GENE_OR_GENE_PRODUCT", 138, 141], ["NCBI non-redundant nucleotide database", "DNA", 52, 90], ["SaV sequences", "DNA", 138, 151], ["the NCBI non-redundant nucleotide database", "TEST", 48, 90]]], ["Another search using BLASTX against the NCBI non-redundant protein database produced hits to SaV sequences, with the most closely related sequence being the RdRp sequence of porcine SaV (GenBank accession number ACT98315) at 43% aa identity.", [["SaV", "GENE_OR_GENE_PRODUCT", 93, 96], ["porcine", "ORGANISM", 174, 181], ["SaV", "GENE_OR_GENE_PRODUCT", 182, 185], ["BLASTX", "DNA", 21, 27], ["NCBI non-redundant protein database", "DNA", 40, 75], ["SaV sequences", "DNA", 93, 106], ["RdRp sequence", "DNA", 157, 170], ["porcine SaV", "DNA", 174, 185], ["porcine", "SPECIES", 174, 181]]], ["A phylogenetic tree was constructed from the nucleotide alignment based on the length of the partial RdRp sequence obtained from bat SaV/TLC72 (GenBank accession number JQ267527) (Figure S2).Genome sequencing and analysis of novel bat SaVs ::: ResultsComplete or nearly full-length genome sequences (with incomplete 5\u2032 ends) were obtained for three positive samples using the sequencing strategy as described in the Methods section.", [["samples", "ANATOMY", 358, 365], ["nucleotide", "CHEMICAL", 45, 55], ["nucleotide", "CHEMICAL", 45, 55], ["bat", "ORGANISM", 231, 234], ["partial RdRp sequence", "DNA", 93, 114], ["SaV", "PROTEIN", 133, 136], ["TLC72", "DNA", 137, 142], ["SaVs", "PROTEIN", 235, 239], ["ResultsComplete or nearly full-length genome sequences", "DNA", 244, 298], ["the partial RdRp sequence", "TEST", 89, 114], ["Genome sequencing", "TEST", 191, 208], ["the sequencing strategy", "TREATMENT", 372, 395], ["phylogenetic tree", "OBSERVATION", 2, 19], ["nucleotide alignment", "OBSERVATION", 45, 65]]], ["For two of the samples that were positive only for RT-PCR screening with specific primers, only sequences for short segments of the viral genome were obtained.", [["samples", "ANATOMY", 15, 22], ["viral genome", "DNA", 132, 144], ["the samples", "TEST", 11, 22], ["RT-PCR screening", "TEST", 51, 67], ["specific primers", "TEST", 73, 89], ["short segments of the viral genome", "PROBLEM", 110, 144], ["viral genome", "OBSERVATION", 132, 144]]], ["Additional viral genome sequencing on these samples was unsuccessful due to limited clinical materials available and possibly low viral titres.", [["samples", "ANATOMY", 44, 51], ["samples", "CANCER", 44, 51], ["Additional viral genome sequencing", "PROBLEM", 0, 34], ["these samples", "TEST", 38, 51], ["limited clinical materials", "PROBLEM", 76, 102], ["low viral titres", "PROBLEM", 126, 142], ["viral genome", "OBSERVATION", 11, 23]]], ["The complete genome of bat SaV strain TLC58 (Genbank accession number JN899075) is 7696 nt in length and has a genomic G+C content of 60.2 mol%.", [["bat SaV strain TLC58", "ORGANISM", 23, 43], ["G+C", "GENE_OR_GENE_PRODUCT", 119, 122], ["TLC58", "DNA", 38, 43], ["a genomic G", "TEST", 109, 120], ["bat SaV strain", "OBSERVATION", 23, 37]]], ["Both the length and G+C content of the bat SaV genome are significantly higher than that of other known SaVs (Table 2).", [["G+C", "CHEMICAL", 20, 23], ["SaV", "GENE_OR_GENE_PRODUCT", 43, 46], ["bat SaV genome", "DNA", 39, 53], ["SaVs", "PROTEIN", 104, 108], ["G+C content", "TEST", 20, 31], ["length", "OBSERVATION_MODIFIER", 9, 15], ["G+C content", "OBSERVATION", 20, 31], ["bat", "OBSERVATION_MODIFIER", 39, 42], ["SaV genome", "OBSERVATION", 43, 53], ["significantly", "OBSERVATION_MODIFIER", 58, 71], ["higher", "OBSERVATION_MODIFIER", 72, 78]]], ["Each genome is predicted to contain 3 overlapping ORFs, comparable to the genome organization of SaVs in GI, GIV and GV (Figure 1).", [["GI", "ANATOMY", 105, 107], ["SaVs", "GENE_OR_GENE_PRODUCT", 97, 101], ["ORFs", "DNA", 50, 54], ["SaVs", "DNA", 97, 101], ["3 overlapping ORFs", "PROBLEM", 36, 54], ["GI", "ANATOMY", 105, 107]]], ["The 5\u2032-UTR and the 3\u2032-UTR are 9 nt and 225 nt in length, respectively.", [["5\u2032-UTR", "DNA", 4, 10], ["3\u2032-UTR", "DNA", 19, 25], ["the 3\u2032-UTR", "TREATMENT", 15, 25]]], ["The length of the 3\u2032-UTR is considerably longer than other SaVs (Table 2).", [["3\u2032-UTR", "DNA", 18, 24], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["The two other nearly full-length bat SaV genomes were found to be highly similar to that of the complete bat SaV/TLC58 genome in nucleotide sequence and genome organization, and were not analysed separately.Genome sequencing and analysis of novel bat SaVs ::: ResultsThe complete ORF1 is 6855 nt long, and encodes a large precursor polyprotein with an estimated molecular mass of 246.8 kDa.", [["nucleotide", "CHEMICAL", 129, 139], ["bat", "ORGANISM", 33, 36], ["SaV", "GENE_OR_GENE_PRODUCT", 37, 40], ["SaV", "GENE_OR_GENE_PRODUCT", 109, 112], ["TLC58", "GENE_OR_GENE_PRODUCT", 113, 118], ["bat", "ORGANISM", 247, 250], ["ORF1", "GENE_OR_GENE_PRODUCT", 280, 284], ["SaV genomes", "DNA", 37, 48], ["SaV", "DNA", 109, 112], ["TLC58 genome", "DNA", 113, 125], ["SaVs", "PROTEIN", 251, 255], ["ORF1", "DNA", 280, 284], ["6855 nt long", "DNA", 288, 300], ["nucleotide sequence", "TEST", 129, 148], ["Genome sequencing", "TEST", 207, 224], ["The complete ORF1", "TEST", 267, 284], ["a large precursor polyprotein", "PROBLEM", 314, 343], ["an estimated molecular mass", "PROBLEM", 349, 376], ["nearly", "OBSERVATION_MODIFIER", 14, 20], ["full", "OBSERVATION_MODIFIER", 21, 25], ["SaV genomes", "OBSERVATION", 37, 48], ["TLC58 genome", "OBSERVATION", 113, 125], ["large", "OBSERVATION_MODIFIER", 316, 321], ["precursor polyprotein", "OBSERVATION", 322, 343], ["mass", "OBSERVATION", 372, 376]]], ["The polyprotein contains characteristic amino acid motifs conserved in caliciviruses: 2C-like NTPase at residue 482 (GPPGIGKT), VPg at residues 958 (KGKTK) and 972 (SEYEE), 3C-like protease at residue 1183 (GDCG), 3D-like RNA-dependent RNA polymerase at residues 1520 (GLPSG) and 1568 (YGDD), and VP1 at residue 1867 (PPG).", [["amino acid", "CHEMICAL", 40, 50], ["amino acid", "CHEMICAL", 40, 50], ["amino acid", "AMINO_ACID", 40, 50], ["caliciviruses: 2C-like NTPase", "GENE_OR_GENE_PRODUCT", 71, 100], ["residue 482", "AMINO_ACID", 104, 115], ["GPPGIGKT", "GENE_OR_GENE_PRODUCT", 117, 125], ["amino acid motifs", "PROTEIN", 40, 57], ["caliciviruses: 2C-like NTPase", "PROTEIN", 71, 100], ["residue 482", "PROTEIN", 104, 115], ["GPPGIGKT", "PROTEIN", 117, 125], ["VPg", "PROTEIN", 128, 131], ["residues 958 (KGKTK) and 972 (SEYEE), 3C-like protease", "PROTEIN", 135, 189], ["3D-like RNA-dependent RNA polymerase", "PROTEIN", 214, 250], ["YGDD", "PROTEIN", 286, 290], ["VP1", "PROTEIN", 297, 300], ["PPG", "PROTEIN", 318, 321], ["The polyprotein", "TREATMENT", 0, 15], ["characteristic amino acid motifs", "TREATMENT", 25, 57], ["NTPase at residue", "TEST", 94, 111], ["VPg at residues", "TEST", 128, 143], ["KGKTK", "TEST", 149, 154], ["SEYEE", "TEST", 165, 170], ["3C", "TEST", 173, 175], ["protease at residue", "TEST", 181, 200], ["GDCG", "TEST", 207, 211], ["3D", "TEST", 214, 216], ["dependent RNA polymerase", "PROBLEM", 226, 250], ["VP1 at residue", "PROBLEM", 297, 311], ["amino acid", "OBSERVATION", 40, 50]]], ["It undergoes proteolytic processing to produce the nonstructural viral proteins and the major capsid protein VP1.", [["VP1", "GENE_OR_GENE_PRODUCT", 109, 112], ["nonstructural viral proteins", "PROTEIN", 51, 79], ["major capsid protein VP1", "PROTEIN", 88, 112], ["proteolytic processing", "PROBLEM", 13, 35], ["the nonstructural viral proteins", "PROBLEM", 47, 79], ["the major capsid protein VP1", "PROBLEM", 84, 112], ["nonstructural viral proteins", "OBSERVATION", 51, 79], ["protein VP1", "OBSERVATION", 101, 112]]], ["Based on comparison with the ORF1 cleavage map of SaV/Mc10 [37], [38], a human SaV GII strain, we predicted the cleavage site that generates the major capsid protein to be located between residues 1740 (E) and 1741 (G).", [["SaV", "GENE_OR_GENE_PRODUCT", 50, 53], ["human", "ORGANISM", 73, 78], ["SaV GII", "ORGANISM", 79, 86], ["ORF1", "DNA", 29, 33], ["SaV", "PROTEIN", 50, 53], ["major capsid protein", "PROTEIN", 145, 165], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["the ORF1 cleavage map", "TEST", 25, 46], ["SaV/Mc10", "TEST", 50, 58], ["a human SaV GII strain", "PROBLEM", 71, 93], ["the cleavage site", "PROBLEM", 108, 125]]], ["An in-frame AUG start codon is located in a favourable context for translation initiation (GUGUUUGUGAUGGA) just upstream to the cleavage site, which has also been reported in other caliciviruses [6], [39].", [["AUG start codon", "DNA", 12, 27], ["GUGUUUGUGAUGGA", "DNA", 91, 105], ["cleavage site", "DNA", 128, 141], ["translation initiation (GUGUUUGUGAUGGA)", "TREATMENT", 67, 106]]], ["This sequence is noted to be similar to the 5\u2032 UTR of the genome, and it was postulated that the site might permit internal translation initiation from subgenomic RNA [39].", [["5\u2032 UTR", "DNA", 44, 50], ["subgenomic RNA", "RNA", 152, 166], ["subgenomic RNA", "PROBLEM", 152, 166]]], ["The sequence identities of the bat SaV/TLC58 with other SaVs in the complete ORF1 protein sequence vary between 36.0% and 37.4% (Table 3).", [["bat", "ORGANISM", 31, 34], ["SaV", "GENE_OR_GENE_PRODUCT", 35, 38], ["TLC58", "GENE_OR_GENE_PRODUCT", 39, 44], ["SaVs", "GENE_OR_GENE_PRODUCT", 56, 60], ["SaV", "PROTEIN", 35, 38], ["TLC58", "PROTEIN", 39, 44], ["SaVs", "DNA", 56, 60], ["ORF1 protein sequence", "DNA", 77, 98], ["the complete ORF1 protein sequence", "TEST", 64, 98], ["bat SaV", "OBSERVATION", 31, 38]]], ["While comparison with caliciviruses of other genera, the ORF1 sequence identities are overall lower (15.6%\u201322.8%) than those between different SaVs (Table S2).", [["ORF1 sequence", "DNA", 57, 70], ["SaVs", "DNA", 143, 147], ["the ORF1 sequence identities", "TEST", 53, 81], ["overall", "OBSERVATION_MODIFIER", 86, 93], ["lower", "OBSERVATION_MODIFIER", 94, 99]]], ["For individual alignment of protease \u2013 polymerase, sequence identities with other SaVs (45.3%\u201348.4%) are overall higher than those with other genera (22.7%\u201332.1%) (Table 3 and Table S2).", [["protease \u2013 polymerase", "PROTEIN", 28, 49], ["protease \u2013 polymerase", "TEST", 28, 49], ["other SaVs", "TEST", 76, 86], ["other genera", "TEST", 136, 148], ["higher", "OBSERVATION_MODIFIER", 113, 119]]], ["The VP1 is predicted to be 546 aa long, and has a molecular mass of 56.6 kDa.", [["VP1", "GENE_OR_GENE_PRODUCT", 4, 7], ["VP1", "DNA", 4, 7], ["The VP1", "TEST", 0, 7], ["a molecular mass", "PROBLEM", 48, 64], ["VP1", "ANATOMY", 4, 7], ["molecular", "OBSERVATION_MODIFIER", 50, 59], ["mass", "OBSERVATION", 60, 64], ["56.6 kDa", "OBSERVATION_MODIFIER", 68, 76]]], ["It shares 36.1% to 39.2% amino acid identities with VP1 of other SaVs (Table 3).", [["amino acid", "CHEMICAL", 25, 35], ["amino acid", "CHEMICAL", 25, 35], ["amino acid", "AMINO_ACID", 25, 35], ["VP1", "PROTEIN", 52, 55], ["SaVs", "PROTEIN", 65, 69], ["amino acid identities", "TEST", 25, 46]]], ["Likewise analysis with caliciviruses of other genera reveals lower similarities with 14.9% to 23.4% sequence identities (Table S2).Genome sequencing and analysis of novel bat SaVs ::: ResultsThe complete ORF2 is 615 nt long, with an overlapping region of 8 nt with the 3\u2032 terminus of ORF1.", [["bat", "ORGANISM", 171, 174], ["ORF2", "GENE_OR_GENE_PRODUCT", 204, 208], ["ORF1", "GENE_OR_GENE_PRODUCT", 284, 288], ["SaVs", "PROTEIN", 175, 179], ["ORF2", "DNA", 204, 208], ["3\u2032 terminus", "DNA", 269, 280], ["ORF1", "DNA", 284, 288], ["Likewise analysis", "TEST", 0, 17], ["caliciviruses of other genera", "TEST", 23, 52], ["Genome sequencing", "TEST", 131, 148], ["The complete ORF2", "TREATMENT", 191, 208], ["lower", "ANATOMY_MODIFIER", 61, 66], ["nt long", "OBSERVATION_MODIFIER", 216, 223], ["8 nt", "OBSERVATION_MODIFIER", 255, 259]]], ["Its reading frame is +1 relative to that of ORF1, unlike most other SaVs (Table 2).", [["ORF1", "GENE_OR_GENE_PRODUCT", 44, 48], ["reading frame", "DNA", 4, 17], ["ORF1", "DNA", 44, 48], ["SaVs", "DNA", 68, 72]]], ["ORF2 encodes the minor structural protein VP2, which has an estimated molecular mass of 21 kDa.", [["ORF2", "GENE_OR_GENE_PRODUCT", 0, 4], ["VP2", "GENE_OR_GENE_PRODUCT", 42, 45], ["ORF2", "DNA", 0, 4], ["minor structural protein VP2", "PROTEIN", 17, 45], ["the minor structural protein VP2", "PROBLEM", 13, 45], ["an estimated molecular mass", "PROBLEM", 57, 84], ["protein VP2", "OBSERVATION", 34, 45], ["molecular", "OBSERVATION_MODIFIER", 70, 79], ["mass", "OBSERVATION", 80, 84], ["21 kDa", "OBSERVATION_MODIFIER", 88, 94]]], ["The mechanism of translation initiation in ORF2 of SaVs has not been fully elucidated.", [["ORF2", "GENE_OR_GENE_PRODUCT", 43, 47], ["SaVs", "GENE_OR_GENE_PRODUCT", 51, 55], ["ORF2", "DNA", 43, 47], ["SaVs", "DNA", 51, 55]]], ["In the present case, a translational upstream ribosome binding site (TURBS) motif (CAUGGGACC; underline indicates region complementary to 18 S ribosomal rRNA sequence) could be identified at 24 nt upstream of the ORF2 start codon.", [["translational upstream ribosome binding site", "DNA", 23, 67], ["TURBS) motif", "DNA", 69, 81], ["CAUGGGACC", "DNA", 83, 92], ["18 S ribosomal rRNA sequence", "DNA", 138, 166], ["ORF2 start codon", "DNA", 213, 229], ["a translational upstream ribosome binding site (TURBS) motif (CAUGGGACC", "TREATMENT", 21, 92], ["ribosomal rRNA sequence", "TEST", 143, 166]]], ["Sequence identities for VP2 with other SaVs vary from 15.5% to 19.9% (Table 3).", [["VP2", "GENE_OR_GENE_PRODUCT", 24, 27], ["VP2", "PROTEIN", 24, 27], ["Sequence identities", "TEST", 0, 19], ["VP2", "TEST", 24, 27], ["other SaVs vary", "TEST", 33, 48]]], ["By comparison with caliciviruses of other genera, sequence identities are generally lower than those between SaVs.", [["SaVs", "GENE_OR_GENE_PRODUCT", 109, 113], ["SaVs", "PROTEIN", 109, 113], ["lower", "OBSERVATION_MODIFIER", 84, 89]]], ["(4.8%\u201312.3%) (Table S2).Phylogenetic and recombination analysis ::: ResultsPhylogenetic trees were constructed using the predicted amino acid sequences of the ORF1 precursor polyprotein (Figure 2), VP1 and VP2 (Figure 3).", [["amino acid", "CHEMICAL", 131, 141], ["amino acid", "CHEMICAL", 131, 141], ["amino acid", "AMINO_ACID", 131, 141], ["ORF1 precursor polyprotein", "PROTEIN", 159, 185], ["VP1", "PROTEIN", 198, 201], ["VP2", "PROTEIN", 206, 209], ["the predicted amino acid sequences", "TREATMENT", 117, 151], ["the ORF1 precursor polyprotein", "TREATMENT", 155, 185], ["VP1", "TEST", 198, 201]]], ["The LG+G+F model was found to be the best-fit substitution model in all cases.", [["The LG+G+F model", "TEST", 0, 16], ["LG", "OBSERVATION_MODIFIER", 4, 6], ["G+F model", "OBSERVATION_MODIFIER", 7, 16]]], ["Phylogenetic analysis was not performed for the putative ORF3 product as no homologous sequences were available.", [["ORF3", "GENE_OR_GENE_PRODUCT", 57, 61], ["ORF3 product", "PROTEIN", 57, 69], ["Phylogenetic analysis", "TEST", 0, 21], ["homologous sequences", "TEST", 76, 96]]], ["Sequence analysis with the Recombination Analysis Tool did not reveal any potential recombination breakpoints in the bat SaV sequences.Phylogenetic and recombination analysis ::: ResultsThere are subtle but important differences in the phylogenetic position of the bat SaV in the three phylogenetic trees.", [["SaV", "GENE_OR_GENE_PRODUCT", 121, 124], ["SaV", "GENE_OR_GENE_PRODUCT", 269, 272], ["bat SaV sequences", "DNA", 117, 134], ["bat SaV", "DNA", 265, 272], ["Sequence analysis", "TEST", 0, 17], ["the Recombination Analysis", "TEST", 23, 49], ["any potential recombination breakpoints", "PROBLEM", 70, 109], ["subtle", "OBSERVATION_MODIFIER", 196, 202]]], ["In the tree based on the full-length amino acid sequences of the ORF1 polyprotein, the bat SaVs are clustered tightly with the porcine SaVs in a monophyletic clade constituting the SaVs.", [["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "AMINO_ACID", 37, 47], ["ORF1", "GENE_OR_GENE_PRODUCT", 65, 69], ["SaVs", "GENE_OR_GENE_PRODUCT", 91, 95], ["porcine", "ORGANISM", 127, 134], ["SaVs", "GENE_OR_GENE_PRODUCT", 135, 139], ["SaVs", "GENE_OR_GENE_PRODUCT", 181, 185], ["ORF1 polyprotein", "DNA", 65, 81], ["SaVs", "PROTEIN", 91, 95], ["porcine SaVs", "DNA", 127, 139], ["SaVs", "DNA", 181, 185], ["the ORF1 polyprotein", "TREATMENT", 61, 81], ["the bat SaVs", "TREATMENT", 83, 95], ["the porcine SaVs", "TREATMENT", 123, 139], ["a monophyletic clade", "TREATMENT", 143, 163], ["tree", "ANATOMY_MODIFIER", 7, 11], ["monophyletic clade", "OBSERVATION", 145, 163]]], ["However, in the VP1 tree, the bat SaVs are positioned just outside the clade of other SaVs.", [["VP1", "ORGANISM", 16, 19], ["SaVs", "GENE_OR_GENE_PRODUCT", 34, 38], ["SaVs", "GENE_OR_GENE_PRODUCT", 86, 90], ["bat SaVs", "DNA", 30, 38], ["SaVs", "DNA", 86, 90], ["the bat SaVs", "TREATMENT", 26, 38], ["VP1", "ANATOMY", 16, 19], ["tree", "ANATOMY_MODIFIER", 20, 24]]], ["In the VP2 tree, the bat SaVs are located approximately equidistant from the GII noroviruses and porcine SaVs.", [["VP2", "GENE_OR_GENE_PRODUCT", 7, 10], ["bat", "ORGANISM", 21, 24], ["SaVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["GII noroviruses", "ORGANISM", 77, 92], ["porcine", "ORGANISM", 97, 104], ["SaVs", "GENE_OR_GENE_PRODUCT", 105, 109], ["bat SaVs", "PROTEIN", 21, 29], ["porcine", "SPECIES", 97, 104], ["VP2", "ANATOMY", 7, 10], ["tree", "ANATOMY_MODIFIER", 11, 15], ["bat", "ANATOMY", 21, 24], ["approximately", "OBSERVATION_MODIFIER", 42, 55], ["equidistant", "OBSERVATION_MODIFIER", 56, 67], ["GII noroviruses", "OBSERVATION", 77, 92]]], ["The phylogenetic positions of the bat SaVs are supported by high Shimodaira-Hasegawa-like approximate likelihood ratio test (SH-like aLRT) branch support values as calculated by PhyML.Phylogenetic and recombination analysis ::: ResultsAlthough the phylogenetic positions of the novel bat virus are slightly divergent in the three trees, they generally show the bat SaV as being most closely related to the SaVs.", [["bat", "ORGANISM", 34, 37], ["SaVs", "GENE_OR_GENE_PRODUCT", 38, 42], ["bat virus", "ORGANISM", 284, 293], ["SaV", "GENE_OR_GENE_PRODUCT", 365, 368], ["SaVs", "GENE_OR_GENE_PRODUCT", 406, 410], ["bat SaVs", "DNA", 34, 42], ["SaV", "PROTEIN", 365, 368], ["SaVs", "DNA", 406, 410], ["bat virus", "SPECIES", 284, 293], ["the novel bat virus", "PROBLEM", 274, 293], ["the bat SaV", "PROBLEM", 357, 368], ["phylogenetic", "OBSERVATION_MODIFIER", 4, 16], ["positions", "OBSERVATION_MODIFIER", 17, 26], ["bat", "ANATOMY", 34, 37], ["phylogenetic positions", "OBSERVATION", 248, 270]]], ["In our opinion, there is insufficient ground for proposing a new genus for the novel virus under the current framework of taxonomic classification.", [["a new genus", "PROBLEM", 59, 70], ["the novel virus", "PROBLEM", 75, 90]]], ["The ORF1 polyprotein and VP1 capsid protein sequences of the novel bat virus showed obvious phylogenetic clustering with other SaV sequences.", [["ORF1", "GENE_OR_GENE_PRODUCT", 4, 8], ["bat virus", "ORGANISM", 67, 76], ["SaV", "GENE_OR_GENE_PRODUCT", 127, 130], ["ORF1 polyprotein and VP1 capsid protein sequences", "DNA", 4, 53], ["SaV sequences", "DNA", 127, 140], ["bat virus", "SPECIES", 67, 76], ["bat virus", "SPECIES", 67, 76], ["The ORF1 polyprotein", "TEST", 0, 20], ["VP1 capsid protein sequences", "TEST", 25, 53], ["the novel bat virus", "TEST", 57, 76]]], ["It should also be noted that the VP2 protein sequences are shorter and more divergent, and therefore are considered to be less useful in the phylogenetic classification of caliciviruses [4].", [["caliciviruses", "DISEASE", 172, 185], ["VP2", "GENE_OR_GENE_PRODUCT", 33, 36], ["VP2 protein sequences", "DNA", 33, 54], ["the VP2 protein sequences", "TEST", 29, 54], ["caliciviruses", "OBSERVATION", 172, 185]]], ["Lastly, the genome organization of the bat SaV is highly similar to that of the SaVs as shown above.", [["bat", "ORGANISM", 39, 42], ["SaV", "GENE_OR_GENE_PRODUCT", 43, 46], ["SaVs", "GENE_OR_GENE_PRODUCT", 80, 84], ["bat SaV", "DNA", 39, 46], ["SaVs", "DNA", 80, 84], ["the bat SaV", "PROBLEM", 35, 46], ["bat SaV", "OBSERVATION", 39, 46]]], ["Hence, together with relatively high sequence identities with other SaVs rather than with calicivirues in other genera (Table S2), we propose that the novel bat virus be classified as a new member of the genus Sapovirus in the family Caliciviridae.Codon usage and compositional bias analysis ::: ResultsAs genomic nucleotide composition is strongly associated with codon usage bias in viruses, we examined the codon usage in the genomes of the novel bat SaV and other SaVs given their different nucleotide composition.", [["nucleotide", "CHEMICAL", 314, 324], ["nucleotide", "CHEMICAL", 495, 505], ["nucleotide", "CHEMICAL", 314, 324], ["nucleotide", "CHEMICAL", 495, 505], ["SaVs", "GENE_OR_GENE_PRODUCT", 68, 72], ["bat virus", "ORGANISM", 157, 166], ["bat", "ORGANISM", 450, 453], ["SaV", "GENE_OR_GENE_PRODUCT", 454, 457], ["SaVs", "GENE_OR_GENE_PRODUCT", 468, 472], ["SaVs", "PROTEIN", 68, 72], ["SaV", "PROTEIN", 454, 457], ["SaVs", "DNA", 468, 472], ["bat virus", "SPECIES", 157, 166], ["the novel bat virus", "PROBLEM", 147, 166], ["the genus Sapovirus", "PROBLEM", 200, 219], ["the family Caliciviridae", "TREATMENT", 223, 247], ["ResultsAs genomic nucleotide composition", "PROBLEM", 296, 336], ["codon usage bias in viruses", "PROBLEM", 365, 392], ["genus Sapovirus", "OBSERVATION", 204, 219]]], ["The bat SaV genome was found to have significantly greater codon usage bias than the other SaV genomes, as measured by their effective number of codons (Nc) (Figure 4).", [["bat", "ORGANISM", 4, 7], ["SaV", "GENE_OR_GENE_PRODUCT", 8, 11], ["SaV", "GENE_OR_GENE_PRODUCT", 91, 94], ["bat SaV genome", "DNA", 4, 18], ["SaV genomes", "DNA", 91, 102], ["significantly greater codon usage bias", "PROBLEM", 37, 75], ["codons (Nc", "TREATMENT", 145, 155], ["SaV genome", "OBSERVATION", 8, 18], ["SaV genomes", "OBSERVATION", 91, 102]]], ["Adjusting Nc for background nucleotide composition (Nc\u2032) did not significantly affect the observed difference in codon usage bias.Codon usage and compositional bias analysis ::: ResultsNext, we examined CpG dinucleotide bias in the SaV genomes, as studies on other animal RNA viruses suggest that CpG suppression is a major factor in their genome evolution [40], [41].", [["SaV genomes", "ANATOMY", 232, 243], ["nucleotide", "CHEMICAL", 28, 38], ["CpG", "CHEMICAL", 297, 300], ["nucleotide", "CHEMICAL", 28, 38], ["CpG", "CHEMICAL", 203, 206], ["CpG", "CHEMICAL", 297, 300], ["SaV", "GENE_OR_GENE_PRODUCT", 232, 235], ["Nc", "DNA", 10, 12], ["SaV genomes", "DNA", 232, 243], ["Nc", "TREATMENT", 10, 12], ["background nucleotide composition", "TREATMENT", 17, 50], ["CpG dinucleotide bias", "PROBLEM", 203, 224], ["other animal RNA viruses", "PROBLEM", 259, 283], ["CpG suppression", "PROBLEM", 297, 312], ["SaV genomes", "OBSERVATION", 232, 243]]], ["Odds ratio of CpG and GpC dinucleotides (\u03c1CG and \u03c1GC) and the CpG/GpC ratio were calculated to assess the degree of CpG suppression.", [["CpG", "CHEMICAL", 14, 17], ["dinucleotides", "CHEMICAL", 26, 39], ["CpG", "CHEMICAL", 62, 65], ["CpG", "CHEMICAL", 116, 119], ["GpC", "GENE_OR_GENE_PRODUCT", 66, 69], ["CpG", "PROBLEM", 14, 17], ["GpC dinucleotides", "PROBLEM", 22, 39], ["CG", "TEST", 42, 44], ["GC", "TEST", 50, 52], ["the CpG/GpC ratio", "TEST", 58, 75], ["CpG suppression", "PROBLEM", 116, 131], ["CpG suppression", "OBSERVATION", 116, 131]]], ["Results confirm the presence of significant CpG suppression (\u03c1CG\u22640.78) in examined SaV genomes, with the only exception being the bat SaV genome (Table 4). \u03c1GC values are similar across examined SaV genomes, suggesting that the difference in CpG suppression is specific.", [["SaV genomes", "ANATOMY", 83, 94], ["CpG", "CHEMICAL", 44, 47], ["CpG", "CHEMICAL", 242, 245], ["SaV", "GENE_OR_GENE_PRODUCT", 83, 86], ["SaV", "GENE_OR_GENE_PRODUCT", 195, 198], ["SaV genomes", "DNA", 83, 94], ["bat SaV genome", "DNA", 130, 144], ["SaV genomes", "DNA", 195, 206], ["significant CpG suppression", "PROBLEM", 32, 59], ["CG", "TEST", 62, 64], ["GC values", "TEST", 157, 166], ["the difference in CpG suppression", "PROBLEM", 224, 257], ["significant", "OBSERVATION_MODIFIER", 32, 43], ["CpG suppression", "OBSERVATION", 44, 59], ["SaV genomes", "OBSERVATION", 83, 94], ["SaV genome", "OBSERVATION", 134, 144], ["SaV genomes", "OBSERVATION", 195, 206], ["CpG suppression", "OBSERVATION", 242, 257]]], ["All SaV genomes are found to have a slightly negative GC skew, and there is no major difference between the degree of GC skew in bat SaV and the other SaVs (Table 4).", [["SaV", "GENE_OR_GENE_PRODUCT", 4, 7], ["SaV genomes", "DNA", 4, 15], ["a slightly negative GC skew", "PROBLEM", 34, 61], ["SaV genomes", "OBSERVATION", 4, 15], ["slightly", "OBSERVATION_MODIFIER", 36, 44], ["negative", "OBSERVATION_MODIFIER", 45, 53], ["GC skew", "OBSERVATION_MODIFIER", 54, 61], ["no", "UNCERTAINTY", 76, 78], ["major", "OBSERVATION_MODIFIER", 79, 84], ["GC skew", "OBSERVATION", 118, 125]]], ["This suggests that the degree of cytosine deamination is not a major factor in the altered GC composition and CpG suppression in the bat SaV genome.DiscussionAlthough the taxonomic classification of caliciviruses has improved with the availability of full-length gene sequences and robust phylogenetic methods [42], the increase in genetic diversity introduced by novel caliciviruses would necessitate further taxonomic revisions within the family.", [["cytosine", "CHEMICAL", 33, 41], ["caliciviruses", "DISEASE", 199, 212], ["caliciviruses", "DISEASE", 370, 383], ["cytosine", "CHEMICAL", 33, 41], ["CpG", "CHEMICAL", 110, 113], ["cytosine", "SIMPLE_CHEMICAL", 33, 41], ["SaV", "GENE_OR_GENE_PRODUCT", 137, 140], ["caliciviruses", "CANCER", 199, 212], ["caliciviruses", "CANCER", 370, 383], ["bat SaV genome", "DNA", 133, 147], ["full-length gene sequences", "DNA", 251, 277], ["bat SaV", "SPECIES", 133, 140], ["cytosine deamination", "PROBLEM", 33, 53], ["a major factor", "PROBLEM", 61, 75], ["the altered GC composition", "PROBLEM", 79, 105], ["CpG suppression", "PROBLEM", 110, 125], ["caliciviruses", "PROBLEM", 199, 212], ["full-length gene sequences", "TREATMENT", 251, 277], ["novel caliciviruses", "PROBLEM", 364, 383], ["further taxonomic revisions", "TREATMENT", 402, 429], ["cytosine deamination", "OBSERVATION", 33, 53], ["altered", "OBSERVATION_MODIFIER", 83, 90], ["GC composition", "OBSERVATION", 91, 105], ["SaV genome", "OBSERVATION", 137, 147], ["caliciviruses", "OBSERVATION", 199, 212], ["increase", "OBSERVATION_MODIFIER", 320, 328]]], ["The International Committee on Taxonomy of Viruses has adopted a systematic polythetic approach towards virus taxonomy, but classification at or below the genus level may be complicated by the specific biology of diverse viruses.", [["Viruses", "TREATMENT", 43, 50], ["a systematic polythetic approach", "TREATMENT", 63, 95], ["virus taxonomy", "TREATMENT", 104, 118], ["diverse viruses", "PROBLEM", 213, 228], ["genus", "ANATOMY", 155, 160], ["diverse", "OBSERVATION_MODIFIER", 213, 220], ["viruses", "OBSERVATION", 221, 228]]], ["As a case in point, the proposed assignment of the novel bat virus to the genus Sapovirus might be opposed on the basis of an increased genomic G+C content, the different reading frame of ORF2, and the increased length of the 3\u2032 UTR.", [["bat virus", "ORGANISM", 57, 66], ["G+C", "GENE_OR_GENE_PRODUCT", 144, 147], ["ORF2", "GENE_OR_GENE_PRODUCT", 188, 192], ["reading frame", "DNA", 171, 184], ["ORF2", "DNA", 188, 192], ["UTR", "DNA", 229, 232], ["bat virus", "SPECIES", 57, 66], ["the novel bat virus", "PROBLEM", 47, 66], ["the genus Sapovirus", "PROBLEM", 70, 89], ["an increased genomic G+C content", "PROBLEM", 123, 155], ["ORF2", "TEST", 188, 192], ["genus Sapovirus", "OBSERVATION", 74, 89], ["increased", "OBSERVATION_MODIFIER", 126, 135], ["genomic G+C content", "OBSERVATION", 136, 155], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["length", "OBSERVATION_MODIFIER", 212, 218]]], ["On the other hand, the polythetic criteria for inclusion in the genus are not fully clear, and phylogenetic distances between viral gene sequences have assumed overriding importance in previous and current classifications.", [["viral gene sequences", "DNA", 126, 146], ["inclusion in the genus", "PROBLEM", 47, 69], ["phylogenetic distances between viral gene sequences", "PROBLEM", 95, 146], ["genus", "ANATOMY", 64, 69], ["clear", "OBSERVATION", 84, 89]]], ["It should be noted that even phylogenetic analysis may be confounded by other factors such as the cleavage pattern of ORF1 polyprotein, which has not been determined experimentally for many caliciviruses.DiscussionAmong the various notable genomic features and properties in the novel bat SaV, we were most intrigued by its remarkably high G+C genomic content.", [["ORF1", "GENE_OR_GENE_PRODUCT", 118, 122], ["caliciviruses", "CANCER", 190, 203], ["bat", "ORGANISM", 285, 288], ["SaV", "GENE_OR_GENE_PRODUCT", 289, 292], ["ORF1 polyprotein", "PROTEIN", 118, 134], ["bat SaV", "PROTEIN", 285, 292], ["phylogenetic analysis", "TEST", 29, 50], ["other factors", "PROBLEM", 72, 85], ["the cleavage pattern of ORF1 polyprotein", "PROBLEM", 94, 134], ["genomic content", "OBSERVATION", 344, 359]]], ["Most caliciviruses have a genomic G+C content of 44.2\u201357.4 mol%.", [["caliciviruses", "CANCER", 5, 18], ["Most caliciviruses", "PROBLEM", 0, 18], ["a genomic G+C content", "TEST", 24, 45]]], ["Among them, the genomic G+C content of the SaVs lie within the relatively narrow range of 49.0\u201353.6 mol% in spite of their genetic diversity.", [["SaVs", "ANATOMY", 43, 47], ["SaVs", "CANCER", 43, 47], ["the genomic G+C content", "TEST", 12, 35], ["the SaVs lie", "TEST", 39, 51], ["G+C content", "OBSERVATION", 24, 35]]], ["Hence, the presently observed G+C genomic content of 60.2% is significantly higher than that for other SaVs or caliciviruses, and indeed would rank amongst mammalian RNA viruses with the highest G+C genomic content [43].", [["G+C", "GENE_OR_GENE_PRODUCT", 30, 33], ["SaVs", "GENE_OR_GENE_PRODUCT", 103, 107], ["caliciviruses", "GENE_OR_GENE_PRODUCT", 111, 124], ["G+C", "GENE_OR_GENE_PRODUCT", 195, 198], ["G+C genomic content", "TEST", 30, 49], ["caliciviruses", "PROBLEM", 111, 124], ["mammalian RNA viruses", "PROBLEM", 156, 177], ["caliciviruses", "OBSERVATION", 111, 124]]], ["Relatively little is known about the evolution of genome composition in caliciviruses.", [["caliciviruses", "ANATOMY", 72, 85], ["caliciviruses", "CANCER", 72, 85], ["genome composition in caliciviruses", "PROBLEM", 50, 85], ["genome composition", "OBSERVATION", 50, 68], ["caliciviruses", "OBSERVATION", 72, 85]]], ["A number of factors have been postulated to exert selectional pressure on the G+C content of viral genomes, including host body temperature, immune pressure, codon and nucleotide usage patterns [44]\u2013[47].", [["body", "ANATOMY", 123, 127], ["nucleotide", "CHEMICAL", 168, 178], ["nucleotide", "CHEMICAL", 168, 178], ["G+C", "GENE_OR_GENE_PRODUCT", 78, 81], ["body", "ORGANISM_SUBDIVISION", 123, 127], ["viral genomes", "DNA", 93, 106], ["selectional pressure", "TEST", 50, 70], ["viral genomes", "PROBLEM", 93, 106], ["host body temperature", "TEST", 118, 139], ["immune pressure", "TEST", 141, 156], ["codon", "TEST", 158, 163], ["nucleotide usage patterns", "TEST", 168, 193], ["viral genomes", "OBSERVATION", 93, 106]]], ["Our results suggested that the increased G+C content is associated with a decrease in CpG suppression, but does not have a direct correlation with codon usage bias.", [["CpG", "CHEMICAL", 86, 89], ["G+C", "SIMPLE_CHEMICAL", 41, 44], ["the increased G+C content", "PROBLEM", 27, 52], ["a decrease in CpG suppression", "PROBLEM", 72, 101], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["decrease", "OBSERVATION_MODIFIER", 74, 82], ["CpG suppression", "OBSERVATION", 86, 101]]], ["We are unaware of any previous findings indicating that genomes of bat viruses are under less CpG suppression, thus the observed reduction in CpG suppresion is unlikely to result from host-related factors.", [["CpG", "CHEMICAL", 94, 97], ["CpG", "CHEMICAL", 142, 145], ["bat viruses", "ORGANISM", 67, 78], ["bat viruses", "PROBLEM", 67, 78], ["less CpG suppression", "TREATMENT", 89, 109], ["the observed reduction in CpG suppresion", "PROBLEM", 116, 156], ["bat", "ANATOMY", 67, 70], ["viruses", "OBSERVATION", 71, 78], ["reduction", "OBSERVATION_MODIFIER", 129, 138]]], ["The greater codon usage bias in the bat SaV genome is another interesting genome feature, which could be associated with altered dinucleotide frequencies.", [["dinucleotide", "CHEMICAL", 129, 141], ["dinucleotide", "CHEMICAL", 129, 141], ["SaV", "GENE_OR_GENE_PRODUCT", 40, 43], ["dinucleotide", "SIMPLE_CHEMICAL", 129, 141], ["bat SaV genome", "DNA", 36, 50], ["altered dinucleotide frequencies", "PROBLEM", 121, 153], ["greater codon", "OBSERVATION", 4, 17], ["bat", "ANATOMY", 36, 39], ["SaV genome", "OBSERVATION", 40, 50], ["dinucleotide frequencies", "OBSERVATION", 129, 153]]], ["The association could be tested by Markov modelling of the dinucleotide and codon frequencies in the SaV genomes, although the small genome sizes and the presently small number of complete genomes would limit the usefulness of this approach [48].DiscussionThe novel SaV described presently is the first known member of the Caliciviridae in bats.", [["SaV genomes", "ANATOMY", 101, 112], ["dinucleotide", "CHEMICAL", 59, 71], ["dinucleotide", "CHEMICAL", 59, 71], ["dinucleotide", "SIMPLE_CHEMICAL", 59, 71], ["SaV", "GENE_OR_GENE_PRODUCT", 101, 104], ["SaV", "GENE_OR_GENE_PRODUCT", 266, 269], ["Caliciviridae", "CANCER", 323, 336], ["bats", "ORGANISM", 340, 344], ["SaV genomes", "DNA", 101, 112], ["SaV", "DNA", 266, 269], ["the dinucleotide and codon frequencies in the SaV genomes", "PROBLEM", 55, 112], ["the small genome sizes", "PROBLEM", 123, 145], ["SaV genomes", "OBSERVATION", 101, 112], ["small", "OBSERVATION_MODIFIER", 127, 132], ["genome", "OBSERVATION_MODIFIER", 133, 139], ["sizes", "OBSERVATION_MODIFIER", 140, 145], ["small", "OBSERVATION_MODIFIER", 164, 169], ["number", "OBSERVATION_MODIFIER", 170, 176], ["complete", "OBSERVATION_MODIFIER", 180, 188], ["genomes", "OBSERVATION", 189, 196]]], ["The approach to its discovery is based on the established strategy of targeted genetic screening informed by conserved sequences of related viruses.", [["targeted genetic screening", "TEST", 70, 96], ["related viruses", "PROBLEM", 132, 147]]], ["Although this \u201chomology-based\u201d strategy has been successful in the discovery of numerous viruses, the advent of affordable high-density microarrays and high-thoughput sequencing has given rise to virus discovery through metagenomics.", [["numerous viruses", "PROBLEM", 80, 96], ["affordable high-density microarrays", "TREATMENT", 112, 147], ["high-thoughput sequencing", "PROBLEM", 152, 177], ["numerous", "OBSERVATION_MODIFIER", 80, 88], ["viruses", "OBSERVATION", 89, 96]]], ["Indeed, the first canine SaVs were discovered recently by metagenome sequencing of canine diarrhoea samples on a high-throughput pyrosequencer [23].", [["samples", "ANATOMY", 100, 107], ["diarrhoea", "DISEASE", 90, 99], ["canine", "ORGANISM", 18, 24], ["SaVs", "GENE_OR_GENE_PRODUCT", 25, 29], ["canine", "ORGANISM", 83, 89], ["canine SaVs", "DNA", 18, 29], ["canine", "SPECIES", 18, 24], ["canine", "SPECIES", 83, 89], ["canine", "SPECIES", 18, 24], ["canine", "SPECIES", 83, 89], ["canine diarrhoea samples", "PROBLEM", 83, 107]]], ["Important advantages of the new method include detection of novel viruses not closely related to known viruses, and the capacity to detect multiple divergent viruses in cases of co-infection.", [["co-infection", "DISEASE", 178, 190], ["the new method", "TREATMENT", 24, 38], ["novel viruses", "PROBLEM", 60, 73], ["known viruses", "PROBLEM", 97, 110], ["the capacity", "PROBLEM", 116, 128], ["multiple divergent viruses", "PROBLEM", 139, 165], ["co-infection", "PROBLEM", 178, 190], ["viruses", "OBSERVATION", 103, 110], ["divergent", "OBSERVATION_MODIFIER", 148, 157], ["viruses", "OBSERVATION", 158, 165], ["co-infection", "OBSERVATION", 178, 190]]], ["However, metagenomics sequencing can suffer from possible bias during sample preparation [49], and it is unlikely to detect very low titres of viruses in a specimen, such as the three bat faecal samples that were positive upon repeat screening with specific PCR primers in the present study.", [["sample", "ANATOMY", 70, 76], ["specimen", "ANATOMY", 156, 164], ["faecal samples", "ANATOMY", 188, 202], ["PCR primers", "DNA", 258, 269], ["very low titres of viruses", "PROBLEM", 124, 150], ["a specimen", "TEST", 154, 164], ["the three bat faecal samples", "TEST", 174, 202], ["repeat screening", "TEST", 227, 243], ["specific PCR primers", "TEST", 249, 269], ["the present study", "TEST", 273, 290], ["viruses", "OBSERVATION", 143, 150]]], ["While we anticipate the increasing utilization of the metagenomics approach, existing methods such as viral culture, electron microscopy and targeted nucleic acid amplification would continue to serve important roles in virus discovery.DiscussionAs Hong Kong is a highly urbanized city, the local roosting sites of bats are mainly man-made structures, such as water tunnels and abandoned mines.", [["nucleic acid", "CHEMICAL", 150, 162], ["the metagenomics approach", "TREATMENT", 50, 75], ["existing methods", "TREATMENT", 77, 93], ["viral culture", "TEST", 102, 115], ["electron microscopy", "TEST", 117, 136], ["targeted nucleic acid amplification", "TREATMENT", 141, 176], ["water tunnels", "TREATMENT", 360, 373], ["abandoned mines", "TREATMENT", 378, 393]]], ["Hipposideros pomona is very common and widespread throughout Hong Kong countryside areas.", [["Hipposideros", "CHEMICAL", 0, 12], ["Hipposideros pomona", "ORGANISM", 0, 19], ["Hipposideros pomona", "SPECIES", 0, 19], ["Hipposideros pomona", "SPECIES", 0, 19], ["very", "OBSERVATION_MODIFIER", 23, 27], ["common", "OBSERVATION_MODIFIER", 28, 34], ["widespread", "OBSERVATION_MODIFIER", 39, 49]]], ["It is a small-sized leaf-nosed bat with body weight ranged from 6\u20138 g.", [["leaf", "ANATOMY", 20, 24], ["body", "ANATOMY", 40, 44], ["leaf", "ORGAN", 20, 24], ["bat", "ORGANISM", 31, 34], ["body", "ORGANISM_SUBDIVISION", 40, 44], ["body weight", "TEST", 40, 51], ["small", "OBSERVATION_MODIFIER", 8, 13], ["sized", "OBSERVATION_MODIFIER", 14, 19], ["leaf", "OBSERVATION_MODIFIER", 20, 24], ["nosed bat", "OBSERVATION", 25, 34]]], ["It possesses a small nose leaf which is simple, small, and lacking of lateral leaflets (Figures S3 and S4).", [["nose leaf", "ANATOMY", 21, 30], ["lateral leaflets", "ANATOMY", 70, 86], ["nose leaf", "ORGAN", 21, 30], ["lateral leaflets", "MULTI-TISSUE_STRUCTURE", 70, 86], ["a small nose leaf", "PROBLEM", 13, 30], ["small", "OBSERVATION_MODIFIER", 15, 20], ["nose leaf", "OBSERVATION", 21, 30], ["simple", "OBSERVATION_MODIFIER", 40, 46], ["small", "OBSERVATION_MODIFIER", 48, 53], ["lateral leaflets", "ANATOMY", 70, 86], ["S3", "ANATOMY_MODIFIER", 96, 98], ["S4", "ANATOMY", 103, 105]]], ["This species may aggregate in small chambers or enclosures where the air flow is relatively limited.", [["This species", "PROBLEM", 0, 12], ["the air flow", "TEST", 65, 77], ["aggregate", "OBSERVATION_MODIFIER", 17, 26], ["small chambers", "OBSERVATION", 30, 44], ["enclosures", "OBSERVATION_MODIFIER", 48, 58], ["air flow", "OBSERVATION", 69, 77]]], ["The 5 SaV-infected specimens were all captured in a place called Tai Lam \u2013 Shek Kong located next to a major country park of Hong Kong, and this roosting site shares similar ecological characteristic with other sampled roosting sites.", [["specimens", "ANATOMY", 19, 28], ["SaV", "GENE_OR_GENE_PRODUCT", 6, 9], ["specimens", "CELL", 19, 28], ["roosting sites", "MULTI-TISSUE_STRUCTURE", 219, 233], ["The 5 SaV-infected specimens", "PROBLEM", 0, 28], ["this roosting site", "PROBLEM", 140, 158], ["5 SaV", "OBSERVATION_MODIFIER", 4, 9]]], ["Due to the extremely high human population density in Hong Kong, direct contact between humans and bats is relatively frequent.", [["human", "ORGANISM", 26, 31], ["humans", "ORGANISM", 88, 94], ["human", "SPECIES", 26, 31], ["humans", "SPECIES", 88, 94], ["human", "SPECIES", 26, 31], ["humans", "SPECIES", 88, 94], ["density", "OBSERVATION", 43, 50]]], ["Fortunately, no local case of bat zoonosis has ever been reported [36].", [["zoonosis", "DISEASE", 34, 42], ["bat", "ORGANISM", 30, 33], ["bat zoonosis", "PROBLEM", 30, 42]]], ["The relatively large genetic distance between the present bat SaV and other mammalian SaVs suggests that the zoonotic risk posed by this virus is likely to be low, though this should be confirmed with further in vitro and in vivo studies.DiscussionThere are two main limitations in the current study.", [["bat", "ORGANISM", 58, 61], ["SaV", "GENE_OR_GENE_PRODUCT", 62, 65], ["SaVs", "GENE_OR_GENE_PRODUCT", 86, 90], ["mammalian SaVs", "PROTEIN", 76, 90], ["this virus", "PROBLEM", 132, 142], ["vivo studies", "TEST", 225, 237], ["the current study", "TEST", 282, 299], ["relatively", "OBSERVATION_MODIFIER", 4, 14], ["large", "OBSERVATION_MODIFIER", 15, 20], ["genetic", "OBSERVATION_MODIFIER", 21, 28], ["distance", "OBSERVATION_MODIFIER", 29, 37], ["bat SaV", "OBSERVATION", 58, 65], ["two", "OBSERVATION_MODIFIER", 258, 261], ["main", "OBSERVATION_MODIFIER", 262, 266]]], ["First and foremost, clinical information on the sampled bats is limited to the brief period of captivity needed for sample collection, which is unlikely to reflect the disease association of the virus accurately.", [["sample collection", "PROBLEM", 116, 133], ["the disease association of the virus", "PROBLEM", 164, 200], ["unlikely to reflect", "UNCERTAINTY", 144, 163], ["disease", "OBSERVATION", 168, 175], ["virus", "OBSERVATION", 195, 200]]], ["In other words, the scope of the study is limited to surveillance of viral diversity and possible discovery of new viruses.", [["the study", "TEST", 29, 38], ["viral diversity", "PROBLEM", 69, 84], ["new viruses", "PROBLEM", 111, 122], ["viral diversity", "OBSERVATION", 69, 84], ["new", "OBSERVATION_MODIFIER", 111, 114], ["viruses", "OBSERVATION", 115, 122]]], ["Secondly, the number of samples for the novel virus is quite small, despite the use of specific PCR primers for screening and the relatively large number of samples collected.", [["samples", "ANATOMY", 24, 31], ["samples", "ANATOMY", 157, 164], ["samples", "CANCER", 24, 31], ["samples", "CANCER", 157, 164], ["PCR primers", "DNA", 96, 107], ["the novel virus", "PROBLEM", 36, 51], ["specific PCR primers", "TREATMENT", 87, 107], ["screening", "TEST", 112, 121], ["small", "OBSERVATION_MODIFIER", 61, 66], ["large", "OBSERVATION_MODIFIER", 141, 146]]], ["To address these limitations, long-term follow-up studies would be required to identify sufficient positive samples with associated clinical data.", [["samples", "ANATOMY", 108, 115]]], ["Increasing the scale of surveillance would also help, though there are practical geographical and logistic constraints in our locality.DiscussionIn conclusion, we identified a novel bat SaV with several genomic features and properties that set it apart from other members of the genus Sapovirus.", [["bat", "ORGANISM", 182, 185], ["SaV", "GENE_OR_GENE_PRODUCT", 186, 189], ["Sapovirus", "GENE_OR_GENE_PRODUCT", 285, 294], ["SaV", "PROTEIN", 186, 189], ["a novel bat SaV", "PROBLEM", 174, 189], ["several genomic features", "PROBLEM", 195, 219], ["the genus Sapovirus", "PROBLEM", 275, 294], ["genus Sapovirus", "OBSERVATION", 279, 294]]], ["Phylogenetic analysis suggests that its ancestral lineage had diverged early from the other SaVs and evolved under different conditions.", [["SaVs", "DNA", 92, 96], ["Phylogenetic analysis", "TEST", 0, 21], ["ancestral lineage", "OBSERVATION", 40, 57]]], ["Further discovery and characterization of additional strains would enhance our understanding of the evolutionary history of the SaVs and other caliciviruses.Surveillance and sample collection ::: Materials and MethodsThe study was approved by the Department of Agriculture, Fisheries and Conservation, HKSAR; and Committee on the Use of Live Animals in Teaching and Research, The University of Hong Kong.", [["SaVs", "GENE_OR_GENE_PRODUCT", 128, 132], ["caliciviruses", "CANCER", 143, 156], ["additional strains", "PROBLEM", 42, 60], ["the SaVs and other caliciviruses", "PROBLEM", 124, 156], ["Surveillance and sample collection", "TEST", 157, 191], ["Methods", "TREATMENT", 210, 217], ["The study", "TEST", 217, 226]]], ["Bats from 14 different locations in rural areas of Hong Kong, including water tunnels, closed mines, sea caves and forested areas, were captured over a 36-month period.", [["Bats", "CELL", 0, 4], ["water tunnels", "TREATMENT", 72, 85], ["closed mines", "TREATMENT", 87, 99], ["sea caves", "TREATMENT", 101, 110], ["forested areas", "TREATMENT", 115, 129], ["14 different", "OBSERVATION_MODIFIER", 10, 22], ["forested", "OBSERVATION_MODIFIER", 115, 123]]], ["Anal swabs were collected by an experienced veterinary surgeon, and kept in viral transport medium at 4\u00b0C before processing.RNA extraction ::: Materials and MethodsViral RNA was extracted from the anal swabs using a QIAamp Viral RNA mini kit (Qiagen).", [["Anal swabs", "ANATOMY", 0, 10], ["anal swabs", "ANATOMY", 197, 207], ["Anal swabs", "ORGANISM_SUBSTANCE", 0, 10], ["C", "GENE_OR_GENE_PRODUCT", 104, 105], ["anal swabs", "ORGANISM_SUBSTANCE", 197, 207], ["MethodsViral RNA", "RNA", 157, 173], ["Anal swabs", "TEST", 0, 10], ["viral transport medium", "TREATMENT", 76, 98], ["MethodsViral RNA", "TREATMENT", 157, 173], ["the anal swabs", "TEST", 193, 207], ["a QIAamp Viral RNA mini kit", "TREATMENT", 214, 241], ["MethodsViral RNA", "OBSERVATION", 157, 173], ["anal", "ANATOMY", 197, 201]]], ["The RNA was eluted into 50 \u00b5l RNase-free water and was used as the template for RT-PCR.RT-PCR of the RdRp region using conserved primers, and sequencing ::: Materials and MethodsScreening was performed by amplifying a 185 nt fragment in the RdRp region of the ORF1 gene of caliciviruses.", [["caliciviruses", "ANATOMY", 273, 286], ["RNase", "GENE_OR_GENE_PRODUCT", 30, 35], ["ORF1", "GENE_OR_GENE_PRODUCT", 260, 264], ["caliciviruses", "CANCER", 273, 286], ["RNase", "PROTEIN", 30, 35], ["RdRp region", "DNA", 101, 112], ["185 nt fragment", "DNA", 218, 233], ["RdRp region", "DNA", 241, 252], ["ORF1 gene", "DNA", 260, 269], ["The RNA", "TEST", 0, 7], ["RT-PCR", "TEST", 80, 86], ["RT-PCR", "TEST", 87, 93], ["MethodsScreening", "TREATMENT", 171, 187], ["a 185 nt fragment", "TREATMENT", 216, 233], ["RdRp", "OBSERVATION", 101, 105], ["RdRp", "ANATOMY_MODIFIER", 241, 245], ["region", "ANATOMY_MODIFIER", 246, 252], ["caliciviruses", "OBSERVATION", 273, 286]]], ["Conserved degenerate primers (5\u2032-GAYTAYTCNMRRTGGGAYTC-3\u2032 and 5\u2032- GGCATNCCNGAKGGNAYNCC -3\u2032) were designed from the multiple sequence alignment of the available calicivirus gene sequences in NCBI GenBank.", [["calicivirus", "ORGANISM", 159, 170], ["Conserved degenerate primers", "DNA", 0, 28], ["calicivirus gene sequences", "DNA", 159, 185], ["NCBI GenBank", "DNA", 189, 201], ["NCBI GenBank", "SPECIES", 189, 201], ["Conserved degenerate primers", "PROBLEM", 0, 28], ["5\u2032-GAYTAYTCNMRRTGGGAYTC", "TEST", 30, 53]]], ["First-strand cDNA synthesis was performed using SuperScript III kit (Invitrogen) according to manufacturer's instructions.", [["strand cDNA synthesis", "TREATMENT", 6, 27], ["SuperScript III kit (Invitrogen)", "TREATMENT", 48, 80]]], ["The PCR mixture (25 \u00b5l) contained cDNA, PCR buffer (10 mM Tris/HCl pH 8.3, 50 mM KCl, 2 mM MgCl2 and 0.01% gelatin), 200 \u00b5M of each dNTP and 1.0 U AmpliTaq Gold polymerase (Applied Biosystems).", [["KCl", "CHEMICAL", 81, 84], ["MgCl2", "CHEMICAL", 91, 96], ["dNTP", "CHEMICAL", 132, 136], ["Tris", "CHEMICAL", 58, 62], ["HCl", "CHEMICAL", 63, 66], ["KCl", "CHEMICAL", 81, 84], ["MgCl2", "CHEMICAL", 91, 96], ["dNTP", "CHEMICAL", 132, 136], ["Gold polymerase", "GENE_OR_GENE_PRODUCT", 156, 171], ["cDNA", "DNA", 34, 38], ["The PCR mixture", "TREATMENT", 0, 15], ["cDNA", "TEST", 34, 38], ["PCR", "TEST", 40, 43], ["Tris", "TEST", 58, 62], ["pH", "TEST", 67, 69], ["50 mM KCl", "TREATMENT", 75, 84], ["2 mM MgCl2", "TREATMENT", 86, 96], ["dNTP", "TEST", 132, 136], ["U AmpliTaq Gold polymerase", "TREATMENT", 145, 171]]], ["PCR cycling conditions were as follows: hot start at 94\u00b0C for 7 min, followed by 50 cycles of 94\u00b0C for 1 min, 50\u00b0C for 1 min and 72\u00b0C for 1 min with a final extension at 72\u00b0C for 10 min in an automated thermal cycler (Applied Biosystems).", [["PCR cycling conditions", "TEST", 0, 22], ["an automated thermal cycler", "TREATMENT", 189, 216]]], ["Standard precautions were taken to avoid PCR contamination and no false-positive signal was observed in the negative controls.", [["Standard precautions", "TREATMENT", 0, 20], ["PCR contamination", "PROBLEM", 41, 58], ["false-positive signal", "PROBLEM", 66, 87]]], ["The PCR products were gel-purified using a QIAquick gel extraction kit (Qiagen).", [["The PCR products", "TREATMENT", 0, 16], ["a QIAquick gel extraction kit", "TREATMENT", 41, 70]]], ["Both strands of the PCR products were sequenced twice with an ABI Prism 3730xl DNA Analyser (Applied Biosystems), using the two PCR primers.RT-PCR screening of bat sapovirus using specific primers ::: Materials and MethodsAdditional RT-PCR screening was performed on the same samples using specific primers designed from the RdRp nucleotide sequences of bat SaVs obtained from previous rounds of RT-PCR and sequencing, as RT-PCR screening with specific primers usually offers higher sensitivity than a comparable screening with consensus degenerate primers.", [["samples", "ANATOMY", 276, 283], ["nucleotide", "CHEMICAL", 330, 340], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["bat", "ORGANISM", 160, 163], ["sapovirus", "ORGANISM", 164, 173], ["PCR products", "DNA", 20, 32], ["PCR primers", "DNA", 128, 139], ["RdRp nucleotide sequences", "DNA", 325, 350], ["consensus degenerate primers", "DNA", 528, 556], ["bat sapovirus", "SPECIES", 160, 173], ["the PCR products", "TREATMENT", 16, 32], ["an ABI Prism", "TEST", 59, 71], ["DNA Analyser", "TEST", 79, 91], ["the two PCR primers", "TREATMENT", 120, 139], ["RT-PCR screening", "TEST", 140, 156], ["MethodsAdditional RT-PCR screening", "TEST", 215, 249], ["specific primers", "TEST", 290, 306], ["the RdRp nucleotide sequences", "TEST", 321, 350], ["bat SaVs", "TEST", 354, 362], ["RT-PCR", "TEST", 396, 402], ["sequencing", "TEST", 407, 417], ["RT-PCR screening", "TEST", 422, 438], ["specific primers", "TEST", 444, 460], ["higher sensitivity", "PROBLEM", 476, 494], ["a comparable screening", "TEST", 500, 522], ["consensus degenerate primers", "PROBLEM", 528, 556], ["strands", "OBSERVATION_MODIFIER", 5, 12]]], ["Sequences of the specific primers are as follows: forward primer 5\u2032- CACAATGCAGCCAGCCA-3\u2032 and reverse primer 5\u2032- GGTGCGCGTGGTGAACAC-3\u2032.", [["reverse primer 5\u2032- GGTGCGCGTGGTGAACAC-3", "DNA", 94, 133], ["the specific primers", "TEST", 13, 33], ["forward primer", "TEST", 50, 64], ["\u2032", "TEST", 66, 67], ["CACAATGCAGCCAGCCA", "TEST", 69, 86], ["reverse primer", "TEST", 94, 108], ["GGTGCGCGTGGTGAACAC", "TEST", 113, 131]]], ["PCR cycling conditions were as follows: hot start at 94\u00b0C for 7 min, followed by 50 cycles of 94\u00b0C for 1 min, 52\u00b0C for 1 min and 72\u00b0C for 1 min with a final extension at 72\u00b0C for 10 min in an automated thermal cycler (Applied Biosystems).", [["PCR cycling conditions", "TEST", 0, 22], ["an automated thermal cycler", "TREATMENT", 189, 216]]], ["Standard precautions were taken to avoid PCR contamination and no false-positive signal was observed in the negative controls.", [["Standard precautions", "TREATMENT", 0, 20], ["PCR contamination", "PROBLEM", 41, 58], ["false-positive signal", "PROBLEM", 66, 87]]], ["PCR product purification and sequencing were performed as above.Cloning of PCR product and sequencing ::: Materials and MethodsPurified PCR products were cloned into a pCR2.1-TOPO vector (Invitrogen) according to manufacturer's instructions.", [["TOPO", "GENE_OR_GENE_PRODUCT", 175, 179], ["MethodsPurified PCR products", "DNA", 120, 148], ["pCR2.1-TOPO vector", "DNA", 168, 186], ["PCR product purification", "TEST", 0, 24], ["sequencing", "TEST", 29, 39], ["MethodsPurified PCR products", "TREATMENT", 120, 148], ["a pCR2", "TREATMENT", 166, 172], ["TOPO vector (Invitrogen)", "TREATMENT", 175, 199]]], ["The vector was then used to transform the competent Escherichia coli strain DH5\u03b1 by electroporation.", [["Escherichia coli", "ORGANISM", 52, 68], ["DH5\u03b1", "GENE_OR_GENE_PRODUCT", 76, 80], ["Escherichia coli", "SPECIES", 52, 68], ["Escherichia coli", "SPECIES", 52, 68], ["The vector", "TREATMENT", 0, 10], ["Escherichia coli strain", "OBSERVATION", 52, 75]]], ["Positive transformants were identified by blue\u2013white screening, and eight colonies were selected for DNA sequencing of the construct using the M13 forward and reverse primers according to the manufacturer's instructions.", [["transformants", "ANATOMY", 9, 22], ["colonies", "ANATOMY", 74, 82], ["transformants", "CELL", 9, 22], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["M13 forward and reverse primers", "DNA", 143, 174], ["Positive transformants", "PROBLEM", 0, 22], ["blue\u2013white screening", "TEST", 42, 62], ["DNA sequencing", "TEST", 101, 115], ["the M13", "TREATMENT", 139, 146], ["reverse primers", "TREATMENT", 159, 174]]], ["Sequencing reactions were performed as described above.Genome sequencing ::: Materials and MethodsViral genome sequences were obtained using strategies we had previously used for other RNA viruses [50]\u2013[52].", [["MethodsViral genome sequences", "DNA", 91, 120], ["Sequencing reactions", "TEST", 0, 20], ["MethodsViral genome sequences", "TEST", 91, 120], ["other RNA viruses", "PROBLEM", 179, 196]]], ["RNA extraction and cDNA generation were performed as described above.", [["RNA extraction", "TREATMENT", 0, 14], ["cDNA generation", "TEST", 19, 34], ["cDNA generation", "OBSERVATION", 19, 34]]], ["PCR primers were designed by targeting conserved regions, which were identified from the multiple alignment of genomes of related SaVs, as primer-binding sites.", [["SaVs", "GENE_OR_GENE_PRODUCT", 130, 134], ["PCR primers", "DNA", 0, 11], ["conserved regions", "DNA", 39, 56], ["SaVs", "DNA", 130, 134], ["primer-binding sites", "DNA", 139, 159], ["PCR primers", "TEST", 0, 11], ["multiple", "OBSERVATION_MODIFIER", 89, 97], ["alignment", "OBSERVATION_MODIFIER", 98, 107], ["genomes", "OBSERVATION_MODIFIER", 111, 118], ["binding sites", "OBSERVATION", 146, 159]]], ["Additional primers for subsequent rounds of PCR were designed based on the results of earlier rounds of genome sequencing.", [["PCR", "TEST", 44, 47], ["genome sequencing", "TEST", 104, 121]]], ["The complete set of primer sequences is available from the authors upon request.", [["primer sequences", "DNA", 20, 36], ["primer sequences", "TEST", 20, 36]]], ["The 5\u2032 and 3\u2032 ends of the viral genomes were sequenced following amplification of the segments by rapid amplification of cDNA ends, which was performed using the SMARTer RACE cDNA Amplification kit (Clontech) according to the manufacturer's instructions.Phylogenetic and genome analysis ::: Materials and MethodsORFs were located using the ORF Finder tool at NCBI (http://www.ncbi.nlm.nih.gov/projects/gorf/).", [["5\u2032 and 3\u2032 ends", "DNA", 4, 18], ["viral genomes", "DNA", 26, 39], ["cDNA ends", "DNA", 121, 130], ["SMARTer RACE cDNA", "DNA", 162, 179], ["ORF", "DNA", 340, 343], ["the viral genomes", "TREATMENT", 22, 39], ["cDNA ends", "TREATMENT", 121, 130], ["the SMARTer RACE cDNA Amplification kit (Clontech)", "TREATMENT", 158, 208], ["viral genomes", "OBSERVATION", 26, 39]]], ["Annotation of the predicted proteins was performed by BLAST sequence similarity search against annotations in the NCBI RefSeq database.", [["NCBI RefSeq database", "DNA", 114, 134], ["BLAST sequence", "TEST", 54, 68]]], ["Multiple sequence alignments were constructed using MUSCLE version 3.8.31 [53], and phylogenetic informative regions were extracted using BMGE [54].", [["Multiple sequence alignments", "TEST", 0, 28], ["MUSCLE version", "TEST", 52, 66]]], ["Maximum-likelihood phylogenetic trees were constructed using PhyML version 3 [55], under the best-fit protein evolution model as selected by ProtTest 3 [56].", [["PhyML version", "TREATMENT", 61, 74], ["phylogenetic trees", "OBSERVATION", 19, 37]]], ["Branch support values were estimated by calculation of SH-like aLRT values [57].", [["Branch support values", "TEST", 0, 21]]], ["Recombination detection was performed by analysing the translated sequences of ORF1 and ORF2 separately using the Recombination Analysis Tool [58].Codon usage and compositional bias analysis ::: Materials and MethodsThe full-length ORF1 and ORF2 coding sequences were extracted from selected SaV genomes and concatenated for codon usage analysis (see Table 4 for the list of included genome sequences).", [["ORF1", "GENE_OR_GENE_PRODUCT", 79, 83], ["ORF2", "GENE_OR_GENE_PRODUCT", 88, 92], ["ORF1", "GENE_OR_GENE_PRODUCT", 232, 236], ["ORF2", "GENE_OR_GENE_PRODUCT", 241, 245], ["ORF1", "DNA", 79, 83], ["ORF2", "DNA", 88, 92], ["ORF1", "DNA", 232, 236], ["ORF2", "DNA", 241, 245], ["SaV genomes", "DNA", 292, 303], ["Recombination detection", "TEST", 0, 23], ["ORF2", "TREATMENT", 88, 92], ["the Recombination Analysis Tool", "TEST", 110, 141], ["Methods", "TREATMENT", 209, 216], ["The full-length ORF1", "TREATMENT", 216, 236], ["ORF2 coding sequences", "TEST", 241, 262], ["codon usage analysis", "TEST", 325, 345], ["genome sequences", "TEST", 384, 400]]], ["Codon usage and summary statistic of codon usage bias (Nc and Nc\u2032) were calculated using the INCA package version 2.1 [59], where Nc is the effective number of codons in the coding regions of the genome [60], and Nc\u2032 is the effective number of codons adjusted for background nucleotide composition [61].", [["nucleotide", "CHEMICAL", 275, 285], ["nucleotide", "CHEMICAL", 275, 285], ["Nc\u2032", "GENE_OR_GENE_PRODUCT", 213, 216], ["Nc", "DNA", 55, 57], ["Nc\u2032", "DNA", 62, 65], ["Nc", "DNA", 130, 132], ["coding regions", "DNA", 174, 188], ["Nc\u2032", "DNA", 213, 216], ["Codon usage", "TREATMENT", 0, 11], ["codon usage bias (Nc and Nc\u2032)", "TREATMENT", 37, 66], ["the INCA package version", "TREATMENT", 89, 113], ["Nc", "TREATMENT", 130, 132], ["background nucleotide composition", "TREATMENT", 264, 297]]], ["For CpG dinucleotide bias analysis, odds ratio of CpG and GpC dinucleotides and the CpG/GpC ratio were calculated as described in previous studies [40], [41].", [["CpG", "CHEMICAL", 4, 7], ["CpG", "CHEMICAL", 50, 53], ["dinucleotides", "CHEMICAL", 62, 75], ["CpG", "CHEMICAL", 84, 87], ["CpG and GpC dinucleotides", "DNA", 50, 75], ["CpG dinucleotide bias analysis", "TEST", 4, 34], ["CpG", "PROBLEM", 50, 53], ["GpC dinucleotides", "PROBLEM", 58, 75], ["the CpG/GpC ratio", "TEST", 80, 97], ["GpC dinucleotides", "OBSERVATION", 58, 75]]], ["Odds ratio of \u22640.78 indicates significant suppression of the dinucleotide, same as the interpretation criteria of previous studies.", [["dinucleotide", "CHEMICAL", 61, 73], ["Odds ratio", "TEST", 0, 10], ["significant suppression of the dinucleotide", "PROBLEM", 30, 73], ["previous studies", "TEST", 114, 130], ["significant", "OBSERVATION_MODIFIER", 30, 41], ["suppression", "OBSERVATION", 42, 53]]], ["Symmetrized nucleotide frequencies and dinucleotide odds ratio were not considered in the present study, as SaV genomes consist of positive-sense ssRNA only.", [["nucleotide", "CHEMICAL", 12, 22], ["dinucleotide", "CHEMICAL", 39, 51], ["nucleotide", "CHEMICAL", 12, 22], ["dinucleotide", "CHEMICAL", 39, 51], ["dinucleotide", "SIMPLE_CHEMICAL", 39, 51], ["SaV", "GENE_OR_GENE_PRODUCT", 108, 111], ["SaV genomes", "DNA", 108, 119], ["Symmetrized nucleotide frequencies", "TEST", 0, 34], ["dinucleotide odds ratio", "TEST", 39, 62], ["SaV genomes", "TEST", 108, 119], ["positive-sense ssRNA", "PROBLEM", 131, 151], ["not considered", "UNCERTAINTY", 68, 82], ["sense ssRNA", "OBSERVATION", 140, 151]]], ["To investigate the possible effects of cytosine deamination, genomic GC skew, which is the ratio (G-C)/(G+C), was calculated for the SaV genomes.", [["cytosine", "CHEMICAL", 39, 47], ["cytosine", "CHEMICAL", 39, 47], ["cytosine", "SIMPLE_CHEMICAL", 39, 47], ["SaV", "GENE_OR_GENE_PRODUCT", 133, 136], ["SaV genomes", "DNA", 133, 144], ["cytosine deamination", "TREATMENT", 39, 59], ["genomic GC skew", "TEST", 61, 76], ["the ratio", "TEST", 87, 96], ["G+C", "TEST", 104, 107], ["the SaV genomes", "PROBLEM", 129, 144], ["cytosine deamination", "OBSERVATION", 39, 59], ["SaV genomes", "OBSERVATION", 133, 144]]], ["The strength of the GC skew had been suggested to correlate with the degree of cytosine deamination [41], [44], [62].", [["cytosine", "CHEMICAL", 79, 87], ["cytosine", "CHEMICAL", 79, 87], ["cytosine", "SIMPLE_CHEMICAL", 79, 87], ["cytosine deamination", "PROBLEM", 79, 99]]]], "PMC7505106": [], "PMC7499413": [["IntroductionHodgkin\u2019s lymphoma occurs within a relatively young mean age of onset.", [["IntroductionHodgkin\u2019s lymphoma", "ANATOMY", 0, 30], ["IntroductionHodgkin\u2019s lymphoma", "DISEASE", 0, 30], ["IntroductionHodgkin\u2019s lymphoma", "CANCER", 0, 30], ["lymphoma", "PROBLEM", 22, 30], ["lymphoma", "OBSERVATION", 22, 30]]], ["To ensure high rates of long-term survivors, combinations of chemotherapy and radiation treatment (RT)\u2014and today immunotherapy and RT\u2014have been proven effective in enhancing tumor control and overall survival for patients [1, 2].", [["tumor", "ANATOMY", 174, 179], ["tumor", "DISEASE", 174, 179], ["tumor", "CANCER", 174, 179], ["patients", "ORGANISM", 213, 221], ["patients", "SPECIES", 213, 221], ["long-term survivors", "TREATMENT", 24, 43], ["chemotherapy", "TREATMENT", 61, 73], ["radiation treatment (RT)", "TREATMENT", 78, 102], ["immunotherapy", "TREATMENT", 113, 126], ["RT", "TREATMENT", 131, 133], ["enhancing tumor control", "TREATMENT", 164, 187], ["high", "OBSERVATION_MODIFIER", 10, 14], ["enhancing", "OBSERVATION_MODIFIER", 164, 173], ["tumor", "OBSERVATION", 174, 179]]], ["However, the therapy itself can cause short-term complications such as pneumonitis or long-term toxicities like fibrosis or second malignancy.", [["pneumonitis", "DISEASE", 71, 82], ["toxicities", "DISEASE", 96, 106], ["fibrosis", "DISEASE", 112, 120], ["malignancy", "DISEASE", 131, 141], ["the therapy", "TREATMENT", 9, 20], ["short-term complications", "PROBLEM", 38, 62], ["pneumonitis", "PROBLEM", 71, 82], ["long-term toxicities", "PROBLEM", 86, 106], ["fibrosis", "PROBLEM", 112, 120], ["second malignancy", "PROBLEM", 124, 141], ["short-term", "OBSERVATION_MODIFIER", 38, 48], ["complications", "OBSERVATION", 49, 62], ["pneumonitis", "OBSERVATION", 71, 82], ["long-term toxicities", "OBSERVATION_MODIFIER", 86, 106], ["fibrosis", "OBSERVATION", 112, 120], ["second", "OBSERVATION_MODIFIER", 124, 130], ["malignancy", "OBSERVATION", 131, 141]]], ["It can also cause significant pulmonary morbidity and mortality, specifically regarding the use of bleomycin as part of standard chemotherapy where older patients are at higher risk [3, 4].IntroductionReducing these therapy-associated toxicities has become a crucial focus in modern lymphoma research [5\u20137].", [["pulmonary", "ANATOMY", 30, 39], ["lymphoma", "ANATOMY", 283, 291], ["bleomycin", "CHEMICAL", 99, 108], ["toxicities", "DISEASE", 235, 245], ["lymphoma", "DISEASE", 283, 291], ["bleomycin", "CHEMICAL", 99, 108], ["pulmonary", "ORGAN", 30, 39], ["bleomycin", "SIMPLE_CHEMICAL", 99, 108], ["patients", "ORGANISM", 154, 162], ["lymphoma", "CANCER", 283, 291], ["patients", "SPECIES", 154, 162], ["significant pulmonary morbidity", "PROBLEM", 18, 49], ["bleomycin", "TREATMENT", 99, 108], ["standard chemotherapy", "TREATMENT", 120, 141], ["these therapy-associated toxicities", "TREATMENT", 210, 245], ["significant", "OBSERVATION_MODIFIER", 18, 29], ["pulmonary", "ANATOMY", 30, 39], ["morbidity", "OBSERVATION", 40, 49], ["crucial", "OBSERVATION_MODIFIER", 259, 266], ["focus", "OBSERVATION_MODIFIER", 267, 272], ["modern lymphoma", "OBSERVATION", 276, 291]]], ["Chemotherapy regimens and radiation doses have been reduced depending on the patients\u2019 initial staging [8, 9] and treatment response [10, 11] in an effort to de-escalate harmful secondary effects.", [["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["Chemotherapy regimens", "TREATMENT", 0, 21], ["radiation doses", "TREATMENT", 26, 41], ["initial staging", "TEST", 87, 102], ["secondary effects", "OBSERVATION", 178, 195]]], ["By contrast, the extent of radiation treatment dose and volume has gradually been downsized from extended field to involved field (IFRT; [12]) and subsequently to the involved site (ISRT) or even involved node radiation therapy (INRT; [13]).IntroductionThe constant adjustment of treatment concepts maintains high tumor control and lowers treatment toxicity.", [["node", "ANATOMY", 205, 209], ["tumor", "ANATOMY", 314, 319], ["tumor", "DISEASE", 314, 319], ["toxicity", "DISEASE", 349, 357], ["node", "MULTI-TISSUE_STRUCTURE", 205, 209], ["tumor", "CANCER", 314, 319], ["radiation treatment dose", "TREATMENT", 27, 51], ["volume", "TEST", 56, 62], ["node radiation therapy", "TREATMENT", 205, 227], ["treatment concepts", "TREATMENT", 280, 298], ["high tumor control", "TREATMENT", 309, 327], ["lowers treatment toxicity", "TREATMENT", 332, 357], ["radiation treatment", "OBSERVATION", 27, 46], ["node", "OBSERVATION", 205, 209], ["high", "OBSERVATION_MODIFIER", 309, 313], ["tumor", "OBSERVATION", 314, 319]]], ["Technical advances allow dose volumes to be distributed more conformally.", [["dose volumes", "TREATMENT", 25, 37]]], ["At the same time, the shift from using three-dimensional conformal radiation therapy (3D-CRT) to intensity-modulated radiation therapy (IMRT) minimizes the exposure to high doses for organs at risk.", [["organs", "ANATOMY", 183, 189], ["organs", "ORGAN", 183, 189], ["three-dimensional conformal radiation therapy", "TREATMENT", 39, 84], ["3D-CRT)", "TREATMENT", 86, 93], ["intensity-modulated radiation therapy (IMRT", "TREATMENT", 97, 140], ["organs at risk", "PROBLEM", 183, 197]]], ["Since different radiotherapeutic techniques result in different distributions of high- and low-dose volumes, the decision on which treatment is best suited remains unclear as the superiority of IMRT over standard anterior-posterior-posterior-anterior (APPA) setups has yet to be proven.IntroductionIn our study, we compared radiation-associated pulmonary toxicity of different IFRT planning solutions for patients with mediastinal Hodgkin\u2019s lymphoma.", [["pulmonary", "ANATOMY", 345, 354], ["mediastinal Hodgkin\u2019s lymphoma", "ANATOMY", 419, 449], ["pulmonary toxicity", "DISEASE", 345, 363], ["mediastinal Hodgkin\u2019s lymphoma", "DISEASE", 419, 449], ["anterior", "MULTI-TISSUE_STRUCTURE", 242, 250], ["pulmonary", "ORGAN", 345, 354], ["patients", "ORGANISM", 405, 413], ["mediastinal Hodgkin\u2019s lymphoma", "CANCER", 419, 449], ["patients", "SPECIES", 405, 413], ["different radiotherapeutic techniques", "TREATMENT", 6, 43], ["low-dose volumes", "TREATMENT", 91, 107], ["treatment", "TREATMENT", 131, 140], ["IMRT over standard anterior-posterior-posterior-anterior (APPA) setups", "TREATMENT", 194, 264], ["our study", "TEST", 301, 310], ["pulmonary toxicity", "PROBLEM", 345, 363], ["different IFRT planning solutions", "TREATMENT", 367, 400], ["mediastinal Hodgkin\u2019s lymphoma", "PROBLEM", 419, 449], ["different", "OBSERVATION_MODIFIER", 54, 63], ["distributions", "OBSERVATION_MODIFIER", 64, 77], ["high", "OBSERVATION_MODIFIER", 81, 85], ["low-dose volumes", "OBSERVATION_MODIFIER", 91, 107], ["posterior", "ANATOMY_MODIFIER", 222, 231], ["posterior", "ANATOMY_MODIFIER", 232, 241], ["anterior", "ANATOMY_MODIFIER", 242, 250], ["pulmonary", "ANATOMY", 345, 354], ["toxicity", "OBSERVATION", 355, 363], ["mediastinal", "ANATOMY", 419, 430], ["Hodgkin\u2019s lymphoma", "OBSERVATION", 431, 449]]], ["Furthermore, we analyzed biological evaluation tools to generate individual normal tissue complication probabilities (NTCP) and their potential benefits for a modern radiation treatment evaluation.Material and methodsData were gathered from a pool of 27 patients treated for Hodgkin\u2019s lymphoma in the Department for Radiation Oncology of the University Hospital of M\u00fcnster between 2009 and 2013.", [["tissue", "ANATOMY", 83, 89], ["Hodgkin\u2019s lymphoma", "ANATOMY", 275, 293], ["Hodgkin\u2019s lymphoma", "DISEASE", 275, 293], ["tissue", "TISSUE", 83, 89], ["patients", "ORGANISM", 254, 262], ["Hodgkin\u2019s lymphoma", "CANCER", 275, 293], ["patients", "SPECIES", 254, 262], ["biological evaluation", "TEST", 25, 46], ["a modern radiation treatment", "TREATMENT", 157, 185], ["evaluation", "TEST", 186, 196], ["methodsData", "TEST", 210, 221], ["Hodgkin\u2019s lymphoma", "PROBLEM", 275, 293], ["Hodgkin\u2019s lymphoma", "OBSERVATION", 275, 293]]], ["A total of 14 male and 13 female patients between 15 and 80 years old were included.", [["patients", "ORGANISM", 33, 41], ["patients", "SPECIES", 33, 41]]], ["Criteria for selection were patients with thoracic manifestation whose lungs were organs at risk for treatment planning.", [["thoracic", "ANATOMY", 42, 50], ["lungs", "ANATOMY", 71, 76], ["organs", "ANATOMY", 82, 88], ["patients", "ORGANISM", 28, 36], ["thoracic", "ORGAN", 42, 50], ["lungs", "ORGAN", 71, 76], ["organs", "ORGAN", 82, 88], ["patients", "SPECIES", 28, 36], ["treatment planning", "TREATMENT", 101, 119], ["thoracic", "ANATOMY", 42, 50], ["lungs", "ANATOMY", 71, 76]]], ["Cases varied in stages (with 22 being in Ann Arbor stage II, two patients in stage I, and three patients in stage IV) and, therefore, in clinically applied treatment strategies.Material and methodsIn order to achieve comparability, three treatment plans for 30.6-Gy IFRT of mediastinal lymphoma manifestation were calculated for each patient.", [["mediastinal lymphoma", "ANATOMY", 274, 294], ["mediastinal lymphoma", "DISEASE", 274, 294], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 96, 104], ["mediastinal lymphoma", "CANCER", 274, 294], ["patient", "ORGANISM", 334, 341], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 96, 104], ["patient", "SPECIES", 334, 341], ["treatment strategies", "TREATMENT", 156, 176], ["mediastinal lymphoma manifestation", "PROBLEM", 274, 308], ["mediastinal", "ANATOMY", 274, 285], ["lymphoma", "OBSERVATION", 286, 294]]], ["Treatment planning was realized based on a computed tomography (CT) scan with i.v. contrast enhancement, using the Varian Eclipse Version 10.0 (provided by Varian Medical Systems located in Palo Alto, CA, USA) for contouring target volumes and organs at risk.", [["organs", "ANATOMY", 244, 250], ["organs", "ORGAN", 244, 250], ["Treatment planning", "TREATMENT", 0, 18], ["a computed tomography (CT) scan", "TEST", 41, 72], ["the Varian Eclipse Version", "TREATMENT", 111, 137]]], ["The definition of planning target volume (PTV) followed the contouring guidelines for IFRT by the International Lymphoma Radiation Oncology Group (ILROG) [13, 14] with each separate plan applying 30.6 Gy in 17 fractions of 1.8 Gy five times a week.Material and methodsPhysical realization of these requirements was achieved in three alternative plans for every case: one using a standard 3D-conformal setup of APPA radiation and two using IMRT solutions, one using five fields (5F-IMRT) and one using seven fields (7F-IMRT).", [["Lymphoma", "DISEASE", 112, 120], ["APPA", "CHEMICAL", 410, 414], ["planning target volume (PTV)", "TREATMENT", 18, 46], ["the contouring guidelines", "TREATMENT", 56, 81], ["IFRT", "TREATMENT", 86, 90], ["APPA radiation", "TREATMENT", 410, 424], ["IMRT solutions", "TREATMENT", 439, 453], ["5F-IMRT", "TREATMENT", 478, 485], ["7F-IMRT", "TREATMENT", 515, 522], ["17 fractions", "OBSERVATION_MODIFIER", 207, 219]]], ["Figure 1 illustrates the dose distributions of these three methods in one exemplary case.Material and methodsIn the planning process, a dose grid of 2.5 mm and the dose calculation algorithm AAA were used, IMRT was performed with fixed-beam angles.", [["the dose calculation algorithm AAA", "TREATMENT", 160, 194], ["IMRT", "TEST", 206, 210]]], ["For the 5\u2011field IMRT beam, angles of 20\u00b0, 145\u00b0, 180\u00b0, 215\u00b0, and 340\u00b0 were used.", [["angles", "TEST", 27, 33]]], ["The 7\u2011field IMRT was equally distributed in 51\u00b0 steps (0\u00b0 up to 306\u00b0).", [["The 7\u2011field IMRT", "TREATMENT", 0, 16]]], ["The Eclipse planning system generates optimal fluences in the optimization process by adjusting the ray weights using a gradient optimization method.", [["the ray weights", "TEST", 96, 111], ["a gradient optimization method", "TREATMENT", 118, 148], ["optimal fluences", "OBSERVATION", 38, 54]]], ["The optimal fluences represent the ideal field modulation in which the physical and mechanical characteristics of the MLC device have not been taken into account.", [["the MLC device", "TREATMENT", 114, 128], ["optimal fluences", "OBSERVATION", 4, 20], ["ideal", "OBSERVATION_MODIFIER", 35, 40], ["field modulation", "OBSERVATION", 41, 57]]], ["The real fluence is achieved by the Leaf Motion Calculator after optimization.", [["the Leaf Motion Calculator", "TREATMENT", 32, 58], ["Leaf Motion", "OBSERVATION", 36, 47]]], ["Initial dose objectives were set to values based on QUANTEC (Quantitative Analyses of Normal Tissue Effects in the Clinic) data [17], followed by patient-individual optimization to achieve ideal treatment plans, which conformed to the ILROG guidelines for dose constraints in Hodgkin\u2019s lymphoma therapy dosimetrically [13].", [["Hodgkin\u2019s lymphoma", "ANATOMY", 276, 294], ["Hodgkin\u2019s lymphoma", "DISEASE", 276, 294], ["patient", "ORGANISM", 146, 153], ["Hodgkin\u2019s lymphoma", "CANCER", 276, 294], ["patient", "SPECIES", 146, 153], ["ideal treatment plans", "TREATMENT", 189, 210], ["dose constraints", "TREATMENT", 256, 272], ["Hodgkin\u2019s lymphoma therapy", "TREATMENT", 276, 302]]], ["Plan normalization to PTV-Dmean = 100% of the prescribed isodose was performed to create identical dose setups.", [["PTV", "TEST", 22, 25], ["Dmean", "TEST", 26, 31], ["the prescribed isodose", "TREATMENT", 42, 64]]], ["After optimization to ensure clinical applicability, dose\u2013volume histogram (DVH) data were gathered as an indication of the difference in dose distributions of the particular methods.", [["clinical applicability", "TEST", 29, 51], ["dose\u2013volume histogram (DVH) data", "TEST", 53, 85]]], ["Each treatment plan was assessed via the tool for biological evaluation implemented in Varian Eclipse and by using the Lyman\u2013Kutscher\u2013Burman model for modelling biological response probabilities of different tissue [15], predicting normal tissue complication probabilities (NTCPs) as well as tumor control rates (TCPs).Material and methodsIn accordance with this model, both lungs were selected as organs of interest.", [["tissue", "ANATOMY", 208, 214], ["tissue", "ANATOMY", 239, 245], ["tumor", "ANATOMY", 292, 297], ["lungs", "ANATOMY", 375, 380], ["organs", "ANATOMY", 398, 404], ["tumor", "DISEASE", 292, 297], ["tissue", "TISSUE", 208, 214], ["tissue", "TISSUE", 239, 245], ["tumor", "CANCER", 292, 297], ["lungs", "ORGAN", 375, 380], ["organs", "ORGAN", 398, 404], ["biological evaluation", "TEST", 50, 71], ["the Lyman\u2013Kutscher\u2013Burman model", "TREATMENT", 115, 146], ["normal tissue complication probabilities", "PROBLEM", 232, 272], ["tumor control rates", "TREATMENT", 292, 311], ["normal tissue", "OBSERVATION_MODIFIER", 232, 245], ["complication", "OBSERVATION", 246, 258], ["tumor", "OBSERVATION", 292, 297], ["lungs", "ANATOMY", 375, 380]]], ["The risk calculation of the endpoint was set to the mildest selectable form of pulmonary toxicity, i.e., \u201csymptomatic or radiographic pneumonitis,\u201d which was evaluated for each treatment plan.", [["pulmonary", "ANATOMY", 79, 88], ["pulmonary toxicity", "DISEASE", 79, 97], ["pneumonitis", "DISEASE", 134, 145], ["pulmonary", "ORGAN", 79, 88], ["pulmonary toxicity", "PROBLEM", 79, 97], ["radiographic pneumonitis", "PROBLEM", 121, 145], ["each treatment plan", "TREATMENT", 172, 191], ["pulmonary", "ANATOMY", 79, 88], ["toxicity", "OBSERVATION", 89, 97], ["symptomatic", "OBSERVATION_MODIFIER", 106, 117], ["pneumonitis", "OBSERVATION", 134, 145]]], ["Furthermore, two sets of parameters were used as a basis for the calculation of the NTCPs: first, the parameters suggested by Burman [16], which are the standard setup when using Varian Eclipse\u2019s biological treatment evaluation.", [["Varian Eclipse", "TREATMENT", 179, 193], ["biological treatment evaluation", "TEST", 196, 227]]], ["Second, the parameters published by QUANTEC [17], which aim at bringing model predictions closer to real clinical outcomes.Material and methodsAdjustable parameters of the model were n and m as parameters representing steepness, TD50 for positioning, and alpha/beta for the curvature of the curve modeling the dose\u2013response of the selected tissue.", [["tissue", "ANATOMY", 340, 346], ["alpha/beta", "GENE_OR_GENE_PRODUCT", 255, 265], ["tissue", "TISSUE", 340, 346], ["alpha/beta", "PROTEIN", 255, 265], ["steepness", "TEST", 218, 227], ["TD50", "TREATMENT", 229, 233], ["positioning", "TEST", 238, 249], ["alpha/beta", "TREATMENT", 255, 265], ["selected tissue", "OBSERVATION", 331, 346]]], ["In order to include long-term toxicity, the induction risk of radiation-associated second malignancies in each plan was assessed using the function developed by Schneider et al. [18].", [["malignancies", "ANATOMY", 90, 102], ["toxicity", "DISEASE", 30, 38], ["malignancies", "DISEASE", 90, 102], ["malignancies", "CANCER", 90, 102], ["long-term toxicity", "PROBLEM", 20, 38], ["second malignancies", "PROBLEM", 83, 102], ["long-term", "OBSERVATION_MODIFIER", 20, 29], ["malignancies", "OBSERVATION", 90, 102]]], ["This function is based on organ-equivalent dose and models dose\u2013response by utilizing several patient-, tissue-, and plan-specific parameters to predict the risk of malignancies.Material and methodsAll data were statistically analyzed to evaluate the potential significance of correlations between the treatment planning modality (APPA vs. 5\u2011field IMRT vs. 7\u2011field IMRT) and associated NTCP as well as second malignancy probability, using the Shapiro\u2013Wilk test and the Kolmogorov\u2013Smirnov test for distribution analysis, and the Wilcoxon rank test to check for significance.", [["organ", "ANATOMY", 26, 31], ["tissue", "ANATOMY", 104, 110], ["malignancies", "ANATOMY", 165, 177], ["malignancies", "DISEASE", 165, 177], ["malignancy", "DISEASE", 409, 419], ["organ", "ORGAN", 26, 31], ["patient", "ORGANISM", 94, 101], ["tissue", "TISSUE", 104, 110], ["malignancies", "CANCER", 165, 177], ["patient", "SPECIES", 94, 101], ["malignancies", "PROBLEM", 165, 177], ["All data", "TEST", 198, 206], ["the treatment planning modality", "TREATMENT", 298, 329], ["APPA vs. 5\u2011field IMRT", "TREATMENT", 331, 352], ["7\u2011field IMRT", "TREATMENT", 357, 369], ["associated NTCP", "PROBLEM", 375, 390], ["second malignancy probability", "PROBLEM", 402, 431], ["the Shapiro\u2013Wilk test", "TEST", 439, 460], ["the Kolmogorov\u2013Smirnov test", "TEST", 465, 492], ["distribution analysis", "TEST", 497, 518], ["the Wilcoxon rank test", "TEST", 524, 546], ["malignancies", "OBSERVATION", 165, 177]]], ["The overall accuracy of these theoretical or predicted risks, respectively, was determined by comparing them with each patient\u2019s clinical follow-up through the examination of medical aftercare reports and radiographic follow-ups.ResultsThe comparison of DVH data of individual treatment plans showed a shift in the balance of tissue affection with low as well as high doses when switching from 3D-CRT to IMRT: Volumes irradiated with low doses from 5 to 15 Gy (V5\u2013V15) were more prominent in median and mean when using IMRT (5-field as well as 7\u2011field) compared with APPA.", [["tissue", "ANATOMY", 326, 332], ["patient", "ORGANISM", 119, 126], ["tissue", "TISSUE", 326, 332], ["V5", "PROTEIN", 461, 463], ["APPA", "PROTEIN", 567, 571], ["patient", "SPECIES", 119, 126], ["the examination", "TEST", 156, 171], ["radiographic follow-ups", "TEST", 205, 228], ["DVH data", "TEST", 254, 262], ["individual treatment", "TREATMENT", 266, 286], ["a shift", "PROBLEM", 300, 307], ["tissue affection", "PROBLEM", 326, 342], ["3D-CRT to IMRT", "TREATMENT", 394, 408], ["Volumes", "TEST", 410, 417], ["IMRT", "TEST", 519, 523], ["tissue", "ANATOMY", 326, 332], ["affection", "OBSERVATION", 333, 342], ["prominent", "OBSERVATION_MODIFIER", 479, 488]]], ["Mean and median volumes with doses between 20 and 30 Gy (V20\u2013V30) in the APPA plans exceeded those in the IMRT plans.", [["Mean", "TEST", 0, 4], ["median volumes", "TEST", 9, 23], ["doses", "TEST", 29, 34], ["the IMRT plans", "TREATMENT", 102, 116], ["median volumes", "OBSERVATION", 9, 23]]], ["Comparing IMRT plans, 5\u2011field IMRT showed dose distributions very similar to 7\u2011field IMRT, but with overall smaller low-dose areas.", [["dose distributions", "PROBLEM", 42, 60], ["smaller", "OBSERVATION_MODIFIER", 108, 115], ["low-dose", "OBSERVATION_MODIFIER", 116, 124]]], ["Additional analysis of the DVH showed that the volumes being affected by a specific dose when using IMRT over APPA were larger up to a dose of 19.3 Gy (being 63% of the target dose of 30.6 Gy).", [["Additional analysis", "TEST", 0, 19], ["the DVH", "TEST", 23, 30], ["the volumes", "PROBLEM", 43, 54], ["IMRT over APPA", "TREATMENT", 100, 114]]], ["Therefore, IMRT showed more tissue affected with low-dose areas, whereas APPA had smaller low-dose areas but larger high-dose areas.ResultsUsing the biological evaluation tool to investigate suspected differences in normal tissue complication probability between these dose distributions, and analysis using the standard parameters by Burman as well as the new QUANTEC parameters, yielded the results shown in Table 1.ResultsThe analysis demonstrated noticeably higher values using the QUANTEC parameters; NTCPs clearly tended to be higher in 5\u2011field IMRT than in APPA and the highest in 7\u2011field IMRT in both analyses.", [["tissue", "ANATOMY", 28, 34], ["tissue", "ANATOMY", 223, 229], ["APPA", "CHEMICAL", 73, 77], ["tissue", "TISSUE", 28, 34], ["tissue", "TISSUE", 223, 229], ["NTCPs", "SIMPLE_CHEMICAL", 506, 511], ["IMRT", "TEST", 11, 15], ["more tissue affected", "PROBLEM", 23, 43], ["low-dose areas", "TREATMENT", 49, 63], ["the biological evaluation tool", "TEST", 145, 175], ["normal tissue complication", "PROBLEM", 216, 242], ["analysis", "TEST", 293, 301], ["the new QUANTEC parameters", "TEST", 353, 379], ["The analysis", "TEST", 425, 437], ["noticeably higher values", "PROBLEM", 451, 475], ["the QUANTEC parameters", "TEST", 482, 504], ["NTCPs", "TEST", 506, 511], ["APPA", "TEST", 564, 568], ["more tissue", "OBSERVATION_MODIFIER", 23, 34], ["affected", "OBSERVATION_MODIFIER", 35, 43], ["low-dose", "OBSERVATION_MODIFIER", 49, 57], ["smaller", "OBSERVATION_MODIFIER", 82, 89], ["low-dose", "OBSERVATION_MODIFIER", 90, 98], ["larger", "OBSERVATION_MODIFIER", 109, 115], ["high", "OBSERVATION_MODIFIER", 116, 120], ["-dose", "OBSERVATION_MODIFIER", 120, 125], ["normal tissue", "OBSERVATION_MODIFIER", 216, 229], ["complication", "OBSERVATION", 230, 242], ["higher", "OBSERVATION_MODIFIER", 533, 539]]], ["The following statistic evaluation showed the differences to be highly significant with values of p<0.01 for the differences between APPA and 5\u2011field IMRT, APPA and 7\u2011field IMRT, as well as 5\u2011field and 7\u2011field IMRT.ResultsIn the next step, the inherent risks of treatment plans were analyzed by employing the formula by Schneider et al. with the following objectives.", [["APPA", "CHEMICAL", 133, 137], ["APPA", "SIMPLE_CHEMICAL", 156, 160], ["statistic evaluation", "TEST", 14, 34], ["APPA", "TEST", 133, 137], ["APPA and 7\u2011field IMRT", "TREATMENT", 156, 177], ["treatment plans", "TREATMENT", 262, 277]]], ["First, scrutinizing the high-grade toxicity of pulmonary second malignoma.", [["pulmonary", "ANATOMY", 47, 56], ["toxicity", "DISEASE", 35, 43], ["pulmonary second malignoma", "DISEASE", 47, 73], ["pulmonary", "ORGAN", 47, 56], ["the high-grade toxicity of pulmonary second malignoma", "PROBLEM", 20, 73], ["high-grade", "OBSERVATION_MODIFIER", 24, 34], ["toxicity", "OBSERVATION", 35, 43], ["pulmonary", "ANATOMY", 47, 56], ["second malignoma", "OBSERVATION", 57, 73]]], ["The risks were calculated as lifetime risks based on the statistical life expectancy of each patient without taking into account their respective medical history.", [["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100]]], ["The results are shown in Table 2.ResultsThe APPA plans were associated with a mean lifetime risk of 0.37% (with a vast range between 0.06 and 1.27%), 5\u2011field IMRT with a mean risk of 0.47% (range: 0.08\u20131.62%) and 7\u2011field IMRT with a mean risk of 0.56% (range: 0.1\u20131.85%).", [["a mean risk", "TEST", 168, 179], ["a mean risk", "TEST", 231, 242]]], ["Again, 3D conformal beam setup demonstrated a significantly lower risk (p < 0.01) for pulmonary toxicity compared with IMRT (with 5\u2011field IMRT bearing a statistically significant lower risk for second malignoma than 7\u2011field IMRT as well, i.e., p < 0.01).ResultsDirect comparison of planning methods led to the following results: Choosing 5\u2011field IMRT over APPA increased the risk for pulmonary second malignancy by a mean 0.1%; i.e., a relative increase of 27%.", [["pulmonary", "ANATOMY", 86, 95], ["pulmonary", "ANATOMY", 384, 393], ["pulmonary toxicity", "DISEASE", 86, 104], ["pulmonary second malignancy", "DISEASE", 384, 411], ["pulmonary", "ORGAN", 86, 95], ["pulmonary", "ORGAN", 384, 393], ["3D conformal beam setup", "TEST", 7, 30], ["a significantly lower risk", "PROBLEM", 44, 70], ["pulmonary toxicity", "PROBLEM", 86, 104], ["IMRT", "TREATMENT", 119, 123], ["5\u2011field IMRT", "TREATMENT", 130, 142], ["second malignoma", "PROBLEM", 194, 210], ["pulmonary second malignancy", "PROBLEM", 384, 411], ["pulmonary", "ANATOMY", 86, 95], ["toxicity", "OBSERVATION", 96, 104], ["pulmonary", "ANATOMY", 384, 393], ["malignancy", "OBSERVATION", 401, 411], ["increase", "OBSERVATION_MODIFIER", 445, 453]]], ["Choosing 7\u2011field IMRT over APPA increased the risk by a mean of 0.19% (relative increase of 51%) and choosing 7\u2011field over 5\u2011field IMRT increased the risk by a mean 0.09% (relative increase of 19%).ResultsOverall, 20 of the patients included were treated with APPA plans, four were treated with 5\u2011field IMRT and three with 7\u2011field IMRT.", [["patients", "ORGANISM", 224, 232], ["patients", "SPECIES", 224, 232], ["APPA plans", "TREATMENT", 260, 270], ["7\u2011field IMRT", "TREATMENT", 323, 335]]], ["When assessing follow-up data to check for validity of the theoretical risks, one patient reported prolonged symptoms of pulmonary toxicity (shortness of breath 6 months after end of RT via 7F-IMRT) without detectable limitations in lung capacity.", [["pulmonary", "ANATOMY", 121, 130], ["lung", "ANATOMY", 233, 237], ["pulmonary toxicity", "DISEASE", 121, 139], ["shortness of breath", "DISEASE", 141, 160], ["patient", "ORGANISM", 82, 89], ["pulmonary", "ORGAN", 121, 130], ["lung", "ORGAN", 233, 237], ["patient", "SPECIES", 82, 89], ["prolonged symptoms", "PROBLEM", 99, 117], ["pulmonary toxicity", "PROBLEM", 121, 139], ["shortness of breath", "PROBLEM", 141, 160], ["RT via 7F-IMRT", "TREATMENT", 183, 197], ["detectable limitations in lung capacity", "PROBLEM", 207, 246], ["pulmonary", "ANATOMY", 121, 130], ["toxicity", "OBSERVATION", 131, 139], ["lung", "ANATOMY", 233, 237], ["capacity", "OBSERVATION", 238, 246]]], ["One follow-up thoracic CT scan showed signs of potential radiation pneumonitis in a low-dose area; the patient neither reported any symptoms nor could any limitations in lung capacity be detected within 6 months of APPA-RT.ResultsTherefore, the reported toxicities drawn from patient aftercare reports as well as radiographic follow-up fit the overall low probabilities of pulmonary toxicity shown in the analysis.", [["thoracic", "ANATOMY", 14, 22], ["lung", "ANATOMY", 170, 174], ["pulmonary", "ANATOMY", 373, 382], ["pneumonitis", "DISEASE", 67, 78], ["APPA", "CHEMICAL", 215, 219], ["toxicities", "DISEASE", 254, 264], ["pulmonary toxicity", "DISEASE", 373, 391], ["thoracic", "ORGAN", 14, 22], ["patient", "ORGANISM", 103, 110], ["lung", "ORGAN", 170, 174], ["patient", "ORGANISM", 276, 283], ["pulmonary", "ORGAN", 373, 382], ["patient", "SPECIES", 103, 110], ["patient", "SPECIES", 276, 283], ["One follow-up thoracic CT scan", "TEST", 0, 30], ["potential radiation pneumonitis", "PROBLEM", 47, 78], ["a low-dose area", "TREATMENT", 82, 97], ["any symptoms", "PROBLEM", 128, 140], ["lung capacity", "PROBLEM", 170, 183], ["APPA-RT", "TREATMENT", 215, 222], ["the reported toxicities", "PROBLEM", 241, 264], ["pulmonary toxicity", "PROBLEM", 373, 391], ["the analysis", "TEST", 401, 413], ["thoracic", "ANATOMY", 14, 22], ["signs of", "UNCERTAINTY", 38, 46], ["potential", "OBSERVATION_MODIFIER", 47, 56], ["radiation", "OBSERVATION_MODIFIER", 57, 66], ["pneumonitis", "OBSERVATION", 67, 78], ["lung", "ANATOMY", 170, 174], ["pulmonary", "ANATOMY", 373, 382], ["toxicity", "OBSERVATION", 383, 391]]], ["No patient developed pulmonary malignancy.", [["pulmonary malignancy", "ANATOMY", 21, 41], ["pulmonary malignancy", "DISEASE", 21, 41], ["patient", "ORGANISM", 3, 10], ["pulmonary", "ORGAN", 21, 30], ["patient", "SPECIES", 3, 10], ["pulmonary malignancy", "PROBLEM", 21, 41], ["pulmonary", "ANATOMY", 21, 30], ["malignancy", "OBSERVATION", 31, 41]]], ["Mean follow-up time was 65 months (95% confidence interval: 53.8\u201376.2 months), with seven patients being lost to follow-up before the benchmark of 60 months.DiscussionThe aim of this study was to evaluate whether the choice of IMRT over classic 3D-CRT benefits patients undergoing treatment for mediastinal Hodgkin\u2019s lymphoma regarding the minimization of lung toxicity.", [["mediastinal Hodgkin\u2019s lymphoma", "ANATOMY", 295, 325], ["lung", "ANATOMY", 356, 360], ["mediastinal Hodgkin\u2019s lymphoma", "DISEASE", 295, 325], ["lung toxicity", "DISEASE", 356, 369], ["patients", "ORGANISM", 90, 98], ["patients", "ORGANISM", 261, 269], ["mediastinal Hodgkin\u2019s lymphoma", "CANCER", 295, 325], ["lung", "ORGAN", 356, 360], ["patients", "SPECIES", 90, 98], ["patients", "SPECIES", 261, 269], ["this study", "TEST", 178, 188], ["IMRT", "TREATMENT", 227, 231], ["treatment", "TREATMENT", 281, 290], ["mediastinal Hodgkin\u2019s lymphoma", "PROBLEM", 295, 325], ["lung toxicity", "PROBLEM", 356, 369], ["mediastinal", "ANATOMY", 295, 306], ["Hodgkin", "OBSERVATION", 307, 314], ["lung", "ANATOMY", 356, 360], ["toxicity", "OBSERVATION", 361, 369]]], ["It must be stated that the analyzed cohort was irradiated with IFRT, which is no longer the standard in target volume definition for lymphoma patients and has since been succeeded by ISRT or INRT.", [["lymphoma", "ANATOMY", 133, 141], ["lymphoma", "DISEASE", 133, 141], ["lymphoma", "CANCER", 133, 141], ["patients", "ORGANISM", 142, 150], ["patients", "SPECIES", 142, 150], ["IFRT", "TREATMENT", 63, 67], ["lymphoma", "PROBLEM", 133, 141], ["no longer", "UNCERTAINTY", 78, 87], ["lymphoma", "OBSERVATION", 133, 141]]], ["This de-escalation in radiotherapy volume has proven to be equally beneficial for tumor control [19] and is currently reviewed further in the German HD17 trial [20].", [["tumor", "ANATOMY", 82, 87], ["tumor", "DISEASE", 82, 87], ["tumor", "CANCER", 82, 87], ["This de-escalation", "TREATMENT", 0, 18], ["radiotherapy volume", "TREATMENT", 22, 41], ["tumor control", "TREATMENT", 82, 95], ["tumor", "OBSERVATION", 82, 87]]], ["Nevertheless, this study focused on IFRT because of its long history of application.", [["this study", "TEST", 14, 24], ["IFRT", "TREATMENT", 36, 40]]], ["This amounts to more clinical data being available due to longer periods of patient follow-up.DiscussionComparing the DVHs of the analyzed treatment plans demonstrated significant differences among the various modalities in terms of dose distribution in organs at risk.", [["organs", "ANATOMY", 254, 260], ["patient", "ORGANISM", 76, 83], ["organs", "ORGAN", 254, 260], ["patient", "SPECIES", 76, 83], ["significant differences", "PROBLEM", 168, 191], ["significant", "OBSERVATION_MODIFIER", 168, 179]]], ["Subsequently, variations in possible treatment toxicities were proven to be statistically significant: In line with other studies, IMRT has proven to be associated with a higher risk of pulmonary toxicity than 3D-CRT [21].", [["pulmonary", "ANATOMY", 186, 195], ["toxicities", "DISEASE", 47, 57], ["pulmonary toxicity", "DISEASE", 186, 204], ["pulmonary", "ORGAN", 186, 195], ["treatment toxicities", "PROBLEM", 37, 57], ["other studies", "TEST", 116, 129], ["IMRT", "TREATMENT", 131, 135], ["pulmonary toxicity", "PROBLEM", 186, 204], ["CRT", "TEST", 213, 216], ["pulmonary", "ANATOMY", 186, 195], ["toxicity", "OBSERVATION", 196, 204]]], ["Other studies point out that this increase of low-dose tissue irradiation might be compensated by superior target volume coverage delivered by IMRT [22, 23].", [["tissue", "ANATOMY", 55, 61], ["tissue", "TISSUE", 55, 61], ["Other studies", "TEST", 0, 13], ["low-dose tissue irradiation", "TREATMENT", 46, 73], ["superior target volume coverage", "TREATMENT", 98, 129], ["low-dose tissue", "OBSERVATION_MODIFIER", 46, 61]]], ["The additional scientific effort has since shown other treatment modalities to effectively achieve more efficient protection of normal tissue: Both proton therapy and VMAT may be beneficial [22, 24] while deep inspiration breath-hold serves as a strategy to reduce treatment toxicity over multiple modalities [22].DiscussionWith a wide array of possible strategies, finding the optimal treatment planning method for mediastinal radiation requires a multifaceted approach.", [["tissue", "ANATOMY", 135, 141], ["mediastinal", "ANATOMY", 416, 427], ["toxicity", "DISEASE", 275, 283], ["normal tissue", "TISSUE", 128, 141], ["other treatment modalities", "TREATMENT", 49, 75], ["Both proton therapy", "TREATMENT", 143, 162], ["VMAT", "TREATMENT", 167, 171], ["deep inspiration breath", "TEST", 205, 228], ["a strategy", "TREATMENT", 244, 254], ["treatment toxicity", "PROBLEM", 265, 283], ["strategies", "TREATMENT", 354, 364], ["the optimal treatment planning method", "TREATMENT", 374, 411], ["mediastinal radiation", "TREATMENT", 416, 437], ["a multifaceted approach", "TREATMENT", 447, 470], ["normal tissue", "OBSERVATION", 128, 141], ["mediastinal", "ANATOMY", 416, 427], ["radiation", "OBSERVATION", 428, 437]]], ["This study has scrutinized lung toxicity as a surrogate organ at risk because it can be detected easily during follow-up.", [["lung", "ANATOMY", 27, 31], ["organ", "ANATOMY", 56, 61], ["lung toxicity", "DISEASE", 27, 40], ["lung", "ORGAN", 27, 31], ["organ", "ORGAN", 56, 61], ["This study", "TEST", 0, 10], ["lung toxicity", "PROBLEM", 27, 40], ["lung", "ANATOMY", 27, 31], ["toxicity", "OBSERVATION", 32, 40]]], ["It has also been chosen because of the variety in possible toxicity, ranging from short-term and relatively mild (i.e., radiation pneumonitis) to long-term and severe (i.e., pulmonary second malignancy) symptoms.", [["pulmonary", "ANATOMY", 174, 183], ["toxicity", "DISEASE", 59, 67], ["pneumonitis", "DISEASE", 130, 141], ["pulmonary second malignancy", "DISEASE", 174, 201], ["pulmonary", "ORGAN", 174, 183], ["toxicity", "PROBLEM", 59, 67], ["relatively mild (i.e., radiation pneumonitis", "PROBLEM", 97, 141], ["pulmonary second malignancy) symptoms", "PROBLEM", 174, 211], ["variety", "OBSERVATION_MODIFIER", 39, 46], ["possible", "UNCERTAINTY", 50, 58], ["toxicity", "OBSERVATION", 59, 67], ["short-term", "OBSERVATION_MODIFIER", 82, 92], ["mild", "OBSERVATION_MODIFIER", 108, 112], ["radiation pneumonitis", "OBSERVATION", 120, 141], ["long-term", "OBSERVATION_MODIFIER", 146, 155], ["severe", "OBSERVATION_MODIFIER", 160, 166], ["pulmonary", "ANATOMY", 174, 183], ["malignancy", "OBSERVATION", 191, 201]]], ["These endpoints were not only already implemented in modules for biological evaluation in standard treatment planning software but also modeled in dose\u2013response equations.", [["biological evaluation", "TEST", 65, 86]]], ["If proven reliable, they could be used in clinical routine.DiscussionThe overall values for pulmonary toxicity for patients with mediastinal Hodgkin\u2019s lymphoma have been determined as marginal, a finding that aligns with other studies showing similar results [21, 25, 26].", [["pulmonary", "ANATOMY", 92, 101], ["mediastinal Hodgkin\u2019s lymphoma", "ANATOMY", 129, 159], ["pulmonary toxicity", "DISEASE", 92, 110], ["mediastinal Hodgkin\u2019s lymphoma", "DISEASE", 129, 159], ["pulmonary", "ORGAN", 92, 101], ["patients", "ORGANISM", 115, 123], ["mediastinal Hodgkin\u2019s lymphoma", "CANCER", 129, 159], ["patients", "SPECIES", 115, 123], ["pulmonary toxicity", "PROBLEM", 92, 110], ["mediastinal Hodgkin\u2019s lymphoma", "PROBLEM", 129, 159], ["other studies", "TEST", 221, 234], ["pulmonary", "ANATOMY", 92, 101], ["mediastinal", "ANATOMY", 129, 140], ["Hodgkin", "OBSERVATION", 141, 148], ["marginal", "OBSERVATION_MODIFIER", 184, 192]]], ["Nevertheless, the focus on lung toxicity represents only a fraction of information when analyzing possible treatment toxicity.", [["lung", "ANATOMY", 27, 31], ["lung toxicity", "DISEASE", 27, 40], ["toxicity", "DISEASE", 117, 125], ["lung", "ORGAN", 27, 31], ["lung toxicity", "PROBLEM", 27, 40], ["treatment toxicity", "PROBLEM", 107, 125], ["lung", "ANATOMY", 27, 31], ["toxicity", "OBSERVATION", 32, 40]]], ["As studies have shown, other thoracic organs such as the heart and the mammary glands also demand a high degree of caution when evaluating treatment plans; exposing them to radiation may lead to severe late treatment toxicity [27].DiscussionMediastinal radiation bears the risk of second malignancy [21, 28].", [["thoracic organs", "ANATOMY", 29, 44], ["heart", "ANATOMY", 57, 62], ["mammary glands", "ANATOMY", 71, 85], ["Mediastinal", "ANATOMY", 241, 252], ["toxicity", "DISEASE", 217, 225], ["malignancy", "DISEASE", 288, 298], ["thoracic organs", "MULTI-TISSUE_STRUCTURE", 29, 44], ["heart", "ORGAN", 57, 62], ["mammary glands", "ORGAN", 71, 85], ["As studies", "TEST", 0, 10], ["other thoracic organs such as the heart and the mammary glands", "PROBLEM", 23, 85], ["treatment plans", "TREATMENT", 139, 154], ["radiation", "TREATMENT", 173, 182], ["severe late treatment toxicity", "PROBLEM", 195, 225], ["Mediastinal radiation", "TREATMENT", 241, 262], ["second malignancy", "PROBLEM", 281, 298], ["thoracic organs", "ANATOMY", 29, 44], ["heart", "ANATOMY", 57, 62], ["mammary glands", "ANATOMY", 71, 85], ["Mediastinal", "ANATOMY", 241, 252], ["radiation", "OBSERVATION", 253, 262], ["malignancy", "OBSERVATION", 288, 298]]], ["It is, therefore, crucial to render it an important focus point in treatment evaluation, especially when treating a disease with a relatively young mean age of onset.", [["treatment evaluation", "TEST", 67, 87], ["a disease", "PROBLEM", 114, 123]]], ["For example, radiation to the mammary glands has proven to be a relevant but reducible risk factor for developing breast cancer [24, 29, 30].DiscussionIn this analysis, possibilities for lifetime risks of pulmonary second malignancy were shown to be wide-ranging\u2014a result of the high variation in the age of onset and life expectancy, respectively.", [["mammary glands", "ANATOMY", 30, 44], ["breast cancer", "ANATOMY", 114, 127], ["pulmonary", "ANATOMY", 205, 214], ["breast cancer", "DISEASE", 114, 127], ["pulmonary second malignancy", "DISEASE", 205, 232], ["mammary glands", "ORGAN", 30, 44], ["breast cancer", "CANCER", 114, 127], ["pulmonary", "ORGAN", 205, 214], ["radiation to the mammary glands", "PROBLEM", 13, 44], ["reducible risk factor", "PROBLEM", 77, 98], ["developing breast cancer", "PROBLEM", 103, 127], ["this analysis", "TEST", 154, 167], ["pulmonary second malignancy", "PROBLEM", 205, 232], ["the high variation", "PROBLEM", 275, 293], ["mammary glands", "ANATOMY", 30, 44], ["reducible", "OBSERVATION_MODIFIER", 77, 86], ["breast", "ANATOMY", 114, 120], ["cancer", "OBSERVATION", 121, 127], ["pulmonary", "ANATOMY", 205, 214], ["malignancy", "OBSERVATION", 222, 232], ["high variation", "OBSERVATION", 279, 293]]], ["Nevertheless, this statistical analysis is proof that the correlation of a higher risk of pulmonary malignancy with IMRT planning vs. APPA planning is statistically significant.", [["pulmonary malignancy", "ANATOMY", 90, 110], ["pulmonary malignancy", "DISEASE", 90, 110], ["pulmonary", "ORGAN", 90, 99], ["this statistical analysis", "TEST", 14, 39], ["pulmonary malignancy", "PROBLEM", 90, 110], ["IMRT planning", "TREATMENT", 116, 129], ["pulmonary", "ANATOMY", 90, 99], ["malignancy", "OBSERVATION", 100, 110], ["significant", "OBSERVATION_MODIFIER", 165, 176]]], ["It demonstrates that modern solutions such as IMRT do not necessarily result in lesser toxicity, at least concerning the lungs.", [["lungs", "ANATOMY", 121, 126], ["toxicity", "DISEASE", 87, 95], ["lungs", "ORGAN", 121, 126], ["modern solutions", "TREATMENT", 21, 37], ["IMRT", "TREATMENT", 46, 50], ["lesser toxicity", "PROBLEM", 80, 95], ["lesser", "OBSERVATION_MODIFIER", 80, 86], ["toxicity", "OBSERVATION", 87, 95], ["lungs", "ANATOMY", 121, 126]]], ["Since this evaluation focused only on pulmonary malignoma, further research concerning other organs at risk (especially regarding the mammary glands) is necessary.", [["pulmonary", "ANATOMY", 38, 47], ["organs", "ANATOMY", 93, 99], ["mammary glands", "ANATOMY", 134, 148], ["pulmonary malignoma", "DISEASE", 38, 57], ["pulmonary", "ORGAN", 38, 47], ["organs", "ORGAN", 93, 99], ["mammary glands", "ORGAN", 134, 148], ["this evaluation", "TEST", 6, 21], ["pulmonary malignoma", "PROBLEM", 38, 57], ["other organs at risk", "PROBLEM", 87, 107], ["pulmonary", "ANATOMY", 38, 47], ["malignoma", "OBSERVATION", 48, 57], ["mammary glands", "ANATOMY", 134, 148]]], ["The fact that no pulmonary malignancies were detected in the patients\u2019 history after initial treatment should not be overestimated since the duration of follow-up is not long enough to present valid data.DiscussionRegarding the calculated differences, it is furthermore important not to over-scrutinize relative differences when comparing different planning techniques: Big relative increases in risk (e.g., the relative increase in risk shown for pulmonary malignancies of 27 and 51% when choosing 5\u2011field or 7\u2011field IMRT over APPA) can accompany marginal absolute differences and should therefore not be overvalued when it comes to clinical relevance.DiscussionSince the complexity of circumstances regarding advantages and disadvantages of every modality does not allow for a universal solution, treatment individualization is the most feasible way to further decrease treatment toxicity.", [["pulmonary malignancies", "ANATOMY", 17, 39], ["pulmonary malignancies", "ANATOMY", 448, 470], ["pulmonary malignancies", "DISEASE", 17, 39], ["pulmonary malignancies", "DISEASE", 448, 470], ["toxicity", "DISEASE", 882, 890], ["pulmonary malignancies", "CANCER", 17, 39], ["patients", "ORGANISM", 61, 69], ["pulmonary", "ORGAN", 448, 457], ["malignancies", "CANCER", 458, 470], ["patients", "SPECIES", 61, 69], ["pulmonary malignancies", "PROBLEM", 17, 39], ["initial treatment", "TREATMENT", 85, 102], ["pulmonary malignancies", "PROBLEM", 448, 470], ["a universal solution", "TREATMENT", 777, 797], ["treatment individualization", "TREATMENT", 799, 826], ["treatment toxicity", "TREATMENT", 872, 890], ["no", "UNCERTAINTY", 14, 16], ["pulmonary", "ANATOMY", 17, 26], ["malignancies", "OBSERVATION", 27, 39], ["increases", "OBSERVATION_MODIFIER", 383, 392], ["pulmonary", "ANATOMY", 448, 457], ["malignancies", "OBSERVATION", 458, 470], ["marginal", "OBSERVATION_MODIFIER", 548, 556], ["absolute", "OBSERVATION", 557, 565]]], ["The NTCP values are an easily accessible source of additional information when comparing treatment plans and allows for a more informed decision on a specific treatment plan.", [["The NTCP values", "TEST", 0, 15], ["a specific treatment plan", "TREATMENT", 148, 173]]], ["Biological evaluation offers the possibility to individually adjust radiation treatment to a patient\u2019s risk profile, specifically regarding preexisting conditions and previous treatment modalities.DiscussionAdditional radiation-associated lung toxicity might be a key risk factor for patients who have been treated with pneumotoxic substances like bleomycin, which is commonly administered when treating Hodgkin\u2019s lymphoma, but has been proven to increase pulmonary morbidity [3].", [["lung", "ANATOMY", 239, 243], ["Hodgkin\u2019s lymphoma", "ANATOMY", 404, 422], ["pulmonary", "ANATOMY", 456, 465], ["lung toxicity", "DISEASE", 239, 252], ["bleomycin", "CHEMICAL", 348, 357], ["Hodgkin\u2019s lymphoma", "DISEASE", 404, 422], ["bleomycin", "CHEMICAL", 348, 357], ["patient", "ORGANISM", 93, 100], ["lung", "ORGAN", 239, 243], ["patients", "ORGANISM", 284, 292], ["bleomycin", "SIMPLE_CHEMICAL", 348, 357], ["Hodgkin\u2019s lymphoma", "CANCER", 404, 422], ["pulmonary", "ORGAN", 456, 465], ["patient", "SPECIES", 93, 100], ["patients", "SPECIES", 284, 292], ["Biological evaluation", "TEST", 0, 21], ["radiation treatment", "TREATMENT", 68, 87], ["preexisting conditions", "PROBLEM", 140, 162], ["previous treatment modalities", "TREATMENT", 167, 196], ["lung toxicity", "PROBLEM", 239, 252], ["pneumotoxic substances", "TREATMENT", 320, 342], ["bleomycin", "TREATMENT", 348, 357], ["Hodgkin\u2019s lymphoma", "PROBLEM", 404, 422], ["increase pulmonary morbidity", "PROBLEM", 447, 475], ["lung", "ANATOMY", 239, 243], ["toxicity", "OBSERVATION", 244, 252], ["lymphoma", "OBSERVATION", 414, 422], ["pulmonary", "ANATOMY", 456, 465], ["morbidity", "OBSERVATION", 466, 475]]], ["In a similar manner, the treatment with immune-modulatory checkpoint inhibitors such as nivolumab potentially increases the probability of pulmonary complication [31].", [["pulmonary", "ANATOMY", 139, 148], ["nivolumab", "CHEMICAL", 88, 97], ["pulmonary complication", "DISEASE", 139, 161], ["nivolumab", "CHEMICAL", 88, 97], ["nivolumab", "SIMPLE_CHEMICAL", 88, 97], ["pulmonary", "ORGAN", 139, 148], ["the treatment", "TREATMENT", 21, 34], ["immune-modulatory checkpoint inhibitors", "TREATMENT", 40, 79], ["nivolumab", "TREATMENT", 88, 97], ["pulmonary complication", "PROBLEM", 139, 161], ["pulmonary", "ANATOMY", 139, 148], ["complication", "OBSERVATION", 149, 161]]], ["With more evidence supporting this treatment as a valid new option [1], this study\u2019s focus on minimizing radiation-associated adverse events gains further importance.DiscussionThis study has shown that choosing 3D-CRT enables a reduction of potential lung toxicity, making it a valuable option when treating mediastinal Hodgkin\u2019s lymphoma.", [["lung", "ANATOMY", 251, 255], ["mediastinal Hodgkin\u2019s lymphoma", "ANATOMY", 308, 338], ["lung toxicity", "DISEASE", 251, 264], ["mediastinal Hodgkin\u2019s lymphoma", "DISEASE", 308, 338], ["lung", "ORGAN", 251, 255], ["mediastinal Hodgkin\u2019s lymphoma", "CANCER", 308, 338], ["this treatment", "TREATMENT", 30, 44], ["this study", "TEST", 72, 82], ["minimizing radiation", "TREATMENT", 94, 114], ["adverse events", "PROBLEM", 126, 140], ["This study", "TEST", 176, 186], ["CRT", "TREATMENT", 214, 217], ["potential lung toxicity", "PROBLEM", 241, 264], ["mediastinal Hodgkin\u2019s lymphoma", "PROBLEM", 308, 338], ["lung", "ANATOMY", 251, 255], ["toxicity", "OBSERVATION", 256, 264], ["mediastinal", "ANATOMY", 308, 319], ["Hodgkin", "OBSERVATION", 320, 327], ["lymphoma", "OBSERVATION", 330, 338]]], ["Taking the previously discussed results of other researchers into consideration, it is obvious that further reductions in radiation treatment toxicity are achievable but complex.", [["toxicity", "DISEASE", 142, 150], ["radiation treatment toxicity", "TREATMENT", 122, 150], ["reductions", "OBSERVATION_MODIFIER", 108, 118], ["radiation treatment", "OBSERVATION", 122, 141]]], ["Methods of biological evaluation can be useful to assess the advantages and disadvantages of treatment plans but must be considered individually for each case.", [["biological evaluation", "TEST", 11, 32], ["treatment plans", "TREATMENT", 93, 108]]], ["Our study shows limitations in terms of the relatively short periods of follow-up regarding secondary neoplasia, which typically occur after long periods.", [["neoplasia", "ANATOMY", 102, 111], ["neoplasia", "DISEASE", 102, 111], ["neoplasia", "CANCER", 102, 111], ["Our study", "TEST", 0, 9], ["secondary neoplasia", "PROBLEM", 92, 111], ["secondary", "OBSERVATION_MODIFIER", 92, 101], ["neoplasia", "OBSERVATION", 102, 111]]], ["Further limitations are related to the focus on IFRT, which is no longer the standard treatment for Hodgkin\u2019s lymphoma.ConclusionThe occurrence of clinically relevant radiation-induced lung toxicity is relatively rare for patients with Hodgkin\u2019s lymphoma.", [["Hodgkin\u2019s lymphoma", "ANATOMY", 100, 118], ["lung", "ANATOMY", 185, 189], ["Hodgkin\u2019s lymphoma", "ANATOMY", 236, 254], ["Hodgkin\u2019s lymphoma", "DISEASE", 100, 118], ["lung toxicity", "DISEASE", 185, 198], ["Hodgkin\u2019s lymphoma", "DISEASE", 236, 254], ["IFRT", "SIMPLE_CHEMICAL", 48, 52], ["Hodgkin\u2019s lymphoma", "CANCER", 100, 118], ["lung", "ORGAN", 185, 189], ["patients", "ORGANISM", 222, 230], ["Hodgkin\u2019s lymphoma", "CANCER", 236, 254], ["patients", "SPECIES", 222, 230], ["the standard treatment", "TREATMENT", 73, 95], ["Hodgkin\u2019s lymphoma", "PROBLEM", 100, 118], ["lung toxicity", "PROBLEM", 185, 198], ["Hodgkin\u2019s lymphoma", "PROBLEM", 236, 254], ["no longer", "UNCERTAINTY", 63, 72], ["lymphoma", "OBSERVATION", 110, 118], ["radiation", "OBSERVATION", 167, 176], ["lung", "ANATOMY", 185, 189], ["toxicity", "OBSERVATION", 190, 198], ["Hodgkin\u2019s lymphoma", "OBSERVATION", 236, 254]]], ["Nonetheless, it can impair treatment outcomes and increase complication probabilities in other organs at risks, such as the heart or the mammary glands.", [["organs", "ANATOMY", 95, 101], ["heart", "ANATOMY", 124, 129], ["mammary glands", "ANATOMY", 137, 151], ["organs", "ORGAN", 95, 101], ["heart", "ORGAN", 124, 129], ["mammary glands", "ORGAN", 137, 151], ["increase complication probabilities in other organs at risks", "PROBLEM", 50, 110], ["heart", "ANATOMY", 124, 129], ["mammary glands", "ANATOMY", 137, 151]]], ["This study shows that using APPA treatment plans over IMRT may reduce the risk of pneumonitis as well as pulmonary second malignancy.", [["pulmonary", "ANATOMY", 105, 114], ["APPA", "CHEMICAL", 28, 32], ["pneumonitis", "DISEASE", 82, 93], ["pulmonary second malignancy", "DISEASE", 105, 132], ["APPA", "SIMPLE_CHEMICAL", 28, 32], ["pulmonary", "ORGAN", 105, 114], ["This study", "TEST", 0, 10], ["APPA treatment", "TREATMENT", 28, 42], ["IMRT", "TREATMENT", 54, 58], ["pneumonitis", "PROBLEM", 82, 93], ["pulmonary second malignancy", "PROBLEM", 105, 132], ["pneumonitis", "OBSERVATION", 82, 93], ["pulmonary", "ANATOMY", 105, 114], ["malignancy", "OBSERVATION", 122, 132]]], ["Therefore, the choice of a specific treatment modality impacts treatment outcome and must be evaluated for each case individually.", [["a specific treatment modality", "TREATMENT", 25, 54]]], ["Especially patients with preexisting conditions affecting the lung (e.g., chronic obstructive pulmonary disease, severe asthma, a history of lung injury due to nicotine dependence, Covid-19 or other diseases) might benefit from a closer evaluation of different treatment methods in this regard.", [["lung", "ANATOMY", 62, 66], ["pulmonary", "ANATOMY", 94, 103], ["lung", "ANATOMY", 141, 145], ["chronic obstructive pulmonary disease", "DISEASE", 74, 111], ["asthma", "DISEASE", 120, 126], ["lung injury", "DISEASE", 141, 152], ["nicotine", "CHEMICAL", 160, 168], ["nicotine", "CHEMICAL", 160, 168], ["patients", "ORGANISM", 11, 19], ["lung", "ORGAN", 62, 66], ["pulmonary", "ORGAN", 94, 103], ["lung", "ORGAN", 141, 145], ["patients", "SPECIES", 11, 19], ["preexisting conditions affecting the lung", "PROBLEM", 25, 66], ["chronic obstructive pulmonary disease", "PROBLEM", 74, 111], ["severe asthma", "PROBLEM", 113, 126], ["lung injury", "PROBLEM", 141, 152], ["nicotine dependence", "PROBLEM", 160, 179], ["Covid", "TEST", 181, 186], ["other diseases", "PROBLEM", 193, 207], ["a closer evaluation", "TEST", 228, 247], ["different treatment methods", "TREATMENT", 251, 278], ["conditions", "OBSERVATION", 37, 47], ["lung", "ANATOMY", 62, 66], ["chronic", "OBSERVATION_MODIFIER", 74, 81], ["obstructive", "OBSERVATION_MODIFIER", 82, 93], ["pulmonary", "ANATOMY", 94, 103], ["disease", "OBSERVATION", 104, 111], ["severe", "OBSERVATION_MODIFIER", 113, 119], ["asthma", "OBSERVATION", 120, 126], ["lung", "ANATOMY", 141, 145], ["injury", "OBSERVATION", 146, 152]]], ["The use of biological evaluation might be a feasible option to further improve patient outcome.", [["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 79, 86], ["biological evaluation", "TEST", 11, 32], ["a feasible option", "TREATMENT", 42, 59]]]], "PMC7144807": [["General Infection PathwaysThe general infectious pathways for respiratory diseases such as influenza, SARS, MERS, andCOVID-19 are illustrated in Figure 1, all of whichstart from virion-laden respiratory fluid droplets (from <1 to 2000 \u03bcm in diameter)released by an infected person through coughing, sneezing, and potentially eventalking.5 These droplets immediately start to evaporate and to shrink.Most of the droplets and dried nuclei deposit on various objects (e.g.,door knobs, tabletops, buttons, handrails, and touchscreens), turning them into potentiallyinfectious \u201cfomites\u201d, but some may even become airborne for a period of time.Direct infection could thus occur through inhalation by other people within close proximity(e.g., 1\u20132 m), especially for a crowd in a relatively closedspace.", [["respiratory", "ANATOMY", 62, 73], ["respiratory fluid droplets", "ANATOMY", 191, 217], ["droplets", "ANATOMY", 411, 419], ["nuclei", "ANATOMY", 430, 436], ["respiratory diseases", "DISEASE", 62, 82], ["influenza", "DISEASE", 91, 100], ["SARS", "DISEASE", 102, 106], ["coughing", "DISEASE", 289, 297], ["sneezing", "DISEASE", 299, 307], ["infection", "DISEASE", 645, 654], ["person", "SPECIES", 274, 280], ["people", "SPECIES", 700, 706], ["General Infection Pathways", "PROBLEM", 0, 26], ["respiratory diseases", "PROBLEM", 62, 82], ["influenza", "PROBLEM", 91, 100], ["SARS", "PROBLEM", 102, 106], ["MERS", "PROBLEM", 108, 112], ["andCOVID", "TEST", 114, 122], ["virion-laden respiratory fluid droplets", "TREATMENT", 178, 217], ["coughing", "PROBLEM", 289, 297], ["sneezing", "PROBLEM", 299, 307], ["the droplets", "PROBLEM", 407, 419], ["dried nuclei deposit", "PROBLEM", 424, 444], ["handrails", "TREATMENT", 502, 511], ["Direct infection", "PROBLEM", 638, 654], ["Infection", "OBSERVATION", 8, 17], ["infectious", "OBSERVATION", 38, 48], ["laden", "OBSERVATION_MODIFIER", 185, 190], ["respiratory", "OBSERVATION", 191, 202], ["fluid droplets", "OBSERVATION", 203, 217], ["infected", "OBSERVATION", 265, 273], ["nuclei deposit", "OBSERVATION", 430, 444], ["infection", "OBSERVATION", 645, 654]]], ["Infection could also occur when virions released by an infected person are spread ontheir hands and clothing and then transferred to others through close contact, such ashandshaking.", [["virions", "ANATOMY", 32, 39], ["person", "SPECIES", 64, 70], ["Infection", "PROBLEM", 0, 9], ["infected", "OBSERVATION", 55, 63]]], ["Fomites infection6 is indirect and rather stealthy; itoccurs only if a person first picks up the virions from contaminated objects and surfaces(e.g., by their hands) and then transfers them to his or her mouth, nose,or eyes.", [["virions", "ANATOMY", 97, 104], ["mouth", "ANATOMY", 204, 209], ["nose", "ANATOMY", 211, 215], ["eyes", "ANATOMY", 219, 223], ["mouth", "ORGANISM_SUBDIVISION", 204, 209], ["nose", "ORGANISM_SUBDIVISION", 211, 215], ["eyes", "ORGAN", 219, 223], ["person", "SPECIES", 71, 77], ["Fomites infection6", "PROBLEM", 0, 18], ["mouth", "ANATOMY", 204, 209], ["nose", "ANATOMY", 211, 215], ["eyes", "ANATOMY", 219, 223]]], ["Throughout these processes, the virions need to endure a complex and dynamic set ofenvironmental conditions outside the human body.", [["body", "ANATOMY", 126, 130], ["human", "ORGANISM", 120, 125], ["body", "ORGANISM_SUBDIVISION", 126, 130], ["human", "SPECIES", 120, 125], ["human", "SPECIES", 120, 125], ["the virions", "TREATMENT", 28, 39], ["human", "ANATOMY", 120, 125], ["body", "ANATOMY_MODIFIER", 126, 130]]], ["Therefore, there are many opportunities toset up barriers using physical sciences and engineering (dashed lines in Figure 1) to block and to deactivate the overwhelming majority ofreleased virions before they reach hosts and breach the final biological and immunologicaldefenses.", [["virions", "ANATOMY", 189, 196], ["physical sciences", "TREATMENT", 64, 81], ["engineering (dashed lines", "TREATMENT", 86, 111]]], ["Some examples include (a) isolating infectious patients and/or reducing the spreadof their respiratory fluid droplets, (b) cleaning and sanitizing objects and surfaces, (c)filtering potentially contaminated air, (d) washing hands frequently, (e) establishingbetter personal hygiene habits, and (f) wearing personal protection equipment (PPE).Understanding the basic structure of virions and their surroundings is required fordesigning inactivation and removal strategies and maximizing the effectiveness of thesebarriers (Figure 1a\u2013f).", [["respiratory fluid droplets", "ANATOMY", 91, 117], ["virions", "ANATOMY", 379, 386], ["patients", "ORGANISM", 47, 55], ["patients", "SPECIES", 47, 55], ["their respiratory fluid droplets", "TREATMENT", 85, 117], ["fordesigning inactivation", "TREATMENT", 422, 447], ["removal strategies", "TREATMENT", 452, 470], ["infectious", "OBSERVATION", 36, 46], ["respiratory", "OBSERVATION", 91, 102], ["fluid droplets", "OBSERVATION", 103, 117], ["contaminated air", "OBSERVATION", 194, 210], ["virions", "OBSERVATION", 379, 386]]], ["All of these defensebarriers contribute to blocking the source of virions, breaking the spread pathways, andprotecting the susceptible hosts.", [["virions", "ANATOMY", 66, 73], ["virions", "PROBLEM", 66, 73]]], ["Compared to other known infectious diseases caused bycoronaviruses, COVID-19 can spread through an additional stealth mode of asymptomatictransmission,7\u22129 which dramaticallyincreases the difficulty of detecting, monitoring, and preventing its spread.Basic Virion StructureGenerally speaking, viruses are essentially metastable, core\u2013shell nanoparticlesthat are biologically produced in cells with a quite remarkable self-assemblyprocess.10 The core is made of a coiled genomic polymer and tightlypackaged in a protective protein shell called a capsid, which is tiled up by presynthesizedsubunits.", [["cells", "ANATOMY", 386, 391], ["infectious diseases", "DISEASE", 24, 43], ["COVID-19", "CHEMICAL", 68, 76], ["asymptomatictransmission", "DISEASE", 126, 150], ["core\u2013shell nanoparticlesthat", "SIMPLE_CHEMICAL", 328, 356], ["cells", "CELL", 386, 391], ["other known infectious diseases", "PROBLEM", 12, 43], ["bycoronaviruses", "PROBLEM", 51, 66], ["COVID", "TEST", 68, 73], ["monitoring", "TEST", 212, 222], ["essentially metastable", "PROBLEM", 304, 326], ["a coiled genomic polymer", "PROBLEM", 460, 484], ["a protective protein shell", "TREATMENT", 508, 534], ["a capsid", "PROBLEM", 542, 550], ["infectious", "OBSERVATION", 24, 34], ["Virion StructureGenerally", "OBSERVATION", 256, 281], ["metastable", "OBSERVATION", 316, 326], ["coiled", "OBSERVATION", 462, 468], ["genomic polymer", "OBSERVATION", 469, 484], ["capsid", "OBSERVATION", 544, 550]]], ["For coronaviruses (Figure 2), such asthose that cause SARS, MERS, and COVID-19, the RNA is directly complexed with and protectedby a helical protein shell to form a coiled nucleocapsid.", [["SARS", "DISEASE", 54, 58], ["asthose", "GENE_OR_GENE_PRODUCT", 35, 42], ["COVID-19", "DNA", 70, 78], ["helical protein shell", "PROTEIN", 133, 154], ["coiled nucleocapsid", "PROTEIN", 165, 184], ["coronaviruses", "PROBLEM", 4, 17], ["SARS", "PROBLEM", 54, 58], ["COVID", "TEST", 70, 75], ["a helical protein shell", "TREATMENT", 131, 154], ["a coiled nucleocapsid", "PROBLEM", 163, 184], ["nucleocapsid", "OBSERVATION", 172, 184]]], ["It is then enveloped by a lipidbilayer membrane decorated with various other proteins, such as the protruding\u201ccorona\u201d spikes, which interact with the host cell.", [["lipidbilayer membrane", "ANATOMY", 26, 47], ["cell", "ANATOMY", 155, 159], ["host cell", "CELL", 150, 159], ["host cell", "CELL_TYPE", 150, 159], ["a lipidbilayer membrane", "TREATMENT", 24, 47], ["various other proteins", "PROBLEM", 63, 85], ["the protruding\u201ccorona\u201d spikes", "PROBLEM", 95, 124], ["protruding", "OBSERVATION_MODIFIER", 99, 109], ["corona", "OBSERVATION_MODIFIER", 110, 116], ["host cell", "OBSERVATION", 150, 159]]], ["The biological function ofviruses to preserve and, eventually, to deliver their nucleic acids to host cells depends onthe virus\u2019 structural integrity.", [["cells", "ANATOMY", 102, 107], ["nucleic acids", "CHEMICAL", 80, 93], ["host cells", "CELL", 97, 107], ["host cells", "CELL_TYPE", 97, 107], ["their nucleic acids", "TREATMENT", 74, 93]]], ["For example, for enveloped viruses, their lipidbilayer must stay intact throughout the pathways to keep them infectious.", [["enveloped viruses", "PROBLEM", 17, 34], ["them infectious", "PROBLEM", 104, 119], ["viruses", "OBSERVATION", 27, 34], ["infectious", "OBSERVATION", 109, 119]]], ["The protein capsidmust be sufficiently strong to confine the elastically strained genomic coil andsufficiently tough to sustain osmotic pressure fluctuation in changing surroundings, yetthey must be able to disassemble readily inside the host cells to release the genomic core.These constraints demand rather intricate protein building blocks that also must maintaindesirable configurations to avoid malfunction.", [["cells", "ANATOMY", 243, 248], ["cells", "CELL", 243, 248], ["host cells", "CELL_TYPE", 238, 248], ["The protein capsidmust", "TEST", 0, 22], ["osmotic pressure fluctuation", "PROBLEM", 128, 156], ["These constraints demand", "PROBLEM", 277, 301], ["protein building blocks", "TREATMENT", 319, 342], ["malfunction", "PROBLEM", 400, 411], ["genomic coil", "OBSERVATION", 82, 94], ["osmotic pressure", "OBSERVATION", 128, 144], ["host cells", "OBSERVATION", 238, 248]]], ["The envelope and capsid, however, can becompromised by an array of physical treatments, such as UV irradiation, heating, anddesiccation, as well as by chemical sanitization using acids, oxidants, alcohols, or somespecialized surfactants.10\u221212 Approaches like these mayseem relatively primitive; however, they can be extremely effective in slowing down or evenpreventing virus spread and transmission.Virions Are Usually a Minority Component in Respiratory Droplets ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringThe first barrier to infection should be put up at the starting point (Figure 1, dashed line a) to reduce the number and viability ofvirions released by an infected person.", [["Respiratory Droplets", "DISEASE", 444, 464], ["infection", "DISEASE", 568, 577], ["alcohols", "CHEMICAL", 196, 204], ["oxidants", "SIMPLE_CHEMICAL", 186, 194], ["alcohols", "SIMPLE_CHEMICAL", 196, 204], ["somespecialized surfactants", "SIMPLE_CHEMICAL", 209, 236], ["person", "SPECIES", 712, 718], ["physical treatments", "TREATMENT", 67, 86], ["UV irradiation", "TREATMENT", 96, 110], ["heating", "TREATMENT", 112, 119], ["anddesiccation", "TREATMENT", 121, 135], ["acids, oxidants", "TREATMENT", 179, 194], ["alcohols", "TREATMENT", 196, 204], ["somespecialized surfactants", "TREATMENT", 209, 236], ["infection", "PROBLEM", 568, 577], ["capsid", "OBSERVATION", 17, 23], ["Minority", "OBSERVATION_MODIFIER", 422, 430], ["Respiratory Droplets", "OBSERVATION", 444, 464], ["infection", "OBSERVATION", 568, 577], ["infected", "OBSERVATION", 703, 711]]], ["To this end, infected patients are required towear medical masks, which can block and absorb large coughed droplets and reroute thesmaller ones to reduce their forward traveling distance.13,14 Masks are an important component in PPE (Figure 1, dashed line f) for frontline healthcareworkers.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["medical masks", "TREATMENT", 51, 64], ["absorb large coughed droplets", "TREATMENT", 86, 115], ["reroute thesmaller ones", "TREATMENT", 120, 143], ["Masks", "TREATMENT", 193, 198], ["frontline healthcareworkers", "TREATMENT", 263, 290], ["infected", "OBSERVATION", 13, 21], ["important", "OBSERVATION_MODIFIER", 206, 215], ["component", "OBSERVATION_MODIFIER", 216, 225]]], ["In the current COVID-19 pandemic, there has been much discussion about whethermasks are capable of blocking virus nanoparticles, which are typically around 100 nm indiameter.15 However, this implies that virions released by aninfected person stay airborne as individual uncoated nanoparticles, which is rathermisleading.", [["virions", "ANATOMY", 204, 211], ["whethermasks", "CANCER", 71, 83], ["person", "SPECIES", 235, 241], ["blocking virus nanoparticles", "PROBLEM", 99, 127], ["individual uncoated nanoparticles", "PROBLEM", 259, 292], ["uncoated nanoparticles", "OBSERVATION", 270, 292]]], ["As shown in Figure 3, respiratoryfluid droplets contain a variety of other components, typically of a few weightpercent,16,17including insoluble particulates such as proteins, enzymes, commensal microflora(i.e., bacteria) colonized in the upper respiratory tract, and celldebris from the respiratory tract lining; amphiphilic liposomal matter such as lungsurfactants and cholesterol; and soluble molecular species such as salt and lactate.Therefore, in the flying droplets or the final dried nuclei, virions are always surroundedby these materials and are usually a minority component, the loading of which varies bythe conditions of the patients.Virions Are Usually a Minority Component in Respiratory Droplets ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringThe pictorial representation in Figure 3 remindsus that when designing physical and chemical approaches to deactivate virions, theirsurrounding respiratory mass must be factored in.", [["respiratoryfluid droplets", "ANATOMY", 22, 47], ["upper respiratory tract", "ANATOMY", 239, 262], ["respiratory tract", "ANATOMY", 288, 305], ["nuclei", "ANATOMY", 492, 498], ["virions", "ANATOMY", 500, 507], ["virions", "ANATOMY", 912, 919], ["cholesterol", "CHEMICAL", 371, 382], ["lactate", "CHEMICAL", 431, 438], ["Respiratory Droplets", "DISEASE", 691, 711], ["lungsurfactants", "CHEMICAL", 351, 366], ["cholesterol", "CHEMICAL", 371, 382], ["lactate", "CHEMICAL", 431, 438], ["respiratoryfluid droplets", "SIMPLE_CHEMICAL", 22, 47], ["upper", "ORGANISM_SUBDIVISION", 239, 244], ["respiratory tract", "ORGANISM_SUBDIVISION", 245, 262], ["respiratory tract", "ORGANISM_SUBDIVISION", 288, 305], ["lungsurfactants", "SIMPLE_CHEMICAL", 351, 366], ["cholesterol", "SIMPLE_CHEMICAL", 371, 382], ["salt", "SIMPLE_CHEMICAL", 422, 426], ["lactate", "SIMPLE_CHEMICAL", 431, 438], ["patients", "ORGANISM", 638, 646], ["enzymes", "PROTEIN", 176, 183], ["patients", "SPECIES", 638, 646], ["respiratoryfluid droplets", "PROBLEM", 22, 47], ["enzymes", "TEST", 176, 183], ["commensal microflora", "PROBLEM", 185, 205], ["bacteria", "PROBLEM", 212, 220], ["colonized in the upper respiratory tract", "PROBLEM", 222, 262], ["celldebris", "PROBLEM", 268, 278], ["the respiratory tract lining", "PROBLEM", 284, 312], ["amphiphilic liposomal matter", "TREATMENT", 314, 342], ["cholesterol", "TEST", 371, 382], ["soluble molecular species", "PROBLEM", 388, 413], ["lactate", "TEST", 431, 438], ["virions", "TREATMENT", 500, 507], ["theirsurrounding respiratory mass", "PROBLEM", 921, 954], ["variety", "OBSERVATION_MODIFIER", 58, 65], ["upper", "ANATOMY_MODIFIER", 239, 244], ["respiratory tract", "ANATOMY", 245, 262], ["respiratory tract", "ANATOMY", 288, 305], ["amphiphilic liposomal matter", "OBSERVATION", 314, 342], ["dried nuclei", "OBSERVATION", 486, 498], ["Minority", "OBSERVATION_MODIFIER", 669, 677], ["Respiratory Droplets", "OBSERVATION", 691, 711], ["respiratory", "ANATOMY", 938, 949], ["mass", "OBSERVATION", 950, 954]]], ["These noninfectious components may actas a protective matrix for the virions, rendering sanitization treatments ineffective, orthey can be manipulated for accelerated inactivation.", [["virions", "ANATOMY", 69, 76], ["matrix", "CELLULAR_COMPONENT", 54, 60], ["These noninfectious components", "PROBLEM", 0, 30], ["a protective matrix", "TREATMENT", 41, 60], ["the virions", "TREATMENT", 65, 76], ["rendering sanitization treatments", "TREATMENT", 78, 111], ["accelerated inactivation", "PROBLEM", 155, 179], ["noninfectious", "OBSERVATION", 6, 19]]], ["For example, it has been reportedthat both SARS-CoV-1 and SARS-CoV-2 virions can remain infectious for days on smoothsurfaces such as glass, plastics, and stainless steel, whereas they remain infectious forjust hours on porous surfaces such as textile and paper materials.18,19 This observation is somewhatsurprising and worrisome, especially because stainless steel is ubiquitous for makingmedical supplies and equipment, as well as most engineering structures and appliances.However, to the best of our knowledge, the effect of surface porosity is notwell-understood.", [["surface", "ANATOMY", 530, 537], ["SARS-CoV-1", "ORGANISM", 43, 53], ["SARS-CoV-2", "ORGANISM", 58, 68], ["virions", "ORGANISM", 69, 76], ["SARS-CoV", "SPECIES", 58, 66], ["SARS", "TEST", 43, 47], ["CoV", "TEST", 48, 51], ["SARS", "PROBLEM", 58, 62], ["CoV", "TEST", 63, 66], ["smoothsurfaces", "TREATMENT", 111, 125], ["plastics", "TREATMENT", 141, 149], ["stainless steel", "TREATMENT", 155, 170], ["surface porosity", "PROBLEM", 530, 546], ["infectious", "OBSERVATION", 88, 98], ["stainless steel", "OBSERVATION_MODIFIER", 155, 170], ["infectious", "OBSERVATION", 192, 202]]], ["One hypothesis is that nuclei particles are more likely to pick upmoisture from the air through capillary condensation on smooth surfaces than on porousones.20,21 Thewater-soluble, hygroscopic components in the nuclei can hold condensed water to protectembedded virions from desiccation.", [["nuclei particles", "ANATOMY", 23, 39], ["capillary", "ANATOMY", 96, 105], ["nuclei", "ANATOMY", 211, 217], ["virions", "ANATOMY", 262, 269], ["nuclei", "CELLULAR_COMPONENT", 23, 29], ["capillary", "TISSUE", 96, 105], ["smooth surfaces", "TISSUE", 122, 137], ["porousones", "SIMPLE_CHEMICAL", 146, 156], ["nuclei", "CELLULAR_COMPONENT", 211, 217], ["nuclei particles", "PROBLEM", 23, 39], ["capillary condensation", "PROBLEM", 96, 118], ["porousones", "TREATMENT", 146, 156], ["Thewater-soluble", "TREATMENT", 163, 179], ["hygroscopic components", "TREATMENT", 181, 203], ["nuclei particles", "OBSERVATION", 23, 39], ["more likely", "UNCERTAINTY", 44, 55], ["air", "OBSERVATION", 84, 87], ["capillary condensation", "OBSERVATION", 96, 118], ["smooth", "OBSERVATION_MODIFIER", 122, 128], ["surfaces", "OBSERVATION_MODIFIER", 129, 137], ["nuclei", "ANATOMY", 211, 217]]], ["On porous surfaces, condensed water can be drained awayfrom the nuclei to equilibrate with the rest of the surface, leading to faster water lossaround the virions.", [["nuclei", "ANATOMY", 64, 70], ["surface", "ANATOMY", 107, 114], ["virions", "ANATOMY", 155, 162], ["water", "SIMPLE_CHEMICAL", 30, 35], ["nuclei", "CELLULAR_COMPONENT", 64, 70], ["surface", "CELLULAR_COMPONENT", 107, 114], ["faster water lossaround the virions", "PROBLEM", 127, 162], ["porous", "OBSERVATION_MODIFIER", 3, 9], ["surfaces", "OBSERVATION_MODIFIER", 10, 18], ["condensed water", "OBSERVATION", 20, 35], ["nuclei", "ANATOMY", 64, 70], ["faster", "OBSERVATION_MODIFIER", 127, 133], ["water lossaround", "OBSERVATION", 134, 150], ["virions", "ANATOMY", 155, 162]]], ["Desiccation is effective for deactivating enveloped virions becausethe assembly of the membrane bilayer relies on water.22,23 Moreover, capillary compression24 can also mechanically squeeze the mixture in the drying droplets andpotentially deform and damage the virion particles inside.Chemical Modulation of Respiratory Fluid Droplets ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringIn addition to blocking the droplets, it would also be effective to deactivate virions atthe origin of the chain events leading up to infection.", [["membrane bilayer", "ANATOMY", 87, 103], ["capillary", "ANATOMY", 136, 145], ["infection", "DISEASE", 552, 561], ["membrane bilayer", "CELLULAR_COMPONENT", 87, 103], ["water", "SIMPLE_CHEMICAL", 114, 119], ["capillary", "TISSUE", 136, 145], ["deactivating enveloped virions", "PROBLEM", 29, 59], ["damage the virion particles", "PROBLEM", 251, 278], ["blocking the droplets", "TREATMENT", 433, 454], ["the chain events", "PROBLEM", 521, 537], ["infection", "PROBLEM", 552, 561], ["virion particles", "OBSERVATION", 262, 278], ["Respiratory Fluid Droplets", "OBSERVATION", 309, 335], ["infection", "OBSERVATION", 552, 561]]], ["Here, one might employ ways to\u201cpollute\u201d virion-laden droplets with antiviral or sanitizingmolecules25 when they pass through a mask.", [["droplets", "ANATOMY", 53, 61], ["sanitizingmolecules25", "SIMPLE_CHEMICAL", 80, 101], ["antiviral or sanitizingmolecules25", "TREATMENT", 67, 101], ["a mask", "TREATMENT", 125, 131]]], ["For example, a usefulstrategy may involve on-mask chemical modulation in which such molecules are loaded on themask to presanitize the exhaled droplets.", [["mask chemical modulation", "TREATMENT", 45, 69], ["themask", "TREATMENT", 108, 115], ["the exhaled droplets", "PROBLEM", 131, 151], ["exhaled droplets", "OBSERVATION", 135, 151]]], ["These molecules should be released in the warmand moisturized air during exhalation but stay fixed on the mask during the inhalation ofcolder and drier air.", [["the mask", "TREATMENT", 102, 110], ["the inhalation ofcolder", "TREATMENT", 118, 141], ["drier air", "OBSERVATION", 146, 155]]], ["It would be most useful to use the chemical modifier as a drop-inaccessory, such as in the form of a sticky and permeable film that can adhere to the outersurface of a mask as needed.", [["the chemical modifier", "TREATMENT", 31, 52], ["a sticky and permeable film", "TREATMENT", 99, 126], ["a mask", "TREATMENT", 166, 172]]], ["This may facilitate widespread use and does not need todisrupt the manufacturing and supply chain management of masks, which is already highlystressed by the explosive surge in demand.26Chemical Modulation of Respiratory Fluid Droplets ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringIt is also well-known that metabolism and food can dramatically affect the composition ofexhaled air (e.g., bad breath).", [["the manufacturing", "TREATMENT", 63, 80], ["chain management of masks", "TREATMENT", 92, 117], ["Respiratory", "OBSERVATION", 209, 220], ["Fluid Droplets", "OBSERVATION", 221, 235]]], ["Therefore, with the help of medicalresearchers and doctors, perhaps one could think of some in situ methodsfor altering the chemical composition of respiratory fluids by taking \u201csalivamodifiers\u201d (e.g., ingredients that help to inactivate virions) inthe form of pills, lozenges, cough drops, or even chewing gums.", [["respiratory fluids", "ANATOMY", 148, 166], ["cough", "DISEASE", 278, 283], ["gums", "ORGANISM_SUBDIVISION", 307, 311], ["respiratory fluids", "TREATMENT", 148, 166], ["pills", "TREATMENT", 261, 266], ["lozenges", "TREATMENT", 268, 276], ["cough drops", "TREATMENT", 278, 289], ["chewing gums", "PROBLEM", 299, 311], ["respiratory fluids", "OBSERVATION", 148, 166]]], ["One may even customize adiet or use food supplements such that antiviral molecules can be self-generated in therespiratory fluids by metabolism.", [["food supplements", "TREATMENT", 36, 52], ["antiviral molecules", "TREATMENT", 63, 82]]], ["Both on-mask and in situ chemicalmodulation approaches would benefit from the third power scaling law of droplet volume anddiameter, which can greatly concentrate the antiviral molecules during dropletevaporation.", [["antiviral molecules", "PROTEIN", 167, 186], ["-mask", "TREATMENT", 7, 12], ["droplet volume anddiameter", "TREATMENT", 105, 131], ["dropletevaporation", "TREATMENT", 194, 212], ["droplet volume", "OBSERVATION", 105, 119], ["antiviral molecules", "OBSERVATION", 167, 186]]], ["Both strategies can be enhanced by deeper and more relevant scientificunderstandings in the molecular mechanisms of virion inactivation.Self-Sanitizing Surfaces ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringFomite transmission is hard to trace but common for many respiratory diseases.6 This transmission is often mitigatable with physical and chemicalsanitization, such as through spraying or wiping.", [["respiratory", "ANATOMY", 300, 311], ["respiratory diseases", "DISEASE", 300, 320], ["virion", "CELLULAR_COMPONENT", 116, 122], ["virion inactivation", "PROBLEM", 116, 135], ["many respiratory diseases", "PROBLEM", 295, 320], ["virion inactivation", "OBSERVATION", 116, 135], ["respiratory diseases", "OBSERVATION", 300, 320]]], ["However, sanitization is labor- andmaterials-intensive, impractical for covering all exposed areas, and needs to be reappliedperiodically.", [["labor", "PROBLEM", 25, 30]]], ["Water- or alcohol-based sanitizers may not be able to act fully anduniformly across entire surfaces during practical operation due to issues related todewetting and volatility.", [["alcohol", "CHEMICAL", 10, 17], ["alcohol", "CHEMICAL", 10, 17], ["alcohol", "SIMPLE_CHEMICAL", 10, 17], ["practical operation", "TREATMENT", 107, 126]]], ["Therefore, it will be useful to engineer self-sanitizingsurfaces that can slowly release disinfecting chemicals to mitigate fomite transmission.Such coatings should be durable against rubbing and washing, long-lasting, and nontoxicand should be grown easily on the surfaces of already-installed objects that peoplefrequently touch.", [["fomite", "SIMPLE_CHEMICAL", 124, 130], ["Such coatings", "TREATMENT", 144, 157], ["rubbing", "PROBLEM", 184, 191]]], ["This direction can leverage knowledge gained through numerous materialstudies about control-release processes and may even define new research needs.Self-Sanitizing Surfaces ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringFor metal objects, copper metal or cations have broad spectrum antiviral effects and lowtoxicity to humans.27,28 Therefore, surface copperization could provide stainless steel objectsself-sanitizing properties, which could significantly cut down fomite infection rates dueto stainless steel\u2019s widespread use in hospitals and public spaces.", [["surface", "ANATOMY", 380, 387], ["copper", "CHEMICAL", 275, 281], ["infection", "DISEASE", 509, 518], ["copper", "CHEMICAL", 275, 281], ["copper metal", "SIMPLE_CHEMICAL", 275, 287], ["cations", "SIMPLE_CHEMICAL", 291, 298], ["humans", "ORGANISM", 356, 362], ["humans", "SPECIES", 356, 362], ["humans", "SPECIES", 356, 362], ["copper metal or cations", "TREATMENT", 275, 298], ["broad spectrum antiviral effects", "TREATMENT", 304, 336], ["lowtoxicity", "TREATMENT", 341, 352], ["surface copperization", "TREATMENT", 380, 401], ["stainless steel objectsself-sanitizing properties", "TREATMENT", 416, 465], ["infection", "PROBLEM", 509, 518], ["antiviral effects", "OBSERVATION", 319, 336]]], ["In addition,properly patterned surfaces can avoid local capillary condensation of water,21 which can bring additional self-desiccation property to deactivatevirions.", [["capillary", "ANATOMY", 56, 65], ["capillary", "TISSUE", 56, 65], ["water", "SIMPLE_CHEMICAL", 82, 87], ["deactivatevirions", "SIMPLE_CHEMICAL", 147, 164], ["capillary condensation", "OBSERVATION", 56, 78]]], ["One may even design active or stimuli-responsive antiviral coatings based onphotocatalytic, photothermal, or electrothermal treatments, either continuously or inpulsed mode, all of which are quite well-studied in materials science.Personal Protection Equipment ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringThe PPE used by healthcare professionals tending COVID-19 patients includes facial masksor respirators, protective suits, spill gowns, gloves, boot covers, and goggles or faceshields for eye protection (Figure 4), and theyare critical for protecting healthcare workers.", [["facial", "ANATOMY", 419, 425], ["eye", "ANATOMY", 530, 533], ["patients", "ORGANISM", 401, 409], ["eye", "ORGAN", 530, 533], ["patients", "SPECIES", 401, 409], ["stimuli-responsive antiviral coatings", "TREATMENT", 30, 67], ["onphotocatalytic", "TREATMENT", 74, 90], ["photothermal", "TREATMENT", 92, 104], ["electrothermal treatments", "TREATMENT", 109, 134], ["facial masksor respirators", "TREATMENT", 419, 445], ["protective suits", "TREATMENT", 447, 463], ["spill gowns", "TREATMENT", 465, 476], ["gloves", "TREATMENT", 478, 484], ["boot covers", "TREATMENT", 486, 497], ["goggles", "TREATMENT", 503, 510], ["faceshields", "TREATMENT", 514, 525], ["spill gowns", "OBSERVATION", 465, 476], ["eye", "ANATOMY", 530, 533]]], ["It typically takes 30 min just to suit upto ensure proper protection, and frontline workers usually need to wear it continuouslyfor extended hours.29 During usage, the entire outer surface of theirPPE must be treated as fomites, which requires extra caution when undressing.30 User experiences under high stress speak for much needed improvement overcurrent PPE.", [["outer surface", "ANATOMY", 175, 188], ["outer surface", "CELLULAR_COMPONENT", 175, 188], ["extra caution", "TREATMENT", 244, 257]]], ["For example, goggle fogging turns out to be quite problematic because onecannot risk contamination to clear them by usual means.", [["goggle fogging", "PROBLEM", 13, 27]]], ["Therefore, antifoggingfunctionality must be added.31 For facial masks such as N95 aspirators,they usually need to be tightly fit to one\u2019s face (e.g., withstrong rubber bands) and can cause a great deal of discomfort or allergicreactions.32 In practice, the one-size-fits-all aspirators sometimesdo not match the diverse facial profiles of different users, leading to potential safetyissues due to leakage or skin damage.", [["facial", "ANATOMY", 57, 63], ["facial", "ANATOMY", 320, 326], ["skin", "ANATOMY", 408, 412], ["allergicreactions", "DISEASE", 219, 236], ["safetyissues", "DISEASE", 377, 389], ["skin damage", "DISEASE", 408, 419], ["face", "ORGANISM_SUBDIVISION", 138, 142], ["skin", "ORGAN", 408, 412], ["antifoggingfunctionality", "TREATMENT", 11, 35], ["facial masks", "TREATMENT", 57, 69], ["discomfort", "PROBLEM", 205, 215], ["allergicreactions", "PROBLEM", 219, 236], ["potential safetyissues", "PROBLEM", 367, 389], ["leakage", "PROBLEM", 397, 404], ["skin damage", "PROBLEM", 408, 419], ["size", "OBSERVATION_MODIFIER", 261, 265], ["diverse", "OBSERVATION_MODIFIER", 312, 319], ["facial", "ANATOMY", 320, 326], ["leakage", "OBSERVATION", 397, 404], ["skin", "ANATOMY", 408, 412], ["damage", "OBSERVATION", 413, 419]]], ["Therefore, more adaptive, skin-friendly materialsand interface design are needed to ensure good seal over extended periods of time andchanging skin conditions due to perspiration.Personal Protection Equipment ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringHazmat suits are usually made of broad-spectrum protective synthetic fabrics withvapor-blocking functions.", [["skin", "ANATOMY", 26, 30], ["skin", "ANATOMY", 143, 147], ["skin", "ORGAN", 26, 30], ["skin", "ORGAN", 143, 147], ["perspiration", "PROBLEM", 166, 178], ["broad-spectrum protective synthetic fabrics", "TREATMENT", 324, 367], ["skin", "ANATOMY", 26, 30], ["good seal", "OBSERVATION_MODIFIER", 91, 100]]], ["Although such fabrics serve as an effective barrier to virionsand virion-laden droplets and nuclei, due to poor ventilation and heat dissipation, theybecome uncomfortable to wear for frontline healthcare workers, who often need to wear themfor extended periods of time when there is a shortage in PPE supply or manpower.", [["nuclei", "ANATOMY", 92, 98], ["nuclei", "CELLULAR_COMPONENT", 92, 98], ["such fabrics", "PROBLEM", 9, 21], ["an effective barrier to virionsand virion", "TREATMENT", 31, 72], ["poor ventilation and heat dissipation", "PROBLEM", 107, 144]]], ["Thisdiscomfort adds to healthcare workers\u2019 already high physical and psychologicalstress.", [["Thisdiscomfort", "CHEMICAL", 0, 14]]], ["Therefore, smart fabrics that can effectively block virions but enable better heattransfer and moisture control would be an ideal suit material.", [["smart fabrics", "TREATMENT", 11, 24], ["effectively block virions", "PROBLEM", 34, 59], ["moisture control", "TREATMENT", 95, 111]]], ["In addition, for theclinicians in emergency departments, the tedious and time-consuming processes of dressingup and undressing the entire set of PPE takes valuable time away from treating criticallyill patients.", [["criticallyill", "DISEASE", 188, 201], ["patients", "ORGANISM", 202, 210], ["patients", "SPECIES", 202, 210], ["dressingup", "TREATMENT", 101, 111]]], ["Therefore, a multifunctional helmet-like unit with integrated maskcompartment, goggles, and face shield, yet still maintain lightweight and durability,would be desirable.", [["a multifunctional helmet", "TREATMENT", 11, 35], ["integrated maskcompartment, goggles", "TREATMENT", 51, 86]]], ["The development of smart, multifunctional PPE suits equipped withwireless communication capabilities and microsensors or even actuators for detectingvirus, controlling humidity and temperature, and monitoring clinicians\u2019physiological conditions without compromising protective function and flexibility, will beextremely helpful.", [["multifunctional PPE suits", "TREATMENT", 26, 51], ["detectingvirus", "TREATMENT", 140, 154]]], ["This need suggests many new research directions for researchers inmaterials chemistry, flexible electronics, and wearable devices, which have rapidlyprogressed in the past decade.Personal Protection Equipment ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringThe shortage of PPE has been reported globally, especially at the early stages ofoutbreak in various areas,33 which prevents frontline healthcareworkers from replacing their PPE as needed and, under extreme conditions, may even need toreuse them.", [["flexible electronics", "TREATMENT", 87, 107], ["wearable devices", "TREATMENT", 113, 129]]], ["Therefore, durable antiviral surface coatings on PPE,34especially at the junctions of different parts, would be useful to prevent users frombeing infected and from infecting others.Personal Protection Equipment ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringOn the other hand, when the supply of PPE is stabilized, another point of concern istheir safe disposal and sustainable waste processing.", [["surface", "ANATOMY", 29, 36], ["PPE", "CHEMICAL", 49, 52], ["PPE", "SIMPLE_CHEMICAL", 49, 52], ["durable antiviral surface coatings", "TREATMENT", 11, 45], ["PPE", "TREATMENT", 49, 52], ["durable", "OBSERVATION_MODIFIER", 11, 18], ["antiviral", "OBSERVATION_MODIFIER", 19, 28], ["surface", "OBSERVATION_MODIFIER", 29, 36], ["infected", "OBSERVATION", 146, 154]]], ["Disposable PPE, such as facialmasks, protective suits, facial shields, gowns, gloves, and boot covers, are mostly madeof plastic materials, and they are used in massive quantities in a global pandemic.", [["facial", "ANATOMY", 55, 61], ["Disposable PPE", "TREATMENT", 0, 14], ["facialmasks", "TREATMENT", 24, 35], ["protective suits", "TREATMENT", 37, 53], ["facial shields", "TREATMENT", 55, 69], ["gowns", "TREATMENT", 71, 76], ["gloves", "TREATMENT", 78, 84], ["boot", "TREATMENT", 90, 94], ["facial shields", "ANATOMY", 55, 69], ["boot", "ANATOMY", 90, 94]]], ["Itwill be worthwhile to develop biodegradable PPE for the future, enabling alternative waysto process this waste safely in addition to incineration.High-Throughput and Reconfigurable Manufacturing ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringAny innovation in diagnosis, prevention, or treatment of infectious respiratory diseasesmust be compatible with high-throughput manufacturing to be relevant because the explosivesurge in demand puts great stress on the healthcare infrastructure and supply chains.", [["respiratory", "ANATOMY", 347, 358], ["infectious respiratory diseasesmust", "DISEASE", 336, 371], ["biodegradable PPE", "TREATMENT", 32, 49], ["infectious respiratory diseasesmust", "PROBLEM", 336, 371], ["the explosivesurge in demand", "PROBLEM", 444, 472], ["infectious", "OBSERVATION_MODIFIER", 336, 346]]], ["Overthe long-term, flexible manufacturing design should be implemented so that the productionlines can be readily reconfigured and repurposed to meet the surging demands during apandemic.", [["flexible manufacturing design", "TREATMENT", 19, 48], ["long-term", "OBSERVATION_MODIFIER", 8, 17]]], ["Innovations that can retrofit existing products(e.g., PPE) or already-installed appliances and surfaces to endow themwith antiviral functions would also be desirable.High-Throughput and Reconfigurable Manufacturing ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringTesting is crucial for monitoring and containing the spread of all infectious disease.Current virus tests are typically accomplished by first collecting samples and thensending them to centralized analytical facilities for genome extraction, amplification,and analysis.", [["samples", "ANATOMY", 450, 457], ["infectious disease", "DISEASE", 364, 382], ["appliances", "TREATMENT", 80, 90], ["surfaces", "TREATMENT", 95, 103], ["antiviral functions", "TREATMENT", 122, 141], ["EngineeringTesting", "TEST", 286, 304], ["monitoring", "TEST", 320, 330], ["all infectious disease", "PROBLEM", 360, 382], ["Current virus tests", "TEST", 383, 402], ["genome extraction", "TREATMENT", 520, 537], ["analysis", "TEST", 557, 565], ["infectious", "OBSERVATION", 364, 374]]], ["If portable systems with sample-in-result-out rapid turnaround becomeavailable and widely deployed, it will enable much faster data acquisition, enablingpublic health workers and policy makers to respond to an outbreak more rapidly andprecisely.", [["portable systems", "TEST", 3, 19], ["sample", "TEST", 25, 31]]], ["To acquire such capability, close collaboration among scientists, engineers,and biomedical researchers will be needed.Model Systems for Virions ::: Questions, Hypotheses, and Research Needs in Physical Sciences and EngineeringOne of the major roadblocks preventing physical scientists and engineers from making morecontributions is the lack of access to virions, such as those causing infectious diseases,because access is limited to only a small number of specialized laboratories.", [["infectious diseases", "DISEASE", 385, 404], ["virions", "TREATMENT", 354, 361], ["infectious diseases", "PROBLEM", 385, 404], ["Virions", "OBSERVATION", 136, 143], ["small", "OBSERVATION_MODIFIER", 441, 446]]], ["Manyphysical sciences and engineering approaches for virion deactivation are based on ratherbroad-spectrum mechanisms, and model systems for such studies, at least in the initialstages, do not need to be genome specific nor to contain any genomic material at all.", [["engineering approaches", "TREATMENT", 26, 48], ["virion deactivation", "TREATMENT", 53, 72], ["such studies", "TEST", 141, 153]]], ["Forexample, model systems that enable the study of how the lipid envelope bilayer isstabilized and destabilized, how the capsid or nucleocapsid is assembled anddisintegrated, or how the virion particles interact with their surroundings in the flyingdroplets and surfaces after they land, with or without the respiratory mass, would beextremely useful and would help accelerate engineering solutions to slow and to preventvirus transmission and spread and to enhance our overall readiness to respond to anyfuture virus outbreaks.OutlookThe COVID-19 pandemic is the type of global challenge that transcends territorial,political, ideological, religious, cultural, and academic boundaries.", [["flyingdroplets", "ANATOMY", 243, 257], ["capsid", "CELLULAR_COMPONENT", 121, 127], ["nucleocapsid", "CELLULAR_COMPONENT", 131, 143], ["anyfuture virus", "ORGANISM", 502, 517], ["capsid or nucleocapsid", "PROTEIN", 121, 143], ["the study", "TEST", 38, 47], ["the lipid envelope bilayer", "TREATMENT", 55, 81], ["the respiratory mass", "PROBLEM", 304, 324], ["engineering solutions", "TREATMENT", 377, 398], ["anyfuture virus outbreaks", "PROBLEM", 502, 527], ["respiratory", "ANATOMY", 308, 319], ["mass", "OBSERVATION", 320, 324], ["territorial", "OBSERVATION_MODIFIER", 605, 616]]], ["Researchers inphysical sciences and engineering should rally to study such challenges, to develop newhypotheses, to define new research problems, to create user-centered solutions, and toeducate ourselves and the general public, so that we can better work with biological andmedical researchers to address the many aspects of challenges associated with thetransmission and spread of infectious respiratory diseases.35", [["respiratory", "ANATOMY", 394, 405], ["infectious respiratory diseases", "DISEASE", 383, 414], ["new research problems", "PROBLEM", 123, 144], ["infectious respiratory diseases", "PROBLEM", 383, 414], ["infectious", "OBSERVATION_MODIFIER", 383, 393], ["respiratory diseases", "OBSERVATION", 394, 414]]]], "c914b8a858f9143c9bfe0bad0eb198a1a6b67dcd": [["IntroductionThe imaging changes in coronavirus disease 2019 (COVID-19) pneumonia have been extensively reported in the literature since its outbreak [1\u22125] , but its atypical computed tomography (CT) presentations are rarely described.", [["coronavirus disease", "DISEASE", 35, 54], ["COVID-19", "CHEMICAL", 61, 69], ["pneumonia", "DISEASE", 71, 80], ["coronavirus", "ORGANISM", 35, 46], ["coronavirus disease 2019 (COVID-19", "SPECIES", 35, 69], ["The imaging changes", "TEST", 12, 31], ["coronavirus disease", "PROBLEM", 35, 54], ["COVID", "TEST", 61, 66], ["pneumonia", "PROBLEM", 71, 80], ["its atypical computed tomography", "TEST", 161, 193], ["coronavirus disease", "OBSERVATION", 35, 54], ["pneumonia", "OBSERVATION", 71, 80]]], ["Timely confirmation of CT imaging data in such patients can provide reference for early clinical diagnosis, timely isolation and treatment, and improving patient prognosis.", [["patients", "ORGANISM", 47, 55], ["patient", "ORGANISM", 154, 161], ["patients", "SPECIES", 47, 55], ["patient", "SPECIES", 154, 161], ["CT imaging data", "TEST", 23, 38], ["treatment", "TREATMENT", 129, 138]]], ["To further improve the radiographic J o u r n a l P r e -p r o o f examination and diagnosis of COVID-19 in patients, this study retrospectively analyzed the clinical and imaging data of 16 patients and selected 6 patients with atypical CT presentations for analysis.", [["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 190, 198], ["patients", "ORGANISM", 214, 222], ["P r e", "DNA", 50, 55], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 190, 198], ["patients", "SPECIES", 214, 222], ["examination", "TEST", 67, 78], ["COVID", "TEST", 96, 101], ["this study", "TEST", 118, 128], ["imaging data", "TEST", 171, 183], ["atypical CT presentations", "TEST", 228, 253], ["analysis", "TEST", 258, 266]]], ["Further, we have summarized the findings with the aim of improving the level of imaging diagnosis.Clinical dataThe Institutional Review Board of Central People's Hospital of Zhanjiang approved this retrospective study and waived the requirement for informed consent due to the nature of the study.", [["imaging diagnosis", "TEST", 80, 97], ["this retrospective study", "TEST", 193, 217], ["the study", "TEST", 287, 296]]], ["We have abided by patient data confidentiality and compliance as set out in the with the Declaration of Helsinki.", [["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25]]], ["Clinical and imaging data of 16 COVID-19 patients diagnosed between January 23, 2020 and February 19, 2020 were collected.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["Clinical and imaging data", "TEST", 0, 25], ["COVID", "TEST", 32, 37]]], ["All patients were diagnosed with COVID-19, as confirmed by two positive test results on reverse transcription polymerase chain reaction for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid test.", [["acute respiratory syndrome coronavirus", "DISEASE", 147, 185], ["nucleic acid", "CHEMICAL", 201, 213], ["patients", "ORGANISM", 4, 12], ["nucleic acid", "SIMPLE_CHEMICAL", 201, 213], ["patients", "SPECIES", 4, 12], ["severe acute respiratory syndrome coronavirus", "SPECIES", 140, 185], ["SARS-CoV", "SPECIES", 189, 197], ["COVID", "TEST", 33, 38], ["reverse transcription polymerase chain reaction", "PROBLEM", 88, 135], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 140, 185], ["SARS", "TEST", 189, 193], ["CoV", "TEST", 194, 197], ["nucleic acid test", "TEST", 201, 218], ["severe", "OBSERVATION_MODIFIER", 140, 146], ["acute", "OBSERVATION_MODIFIER", 147, 152], ["respiratory syndrome", "OBSERVATION", 153, 173]]], ["Among them, 6 patients (2 men and 4 women) aged between 25 and 68 years (average age, 44.6 years) exhibited atypical CT presentation.", [["patients", "ORGANISM", 14, 22], ["men", "ORGANISM", 26, 29], ["women", "ORGANISM", 36, 41], ["patients", "SPECIES", 14, 22], ["men", "SPECIES", 26, 29], ["women", "SPECIES", 36, 41], ["atypical CT presentation", "PROBLEM", 108, 132]]], ["All these 6 patients had history of travel or residence in Wuhan 2 weeks before the onset of illness or had close contact with patients having fever from Wuhan before the onset of illness.", [["illness", "DISEASE", 93, 100], ["fever", "DISEASE", 143, 148], ["illness", "DISEASE", 180, 187], ["patients", "ORGANISM", 12, 20], ["patients", "ORGANISM", 127, 135], ["patients", "SPECIES", 12, 20], ["patients", "SPECIES", 127, 135], ["illness", "PROBLEM", 93, 100], ["fever", "PROBLEM", 143, 148], ["illness", "PROBLEM", 180, 187]]], ["Patients' general clinical data, body temperature, peripheral white blood cell (WBC) count, and C-reactive protein, procalcitonin, D-dimer, fibrinogen, and lactate dehydrogenase levels are shown in Table 1 .Examination protocolThe SIEMENS SOMATOM Definition 16-row spiral CT was used for chest CT scanning.", [["body", "ANATOMY", 33, 37], ["peripheral white blood cell", "ANATOMY", 51, 78], ["WBC", "ANATOMY", 80, 83], ["chest", "ANATOMY", 288, 293], ["lactate", "CHEMICAL", 156, 163], ["lactate", "CHEMICAL", 156, 163], ["Patients", "ORGANISM", 0, 8], ["body", "ORGANISM_SUBDIVISION", 33, 37], ["peripheral white blood cell", "CELL", 51, 78], ["WBC", "CELL", 80, 83], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 96, 114], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 116, 129], ["D-dimer", "SIMPLE_CHEMICAL", 131, 138], ["fibrinogen", "GENE_OR_GENE_PRODUCT", 140, 150], ["lactate dehydrogenase", "GENE_OR_GENE_PRODUCT", 156, 177], ["C-reactive protein", "PROTEIN", 96, 114], ["procalcitonin", "PROTEIN", 116, 129], ["D-dimer", "PROTEIN", 131, 138], ["fibrinogen", "PROTEIN", 140, 150], ["lactate dehydrogenase", "PROTEIN", 156, 177], ["Patients", "SPECIES", 0, 8], ["body temperature", "TEST", 33, 49], ["peripheral white blood cell", "TEST", 51, 78], ["WBC", "TEST", 80, 83], ["count", "TEST", 85, 90], ["C", "TEST", 96, 97], ["reactive protein", "TEST", 98, 114], ["procalcitonin", "TEST", 116, 129], ["D-dimer", "TEST", 131, 138], ["fibrinogen", "TEST", 140, 150], ["lactate dehydrogenase levels", "TEST", 156, 184], ["Examination protocol", "TEST", 207, 227], ["The SIEMENS SOMATOM Definition", "TEST", 227, 257], ["row spiral CT", "TEST", 261, 274], ["chest CT scanning", "TEST", 288, 305], ["chest", "ANATOMY", 288, 293]]], ["During CT, patients were placed in a supine position with their hands raised, and the scan was performed from the apex to the base of the lung while the patients held their breath.", [["lung", "ANATOMY", 138, 142], ["patients", "ORGANISM", 11, 19], ["hands", "ORGANISM_SUBDIVISION", 64, 69], ["lung", "ORGAN", 138, 142], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 11, 19], ["patients", "SPECIES", 153, 161], ["CT", "TEST", 7, 9], ["the scan", "TEST", 82, 90], ["apex", "ANATOMY_MODIFIER", 114, 118], ["base", "ANATOMY_MODIFIER", 126, 130], ["lung", "ANATOMY", 138, 142]]], ["The scanning conditions were as follows: tube voltage, 100 kV (CARE Dose4D automatic tube current modulation technology was used to adjust tube current); reference tube current, 50 mA; slice thickness, 5 mm; and slice interval, 5 mm.", [["tube", "ANATOMY", 139, 143], ["slice", "ANATOMY", 185, 190], ["slice", "ANATOMY", 212, 217], ["tube", "TISSUE", 41, 45], ["tube", "TISSUE", 139, 143], ["tube", "TISSUE", 164, 168], ["The scanning conditions", "TEST", 0, 23], ["tube voltage", "TEST", 41, 53], ["automatic tube current modulation technology", "TREATMENT", 75, 119], ["tube current)", "TREATMENT", 139, 152]]], ["After the scan was completed, multislice CT thin-layer reconstruction technology was used to reconstruct the images with a thickness of 1.0 mm and an interval of 1.0 mm.Image analysisDynamic changes in the shape, distribution, density, margins, and images of multiple chest CT lesions in the early, progressive, and recovery stages were observed and analyzed.", [["chest CT lesions", "ANATOMY", 268, 284], ["chest CT lesions", "CANCER", 268, 284], ["the scan", "TEST", 6, 14], ["multislice CT", "TEST", 30, 43], ["Image analysisDynamic changes in the shape, distribution, density, margins", "PROBLEM", 169, 243], ["images", "TEST", 249, 255], ["multiple chest CT lesions", "PROBLEM", 259, 284], ["1.0 mm", "OBSERVATION_MODIFIER", 162, 168], ["shape", "OBSERVATION_MODIFIER", 206, 211], ["distribution", "OBSERVATION_MODIFIER", 213, 225], ["density", "OBSERVATION", 227, 234], ["margins", "OBSERVATION_MODIFIER", 236, 243], ["multiple", "OBSERVATION_MODIFIER", 259, 267], ["chest", "ANATOMY", 268, 273], ["lesions", "OBSERVATION", 277, 284], ["progressive", "OBSERVATION_MODIFIER", 299, 310]]], ["All radiographic images were independently analyzed by two attending radiologists, and consistent results were achieved through discussion and consensus.", [["All radiographic images", "TEST", 0, 23]]], ["SPSS22.0 statistical software was used for statistical analysis.", [["statistical analysis", "TEST", 43, 63]]], ["Consistency test was used to J o u r n a l P r e -p r o o f evaluate whether the chest CT manifestations of COVID-19 patients were typical and Kappa value was calculated.ResultsThe results of chest CT were consistent between the two observers (Kappa =0.72), and 6 cases (6/16,37.5%) were relatively atypical.", [["chest", "ANATOMY", 81, 86], ["patients", "ORGANISM", 117, 125], ["chest", "ORGAN", 192, 197], ["patients", "SPECIES", 117, 125], ["Consistency test", "TEST", 0, 16], ["the chest CT", "TEST", 77, 89], ["COVID", "TEST", 108, 113], ["Kappa value", "TEST", 143, 154], ["chest CT", "TEST", 192, 200], ["Kappa", "TEST", 244, 249], ["chest", "ANATOMY", 81, 86], ["chest", "ANATOMY", 192, 197], ["atypical", "OBSERVATION_MODIFIER", 299, 307]]], ["The clinical types of the 6 atypical cases were all of the common type, including 2 cases of faint shadows (Fig. 1 ), 2 cases of single nodular type (Fig. 2 ), 1 case of predominantly linear shadows 1 case of bilateral faint shadows in the upper lungs that had generally dissipated; and 1 case of interlobular septal thickening and bronchovascular bundle thickening appearing as a reticular opacity in the lateral basal segment of the lower right lung that had higher extent than that observed before.", [["lungs", "ANATOMY", 246, 251], ["interlobular septal", "ANATOMY", 297, 316], ["bronchovascular bundle", "ANATOMY", 332, 354], ["reticular opacity", "ANATOMY", 381, 398], ["lateral basal segment", "ANATOMY", 406, 427], ["lower right lung", "ANATOMY", 435, 451], ["nodular type", "CANCER", 136, 148], ["upper", "ORGAN", 240, 245], ["lungs", "ORGAN", 246, 251], ["interlobular septal", "PATHOLOGICAL_FORMATION", 297, 316], ["lung", "ORGAN", 447, 451], ["the 6 atypical cases", "PROBLEM", 22, 42], ["faint shadows", "PROBLEM", 93, 106], ["single nodular type (Fig.", "PROBLEM", 129, 154], ["predominantly linear shadows", "PROBLEM", 170, 198], ["bilateral faint shadows in the upper lungs", "PROBLEM", 209, 251], ["interlobular septal thickening", "PROBLEM", 297, 327], ["bronchovascular bundle thickening", "PROBLEM", 332, 365], ["a reticular opacity", "PROBLEM", 379, 398], ["common type", "OBSERVATION_MODIFIER", 59, 70], ["faint", "OBSERVATION_MODIFIER", 93, 98], ["shadows", "OBSERVATION", 99, 106], ["nodular", "OBSERVATION_MODIFIER", 136, 143], ["predominantly", "OBSERVATION_MODIFIER", 170, 183], ["linear", "OBSERVATION_MODIFIER", 184, 190], ["shadows", "OBSERVATION", 191, 198], ["bilateral", "ANATOMY_MODIFIER", 209, 218], ["faint", "OBSERVATION_MODIFIER", 219, 224], ["shadows", "OBSERVATION", 225, 232], ["upper", "ANATOMY_MODIFIER", 240, 245], ["lungs", "ANATOMY", 246, 251], ["dissipated", "OBSERVATION_MODIFIER", 271, 281], ["interlobular", "ANATOMY_MODIFIER", 297, 309], ["septal", "ANATOMY_MODIFIER", 310, 316], ["thickening", "OBSERVATION", 317, 327], ["bronchovascular", "ANATOMY_MODIFIER", 332, 347], ["bundle", "ANATOMY_MODIFIER", 348, 354], ["thickening", "OBSERVATION", 355, 365], ["reticular", "OBSERVATION_MODIFIER", 381, 390], ["opacity", "OBSERVATION", 391, 398], ["lateral", "ANATOMY_MODIFIER", 406, 413], ["basal", "ANATOMY_MODIFIER", 414, 419], ["segment", "ANATOMY_MODIFIER", 420, 427], ["lower", "ANATOMY_MODIFIER", 435, 440], ["right", "ANATOMY_MODIFIER", 441, 446], ["lung", "ANATOMY", 447, 451], ["higher", "OBSERVATION_MODIFIER", 461, 467], ["extent", "OBSERVATION_MODIFIER", 468, 474]]], ["A third CT examination was performed on days 6-9, and there were 2 cases of dissipated single subpleural lesions; 1 case of dissipation and reduction of lesions in the lateral basal segment of the lower right lung than that observed before, with a new reticular opacity in the medial basal segment and a small amount of ground-glass opacity; and 1 case of bilateral multiple linear opacities on initial CT examination after transfer from an outside hospital at day 7 after disease onset.", [["subpleural lesions", "ANATOMY", 94, 112], ["lesions", "ANATOMY", 153, 160], ["lateral basal segment", "ANATOMY", 168, 189], ["lower right lung", "ANATOMY", 197, 213], ["reticular opacity", "ANATOMY", 252, 269], ["medial basal segment", "ANATOMY", 277, 297], ["opacities", "DISEASE", 382, 391], ["subpleural lesions", "PATHOLOGICAL_FORMATION", 94, 112], ["lesions", "PATHOLOGICAL_FORMATION", 153, 160], ["lung", "ORGAN", 209, 213], ["reticular", "TISSUE", 252, 261], ["A third CT examination", "TEST", 0, 22], ["dissipated single subpleural lesions", "PROBLEM", 76, 112], ["lesions", "PROBLEM", 153, 160], ["a new reticular opacity in the medial basal segment", "PROBLEM", 246, 297], ["ground-glass opacity", "PROBLEM", 320, 340], ["bilateral multiple linear opacities", "PROBLEM", 356, 391], ["initial CT examination", "TEST", 395, 417], ["subpleural", "ANATOMY", 94, 104], ["lesions", "OBSERVATION", 105, 112], ["reduction", "OBSERVATION_MODIFIER", 140, 149], ["lesions", "OBSERVATION", 153, 160], ["lateral", "ANATOMY_MODIFIER", 168, 175], ["basal", "ANATOMY_MODIFIER", 176, 181], ["segment", "ANATOMY_MODIFIER", 182, 189], ["lower", "ANATOMY_MODIFIER", 197, 202], ["right", "ANATOMY_MODIFIER", 203, 208], ["lung", "ANATOMY", 209, 213], ["new", "OBSERVATION_MODIFIER", 248, 251], ["reticular", "OBSERVATION_MODIFIER", 252, 261], ["opacity", "OBSERVATION", 262, 269], ["medial", "ANATOMY_MODIFIER", 277, 283], ["basal", "ANATOMY_MODIFIER", 284, 289], ["segment", "ANATOMY_MODIFIER", 290, 297], ["small", "OBSERVATION_MODIFIER", 304, 309], ["amount", "OBSERVATION_MODIFIER", 310, 316], ["ground-glass opacity", "OBSERVATION", 320, 340], ["bilateral", "ANATOMY_MODIFIER", 356, 365], ["multiple", "OBSERVATION_MODIFIER", 366, 374], ["linear", "OBSERVATION_MODIFIER", 375, 381], ["opacities", "OBSERVATION", 382, 391]]], ["On day 15, there was a slight progression of the lesion in the lateral basal segment of the lower right lung, and the lesions in the medial basal segment had dissipated than that observed before.COVID-19 clinical presentation and laboratory examinationCOVID-19 is clinically characterized by fever, fatigue, and dry cough, which is accompanied by nasal congestion, runny nose, sore throat, and diarrhea in a small number of patients [6] .", [["lesion", "ANATOMY", 49, 55], ["lateral basal segment", "ANATOMY", 63, 84], ["lower right lung", "ANATOMY", 92, 108], ["lesions", "ANATOMY", 118, 125], ["medial basal segment", "ANATOMY", 133, 153], ["nasal", "ANATOMY", 347, 352], ["fever", "DISEASE", 292, 297], ["fatigue", "DISEASE", 299, 306], ["dry cough", "DISEASE", 312, 321], ["nasal congestion", "DISEASE", 347, 363], ["runny nose", "DISEASE", 365, 375], ["sore throat", "DISEASE", 377, 388], ["diarrhea", "DISEASE", 394, 402], ["lesion", "CANCER", 49, 55], ["lateral basal segment", "MULTI-TISSUE_STRUCTURE", 63, 84], ["lung", "ORGAN", 104, 108], ["lesions", "PATHOLOGICAL_FORMATION", 118, 125], ["nasal", "ORGANISM_SUBDIVISION", 347, 352], ["nose", "ORGANISM_SUBDIVISION", 371, 375], ["patients", "ORGANISM", 424, 432], ["patients", "SPECIES", 424, 432], ["a slight progression of the lesion", "PROBLEM", 21, 55], ["the lesions in the medial basal segment", "PROBLEM", 114, 153], ["COVID", "TEST", 195, 200], ["laboratory examinationCOVID", "TEST", 230, 257], ["fever", "PROBLEM", 292, 297], ["fatigue", "PROBLEM", 299, 306], ["dry cough", "PROBLEM", 312, 321], ["nasal congestion", "PROBLEM", 347, 363], ["runny nose", "PROBLEM", 365, 375], ["sore throat", "PROBLEM", 377, 388], ["diarrhea", "PROBLEM", 394, 402], ["slight", "OBSERVATION_MODIFIER", 23, 29], ["progression", "OBSERVATION_MODIFIER", 30, 41], ["lesion", "OBSERVATION", 49, 55], ["lateral", "ANATOMY_MODIFIER", 63, 70], ["basal", "ANATOMY_MODIFIER", 71, 76], ["segment", "ANATOMY_MODIFIER", 77, 84], ["lower", "ANATOMY_MODIFIER", 92, 97], ["right", "ANATOMY_MODIFIER", 98, 103], ["lung", "ANATOMY", 104, 108], ["lesions", "OBSERVATION", 118, 125], ["medial", "ANATOMY_MODIFIER", 133, 139], ["basal", "ANATOMY_MODIFIER", 140, 145], ["segment", "ANATOMY_MODIFIER", 146, 153], ["dissipated", "OBSERVATION_MODIFIER", 158, 168], ["fever", "OBSERVATION", 292, 297], ["dry", "OBSERVATION_MODIFIER", 312, 315], ["cough", "OBSERVATION", 316, 321], ["nasal", "ANATOMY", 347, 352], ["congestion", "OBSERVATION", 353, 363], ["runny nose", "ANATOMY", 365, 375], ["sore throat", "ANATOMY", 377, 388], ["diarrhea", "OBSERVATION", 394, 402], ["small", "OBSERVATION_MODIFIER", 408, 413]]], ["Among the clinical symptoms of the 6 patients in this cohort, 3 patients presented with fever at early stages and gradually developed J o u r n a l P r e -p r o o f cough and sputum symptoms, 2 patients presented with only fever, and 1 patient presented only with cough and not fever.", [["sputum", "ANATOMY", 175, 181], ["fever", "DISEASE", 88, 93], ["cough", "DISEASE", 165, 170], ["sputum symptoms", "DISEASE", 175, 190], ["fever", "DISEASE", 223, 228], ["cough", "DISEASE", 264, 269], ["fever", "DISEASE", 278, 283], ["patients", "ORGANISM", 37, 45], ["patients", "ORGANISM", 64, 72], ["patients", "ORGANISM", 194, 202], ["patient", "ORGANISM", 236, 243], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 64, 72], ["patients", "SPECIES", 194, 202], ["patient", "SPECIES", 236, 243], ["the clinical symptoms", "PROBLEM", 6, 27], ["fever", "PROBLEM", 88, 93], ["cough", "PROBLEM", 165, 170], ["sputum symptoms", "PROBLEM", 175, 190], ["fever", "PROBLEM", 223, 228], ["cough", "PROBLEM", 264, 269], ["fever", "PROBLEM", 278, 283], ["fever", "OBSERVATION", 88, 93], ["cough", "OBSERVATION", 264, 269], ["not", "UNCERTAINTY", 274, 277], ["fever", "OBSERVATION", 278, 283]]], ["It can be observed that some COVID-19 symptoms in this cohort are atypical and have hidden characteristics.", [["some COVID-19 symptoms", "PROBLEM", 24, 46]]], ["Laboratory tests at the early stages of the disease usually reveal that the total peripheral WBC count is normal or decreased, the lymphocyte count is decreased, and liver enzyme, creatine kinase, and myoglobin levels are occasionally increased.", [["peripheral WBC", "ANATOMY", 82, 96], ["lymphocyte", "ANATOMY", 131, 141], ["liver", "ANATOMY", 166, 171], ["creatine", "CHEMICAL", 180, 188], ["creatine", "CHEMICAL", 180, 188], ["peripheral WBC", "CELL", 82, 96], ["lymphocyte", "CELL", 131, 141], ["liver", "ORGAN", 166, 171], ["creatine kinase", "GENE_OR_GENE_PRODUCT", 180, 195], ["myoglobin", "GENE_OR_GENE_PRODUCT", 201, 210], ["liver enzyme", "PROTEIN", 166, 178], ["creatine kinase", "PROTEIN", 180, 195], ["myoglobin", "PROTEIN", 201, 210], ["Laboratory tests", "TEST", 0, 16], ["the disease", "PROBLEM", 40, 51], ["the total peripheral WBC count", "TEST", 72, 102], ["the lymphocyte count", "TEST", 127, 147], ["liver enzyme", "TEST", 166, 178], ["creatine kinase", "TEST", 180, 195], ["myoglobin levels", "TEST", 201, 217], ["disease", "OBSERVATION", 44, 51], ["WBC count", "OBSERVATION", 93, 102], ["normal", "OBSERVATION", 106, 112], ["decreased", "OBSERVATION_MODIFIER", 116, 125], ["lymphocyte count", "OBSERVATION", 131, 147], ["decreased", "OBSERVATION_MODIFIER", 151, 160], ["liver", "ANATOMY", 166, 171], ["occasionally", "OBSERVATION_MODIFIER", 222, 234], ["increased", "OBSERVATION_MODIFIER", 235, 244]]], ["Additionally, most patients have elevated C-reactive protein levels and erythrocyte sedimentation rates and normal procalcitonin levels, with elevated D-dimer levels in patients with severe COVID-19 [6] .", [["erythrocyte", "ANATOMY", 72, 83], ["COVID-19", "CHEMICAL", 190, 198], ["patients", "ORGANISM", 19, 27], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 42, 60], ["erythrocyte", "CELL", 72, 83], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 115, 128], ["D-dimer", "GENE_OR_GENE_PRODUCT", 151, 158], ["patients", "ORGANISM", 169, 177], ["C-reactive protein", "PROTEIN", 42, 60], ["procalcitonin", "PROTEIN", 115, 128], ["D-dimer", "PROTEIN", 151, 158], ["patients", "SPECIES", 19, 27], ["patients", "SPECIES", 169, 177], ["elevated C-reactive protein levels", "PROBLEM", 33, 67], ["erythrocyte sedimentation rates", "TEST", 72, 103], ["procalcitonin levels", "TEST", 115, 135], ["elevated D-dimer levels", "PROBLEM", 142, 165], ["severe COVID", "PROBLEM", 183, 195], ["erythrocyte sedimentation", "OBSERVATION", 72, 97]]], ["In this cohort of 6 patients, the WBC count was normal or decreased and lymphocyte count was decreased in 3 patients (50%), suggesting that the patients had significant immune damage to the body's cells, which may be associated with infection of lymphocytes or induction of cytotoxicity or apoptosis by SARS-CoV-2 [7] .", [["WBC", "ANATOMY", 34, 37], ["lymphocyte", "ANATOMY", 72, 82], ["body's cells", "ANATOMY", 190, 202], ["lymphocytes", "ANATOMY", 246, 257], ["infection", "DISEASE", 233, 242], ["patients", "ORGANISM", 20, 28], ["WBC", "CELL", 34, 37], ["lymphocyte", "CELL", 72, 82], ["patients", "ORGANISM", 108, 116], ["patients", "ORGANISM", 144, 152], ["body's cells", "CELL", 190, 202], ["lymphocytes", "CELL", 246, 257], ["lymphocytes", "CELL_TYPE", 246, 257], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 108, 116], ["patients", "SPECIES", 144, 152], ["SARS-CoV", "SPECIES", 303, 311], ["the WBC count", "TEST", 30, 43], ["lymphocyte count", "TEST", 72, 88], ["significant immune damage to the body's cells", "PROBLEM", 157, 202], ["infection of lymphocytes", "PROBLEM", 233, 257], ["cytotoxicity", "PROBLEM", 274, 286], ["apoptosis", "PROBLEM", 290, 299], ["SARS", "TEST", 303, 307], ["CoV", "TEST", 308, 311], ["normal", "OBSERVATION", 48, 54], ["decreased", "OBSERVATION_MODIFIER", 58, 67], ["decreased", "OBSERVATION_MODIFIER", 93, 102], ["significant", "OBSERVATION_MODIFIER", 157, 168], ["immune damage", "OBSERVATION", 169, 182], ["may be associated with", "UNCERTAINTY", 210, 232], ["infection", "OBSERVATION", 233, 242]]], ["Etiological evidence is key to the diagnosis of COVID-19.", [["COVID-19", "CHEMICAL", 48, 56], ["COVID", "TEST", 48, 53]]], ["Positive SARS-CoV-2 nucleic acid test results can be obtained from pharyngeal swabs, sputum, lower respiratory tract secretions, and blood, but false-negative nucleic acid test results are possible when the viral load is low.COVID-19 clinical presentation and laboratory examinationTherefore, when the patient's epidemiological history is known and chest CT findings support changes associated with viral pneumonia, a diagnosis cannot be completely ruled out even with multiple negative nucleic acid test results, and the patient should be followed up closely [8] .Atypical computed tomography presentation of COVID-19 and its pathological mechanismThere have been several reports on the typical presentation of COVID-19 on chest CT (1\u22125).", [["pharyngeal swabs", "ANATOMY", 67, 83], ["sputum", "ANATOMY", 85, 91], ["lower respiratory tract secretions", "ANATOMY", 93, 127], ["blood", "ANATOMY", 133, 138], ["chest", "ANATOMY", 724, 729], ["nucleic acid", "CHEMICAL", 20, 32], ["nucleic acid", "CHEMICAL", 159, 171], ["viral pneumonia", "DISEASE", 399, 414], ["COVID-19", "CHEMICAL", 610, 618], ["pharyngeal swabs", "MULTI-TISSUE_STRUCTURE", 67, 83], ["sputum", "ORGANISM_SUBSTANCE", 85, 91], ["lower", "ORGANISM_SUBDIVISION", 93, 98], ["respiratory tract", "ORGANISM_SUBDIVISION", 99, 116], ["secretions", "ORGANISM_SUBSTANCE", 117, 127], ["blood", "ORGANISM_SUBSTANCE", 133, 138], ["patient", "ORGANISM", 302, 309], ["patient", "ORGANISM", 522, 529], ["chest", "ORGAN", 724, 729], ["patient", "SPECIES", 302, 309], ["patient", "SPECIES", 522, 529], ["CoV", "TEST", 14, 17], ["nucleic acid test", "TEST", 20, 37], ["pharyngeal swabs", "TEST", 67, 83], ["sputum", "TEST", 85, 91], ["lower respiratory tract secretions", "PROBLEM", 93, 127], ["blood", "TEST", 133, 138], ["false", "TEST", 144, 149], ["nucleic acid test", "TEST", 159, 176], ["the viral load", "TEST", 203, 217], ["laboratory examination", "TEST", 260, 282], ["chest CT", "TEST", 349, 357], ["viral pneumonia", "PROBLEM", 399, 414], ["nucleic acid test", "TEST", 487, 504], ["Atypical computed tomography presentation", "TEST", 565, 606], ["COVID", "TEST", 610, 615], ["COVID", "TEST", 712, 717], ["chest CT", "TEST", 724, 732], ["SARS", "OBSERVATION", 9, 13], ["pharyngeal", "ANATOMY", 67, 77], ["lower", "ANATOMY_MODIFIER", 93, 98], ["respiratory tract", "ANATOMY", 99, 116], ["chest", "ANATOMY", 349, 354], ["viral", "OBSERVATION_MODIFIER", 399, 404], ["pneumonia", "OBSERVATION", 405, 414], ["chest", "ANATOMY", 724, 729]]], ["Common CT manifestations include multiple bilateral patchy ground-glass opacities and consolidation opacities that are predominantly distributed along the bronchovascular bundles and in the subpleural space, between which vascular thickening opacities and fine reticular opacities can be observed, which appear as a \"crazy-paving pattern.\"", [["bronchovascular bundles", "ANATOMY", 155, 178], ["subpleural space", "ANATOMY", 190, 206], ["vascular", "ANATOMY", 222, 230], ["reticular opacities", "ANATOMY", 261, 280], ["opacities", "DISEASE", 100, 109], ["reticular opacities", "DISEASE", 261, 280], ["bronchovascular bundles", "MULTI-TISSUE_STRUCTURE", 155, 178], ["subpleural space", "MULTI-TISSUE_STRUCTURE", 190, 206], ["vascular", "MULTI-TISSUE_STRUCTURE", 222, 230], ["Common CT manifestations", "TEST", 0, 24], ["multiple bilateral patchy ground-glass opacities", "PROBLEM", 33, 81], ["consolidation opacities", "PROBLEM", 86, 109], ["vascular thickening opacities", "PROBLEM", 222, 251], ["fine reticular opacities", "PROBLEM", 256, 280], ["multiple", "OBSERVATION_MODIFIER", 33, 41], ["bilateral", "ANATOMY_MODIFIER", 42, 51], ["patchy", "OBSERVATION_MODIFIER", 52, 58], ["ground-glass opacities", "OBSERVATION", 59, 81], ["consolidation opacities", "OBSERVATION", 86, 109], ["predominantly", "OBSERVATION_MODIFIER", 119, 132], ["bronchovascular bundles", "ANATOMY", 155, 178], ["subpleural", "ANATOMY_MODIFIER", 190, 200], ["vascular", "ANATOMY", 222, 230], ["thickening", "OBSERVATION_MODIFIER", 231, 241], ["opacities", "OBSERVATION", 242, 251], ["fine", "OBSERVATION_MODIFIER", 256, 260], ["reticular", "OBSERVATION_MODIFIER", 261, 270], ["opacities", "OBSERVATION", 271, 280]]], ["The 6 patients in this cohort had rare, atypical CT presentations such as faint shadows, single nodules, linear opacities, and reticular opacities.", [["nodules", "ANATOMY", 96, 103], ["reticular opacities", "ANATOMY", 127, 146], ["opacities", "DISEASE", 112, 121], ["reticular opacities", "DISEASE", 127, 146], ["patients", "ORGANISM", 6, 14], ["reticular opacities", "PATHOLOGICAL_FORMATION", 127, 146], ["patients", "SPECIES", 6, 14], ["atypical CT presentations", "PROBLEM", 40, 65], ["faint shadows", "PROBLEM", 74, 87], ["single nodules", "PROBLEM", 89, 103], ["linear opacities", "PROBLEM", 105, 121], ["reticular opacities", "PROBLEM", 127, 146], ["faint", "OBSERVATION_MODIFIER", 74, 79], ["shadows", "OBSERVATION", 80, 87], ["single", "OBSERVATION_MODIFIER", 89, 95], ["nodules", "OBSERVATION", 96, 103], ["linear", "OBSERVATION_MODIFIER", 105, 111], ["opacities", "OBSERVATION", 112, 121], ["reticular", "ANATOMY_MODIFIER", 127, 136], ["opacities", "OBSERVATION", 137, 146]]], ["It may be related to the time of onset, length of disease and the underlying lung diseases, which should be closely related to clinical comprehensive analysis.", [["lung", "ANATOMY", 77, 81], ["lung diseases", "DISEASE", 77, 90], ["lung", "ORGAN", 77, 81], ["length of disease", "PROBLEM", 40, 57], ["the underlying lung diseases", "PROBLEM", 62, 90], ["clinical comprehensive analysis", "TEST", 127, 158], ["may be related to", "UNCERTAINTY", 3, 20], ["lung", "ANATOMY", 77, 81], ["diseases", "OBSERVATION", 82, 90]]], ["In the 2 cases with faint shadows, the lesions could be easily overlooked.", [["lesions", "ANATOMY", 39, 46], ["lesions", "PATHOLOGICAL_FORMATION", 39, 46], ["faint shadows", "PROBLEM", 20, 33], ["the lesions", "PROBLEM", 35, 46], ["faint", "OBSERVATION_MODIFIER", 20, 25], ["shadows", "OBSERVATION", 26, 33], ["lesions", "OBSERVATION", 39, 46], ["could be", "UNCERTAINTY", 47, 55]]], ["The patient may have been in the early stages of the disease, which is related to a small amount of virus replication, swelling of the alveolar wall epithelium, and mild involvement of the interlobular interstitial tissue [1, 2] .", [["alveolar wall epithelium", "ANATOMY", 135, 159], ["interlobular interstitial tissue", "ANATOMY", 189, 221], ["swelling", "DISEASE", 119, 127], ["patient", "ORGANISM", 4, 11], ["alveolar wall epithelium", "TISSUE", 135, 159], ["interlobular interstitial tissue", "TISSUE", 189, 221], ["patient", "SPECIES", 4, 11], ["the disease", "PROBLEM", 49, 60], ["a small amount of virus replication", "PROBLEM", 82, 117], ["swelling of the alveolar wall epithelium", "PROBLEM", 119, 159], ["mild involvement of the interlobular interstitial tissue", "PROBLEM", 165, 221], ["early stages", "OBSERVATION_MODIFIER", 33, 45], ["disease", "OBSERVATION", 53, 60], ["small", "OBSERVATION_MODIFIER", 84, 89], ["amount", "OBSERVATION_MODIFIER", 90, 96], ["virus replication", "OBSERVATION", 100, 117], ["swelling", "OBSERVATION", 119, 127], ["alveolar", "ANATOMY_MODIFIER", 135, 143], ["wall", "ANATOMY_MODIFIER", 144, 148], ["epithelium", "ANATOMY_MODIFIER", 149, 159], ["mild", "OBSERVATION_MODIFIER", 165, 169], ["involvement", "OBSERVATION", 170, 181], ["interlobular", "ANATOMY_MODIFIER", 189, 201], ["interstitial tissue", "ANATOMY", 202, 221]]], ["In the 2 cases, single nodules were located in the subpleural space outside the lung tissue, meeting the distribution characteristics typical of COVID-19.", [["nodules", "ANATOMY", 23, 30], ["subpleural space", "ANATOMY", 51, 67], ["lung tissue", "ANATOMY", 80, 91], ["nodules", "CANCER", 23, 30], ["subpleural space", "MULTI-TISSUE_STRUCTURE", 51, 67], ["lung tissue", "TISSUE", 80, 91], ["COVID-19", "DNA", 145, 153], ["single nodules", "PROBLEM", 16, 30], ["COVID", "TEST", 145, 150], ["single", "OBSERVATION_MODIFIER", 16, 22], ["nodules", "OBSERVATION", 23, 30], ["subpleural", "ANATOMY_MODIFIER", 51, 61], ["lung", "ANATOMY", 80, 84], ["tissue", "ANATOMY_MODIFIER", 85, 91]]], ["Because of the small size of the virus (diameter: 60-140 nm), it can easily reach the distal airway, subsequently affecting the terminal bronchioles and lung interstitial tissue surrounding the respiratory bronchioles.", [["distal airway", "ANATOMY", 86, 99], ["terminal bronchioles", "ANATOMY", 128, 148], ["lung interstitial tissue", "ANATOMY", 153, 177], ["respiratory bronchioles", "ANATOMY", 194, 217], ["airway", "MULTI-TISSUE_STRUCTURE", 93, 99], ["terminal bronchioles", "TISSUE", 128, 148], ["lung interstitial tissue", "TISSUE", 153, 177], ["respiratory bronchioles", "MULTI-TISSUE_STRUCTURE", 194, 217], ["lung interstitial tissue", "PROBLEM", 153, 177], ["small", "OBSERVATION_MODIFIER", 15, 20], ["size", "OBSERVATION_MODIFIER", 21, 25], ["virus", "OBSERVATION", 33, 38], ["diameter", "OBSERVATION_MODIFIER", 40, 48], ["distal", "ANATOMY_MODIFIER", 86, 92], ["airway", "ANATOMY", 93, 99], ["terminal", "ANATOMY_MODIFIER", 128, 136], ["bronchioles", "ANATOMY", 137, 148], ["lung", "ANATOMY", 153, 157], ["interstitial tissue", "OBSERVATION", 158, 177], ["respiratory bronchioles", "ANATOMY", 194, 217]]], ["However, the 2 patients only exhibited a single small nodule, in contrast to the typical multiple ground-glass opacities, which J o u r n a l P r e -p r o o f may be related to the extent of virus involvement being limited to only the interstitial tissue of the lobular core.Atypical computed tomography presentation of COVID-19 and its pathological mechanismSince lymphatic reflux in the lobular core area is centripetal, a round lobular core nodule can form easily.", [["nodule", "ANATOMY", 54, 60], ["interstitial tissue", "ANATOMY", 235, 254], ["lobular core", "ANATOMY", 262, 274], ["lymphatic", "ANATOMY", 365, 374], ["lobular core area", "ANATOMY", 389, 406], ["round lobular core nodule", "ANATOMY", 425, 450], ["lymphatic reflux", "DISEASE", 365, 381], ["patients", "ORGANISM", 15, 23], ["nodule", "CANCER", 54, 60], ["interstitial tissue", "TISSUE", 235, 254], ["lobular core", "CANCER", 262, 274], ["lymphatic reflux", "CANCER", 365, 381], ["lobular core area", "CANCER", 389, 406], ["lobular core nodule", "CANCER", 431, 450], ["patients", "SPECIES", 15, 23], ["a single small nodule", "PROBLEM", 39, 60], ["the typical multiple ground-glass opacities", "PROBLEM", 77, 120], ["virus involvement", "PROBLEM", 191, 208], ["Atypical computed tomography presentation", "TEST", 275, 316], ["COVID", "TEST", 320, 325], ["its pathological mechanismSince lymphatic reflux in the lobular core area", "PROBLEM", 333, 406], ["a round lobular core nodule", "PROBLEM", 423, 450], ["small", "OBSERVATION_MODIFIER", 48, 53], ["nodule", "OBSERVATION", 54, 60], ["typical", "OBSERVATION_MODIFIER", 81, 88], ["multiple", "OBSERVATION_MODIFIER", 89, 97], ["ground-glass opacities", "OBSERVATION", 98, 120], ["l", "ANATOMY_MODIFIER", 140, 141], ["may be related to", "UNCERTAINTY", 159, 176], ["virus", "OBSERVATION", 191, 196], ["interstitial", "ANATOMY_MODIFIER", 235, 247], ["tissue", "OBSERVATION", 248, 254], ["lobular", "OBSERVATION_MODIFIER", 262, 269], ["lymphatic", "ANATOMY", 365, 374], ["reflux", "OBSERVATION", 375, 381], ["lobular", "ANATOMY_MODIFIER", 389, 396], ["core", "ANATOMY_MODIFIER", 397, 401], ["area", "ANATOMY_MODIFIER", 402, 406], ["centripetal", "OBSERVATION_MODIFIER", 410, 421], ["round", "OBSERVATION_MODIFIER", 425, 430], ["lobular", "OBSERVATION_MODIFIER", 431, 438], ["core", "OBSERVATION_MODIFIER", 439, 443], ["nodule", "OBSERVATION", 444, 450]]], ["As the disease progresses, the area around the lobule also becomes involved, which subsequently spreads to the entire secondary lobule and diffuses to the surroundings, forming a small flaky consolidation opacity.", [["lobule", "ANATOMY", 47, 53], ["lobule", "ANATOMY", 128, 134], ["opacity", "DISEASE", 205, 212], ["lobule", "CANCER", 47, 53], ["lobule", "ORGAN", 128, 134], ["the disease", "PROBLEM", 3, 14], ["a small flaky consolidation opacity", "PROBLEM", 177, 212], ["disease", "OBSERVATION", 7, 14], ["area", "OBSERVATION_MODIFIER", 31, 35], ["lobule", "ANATOMY", 47, 53], ["entire", "OBSERVATION_MODIFIER", 111, 117], ["secondary lobule", "OBSERVATION", 118, 134], ["diffuses", "OBSERVATION_MODIFIER", 139, 147], ["small", "OBSERVATION_MODIFIER", 179, 184], ["flaky", "OBSERVATION_MODIFIER", 185, 190], ["consolidation", "OBSERVATION", 191, 204], ["opacity", "OBSERVATION", 205, 212]]], ["There was 1 case of predominantly reticular opacities involving the lower right lobe.", [["reticular opacities", "ANATOMY", 34, 53], ["lower right lobe", "ANATOMY", 68, 84], ["reticular opacities involving the lower right lobe", "DISEASE", 34, 84], ["reticular opacities", "PATHOLOGICAL_FORMATION", 34, 53], ["lobe", "ORGAN", 80, 84], ["predominantly reticular opacities involving the lower right lobe", "PROBLEM", 20, 84], ["predominantly", "OBSERVATION_MODIFIER", 20, 33], ["reticular", "ANATOMY_MODIFIER", 34, 43], ["opacities", "OBSERVATION", 44, 53], ["lower", "ANATOMY_MODIFIER", 68, 73], ["right lobe", "ANATOMY", 74, 84]]], ["This may be because the bronchi in the lower right lobe are thick and short, the virus could enter more easily, and the target cells of COVID-19 might be located in the lower respiratory tract [9] .", [["bronchi", "ANATOMY", 24, 31], ["lower right lobe", "ANATOMY", 39, 55], ["cells", "ANATOMY", 127, 132], ["lower respiratory tract", "ANATOMY", 169, 192], ["COVID-19", "CHEMICAL", 136, 144], ["bronchi", "MULTI-TISSUE_STRUCTURE", 24, 31], ["lower", "ORGANISM_SUBDIVISION", 39, 44], ["right lobe", "ORGAN", 45, 55], ["cells", "CELL", 127, 132], ["COVID-19", "GENE_OR_GENE_PRODUCT", 136, 144], ["target cells", "CELL_TYPE", 120, 132], ["COVID", "PROTEIN", 136, 141], ["thick and short, the virus", "PROBLEM", 60, 86], ["COVID", "TEST", 136, 141], ["may be", "UNCERTAINTY", 5, 11], ["bronchi", "ANATOMY", 24, 31], ["lower right lobe", "ANATOMY", 39, 55], ["thick", "OBSERVATION", 60, 65], ["short", "OBSERVATION_MODIFIER", 70, 75], ["lower", "ANATOMY_MODIFIER", 169, 174], ["respiratory tract", "ANATOMY", 175, 192]]], ["In this case, reticular opacities were predominant because the patient had chronic bronchitis and emphysema as underlying diseases.", [["reticular opacities", "ANATOMY", 14, 33], ["reticular opacities", "DISEASE", 14, 33], ["bronchitis", "DISEASE", 83, 93], ["emphysema", "DISEASE", 98, 107], ["reticular opacities", "PATHOLOGICAL_FORMATION", 14, 33], ["patient", "ORGANISM", 63, 70], ["patient", "SPECIES", 63, 70], ["reticular opacities", "PROBLEM", 14, 33], ["chronic bronchitis", "PROBLEM", 75, 93], ["emphysema", "PROBLEM", 98, 107], ["underlying diseases", "PROBLEM", 111, 130], ["reticular", "OBSERVATION_MODIFIER", 14, 23], ["opacities", "OBSERVATION", 24, 33], ["predominant", "OBSERVATION_MODIFIER", 39, 50], ["chronic", "OBSERVATION_MODIFIER", 75, 82], ["bronchitis", "OBSERVATION", 83, 93], ["emphysema", "OBSERVATION", 98, 107]]], ["Hence, interlobular septal thickening and bronchovascular bundle thickening were observed in varying degrees from the early stages of the disease through the progressive stage and the recovery stage and only a few ground glass-like lesions were observed.Atypical computed tomography presentation of COVID-19 and its pathological mechanismDuring progression and dissipation, some lesions resolved but again progressed after treatment, suggesting that the imaging changes not only were restricted by the pattern of disease development but also were related to the treatment protocol, efficacy of treatment, presence of underlying diseases, age, and immune function.", [["interlobular septal", "ANATOMY", 7, 26], ["bronchovascular bundle", "ANATOMY", 42, 64], ["lesions", "ANATOMY", 232, 239], ["lesions", "ANATOMY", 379, 386], ["interlobular septal", "MULTI-TISSUE_STRUCTURE", 7, 26], ["glass-like lesions", "CANCER", 221, 239], ["lesions", "PATHOLOGICAL_FORMATION", 379, 386], ["interlobular septal thickening", "PROBLEM", 7, 37], ["bronchovascular bundle thickening", "PROBLEM", 42, 75], ["the disease", "PROBLEM", 134, 145], ["the progressive stage", "PROBLEM", 154, 175], ["a few ground glass-like lesions", "PROBLEM", 208, 239], ["Atypical computed tomography presentation", "TEST", 254, 295], ["COVID", "TEST", 299, 304], ["its pathological mechanismDuring progression", "PROBLEM", 312, 356], ["dissipation", "PROBLEM", 361, 372], ["some lesions", "PROBLEM", 374, 386], ["treatment", "TREATMENT", 423, 432], ["the imaging", "TEST", 450, 461], ["disease development", "PROBLEM", 513, 532], ["the treatment protocol", "TREATMENT", 558, 580], ["treatment", "TREATMENT", 594, 603], ["underlying diseases", "PROBLEM", 617, 636], ["interlobular", "ANATOMY_MODIFIER", 7, 19], ["septal", "ANATOMY_MODIFIER", 20, 26], ["thickening", "OBSERVATION", 27, 37], ["bronchovascular", "ANATOMY_MODIFIER", 42, 57], ["bundle", "ANATOMY_MODIFIER", 58, 64], ["thickening", "OBSERVATION", 65, 75], ["varying degrees", "OBSERVATION_MODIFIER", 93, 108], ["early stages", "OBSERVATION_MODIFIER", 118, 130], ["disease", "OBSERVATION", 138, 145], ["progressive", "OBSERVATION_MODIFIER", 158, 169], ["stage", "OBSERVATION_MODIFIER", 170, 175], ["recovery stage", "OBSERVATION_MODIFIER", 184, 198], ["few", "OBSERVATION_MODIFIER", 210, 213], ["ground glass", "OBSERVATION", 214, 226], ["-like", "OBSERVATION_MODIFIER", 226, 231], ["lesions", "OBSERVATION", 232, 239], ["progression", "OBSERVATION_MODIFIER", 345, 356], ["some", "OBSERVATION_MODIFIER", 374, 378], ["lesions", "OBSERVATION", 379, 386], ["disease", "OBSERVATION", 513, 520], ["diseases", "OBSERVATION", 628, 636]]], ["There was 1 case of predominantly linear opacities, which was transferred from an outside hospital.", [["opacities", "DISEASE", 41, 50], ["predominantly linear opacities", "PROBLEM", 20, 50], ["predominantly", "OBSERVATION_MODIFIER", 20, 33], ["linear", "OBSERVATION_MODIFIER", 34, 40], ["opacities", "OBSERVATION", 41, 50]]], ["The initial CT examination performed at day 7 after onset in this case revealed multiple bilateral linear opacities in the lungs, classifying it as the resolution stage of disease.", [["lungs", "ANATOMY", 123, 128], ["lungs", "ORGAN", 123, 128], ["The initial CT examination", "TEST", 0, 26], ["multiple bilateral linear opacities in the lungs", "PROBLEM", 80, 128], ["disease", "PROBLEM", 172, 179], ["multiple", "OBSERVATION_MODIFIER", 80, 88], ["bilateral", "ANATOMY_MODIFIER", 89, 98], ["linear", "OBSERVATION_MODIFIER", 99, 105], ["opacities", "OBSERVATION", 106, 115], ["lungs", "ANATOMY", 123, 128], ["resolution", "OBSERVATION_MODIFIER", 152, 162], ["stage", "OBSERVATION_MODIFIER", 163, 168], ["disease", "OBSERVATION", 172, 179]]], ["Since the virus primarily exhibits interstitial involvement with more lymphocyte infiltration, the alveolar pores are smaller, and the lesions dissipate relatively slowly, linear opacities persist for a long period of time during the process of dissipation, and a comprehensive judgment should be made in close conjunction with the clinical course to avoid misdiagnosis as chronic inflammation.Atypical computed tomography presentation of COVID-19 and its pathological mechanismDifferent types of lung injury are caused by different viruses, but the same family of viruses causes similar pathological changes [10] .", [["interstitial", "ANATOMY", 35, 47], ["lymphocyte", "ANATOMY", 70, 80], ["alveolar pores", "ANATOMY", 99, 113], ["lesions", "ANATOMY", 135, 142], ["lung", "ANATOMY", 497, 501], ["opacities", "DISEASE", 179, 188], ["inflammation", "DISEASE", 381, 393], ["COVID-19", "CHEMICAL", 439, 447], ["lung injury", "DISEASE", 497, 508], ["lymphocyte", "CELL", 70, 80], ["alveolar pores", "MULTI-TISSUE_STRUCTURE", 99, 113], ["lesions", "PATHOLOGICAL_FORMATION", 135, 142], ["lung", "ORGAN", 497, 501], ["the virus", "PROBLEM", 6, 15], ["interstitial involvement", "PROBLEM", 35, 59], ["more lymphocyte infiltration", "PROBLEM", 65, 93], ["the lesions", "PROBLEM", 131, 142], ["linear opacities", "PROBLEM", 172, 188], ["misdiagnosis", "PROBLEM", 357, 369], ["chronic inflammation", "PROBLEM", 373, 393], ["Atypical computed tomography presentation", "TEST", 394, 435], ["COVID", "TEST", 439, 444], ["lung injury", "PROBLEM", 497, 508], ["different viruses", "PROBLEM", 523, 540], ["similar pathological changes", "PROBLEM", 580, 608], ["virus", "OBSERVATION", 10, 15], ["interstitial", "ANATOMY_MODIFIER", 35, 47], ["more", "OBSERVATION_MODIFIER", 65, 69], ["lymphocyte infiltration", "OBSERVATION", 70, 93], ["alveolar", "ANATOMY_MODIFIER", 99, 107], ["pores", "OBSERVATION_MODIFIER", 108, 113], ["smaller", "OBSERVATION_MODIFIER", 118, 125], ["lesions", "OBSERVATION", 135, 142], ["relatively", "OBSERVATION_MODIFIER", 153, 163], ["slowly", "OBSERVATION_MODIFIER", 164, 170], ["linear", "OBSERVATION_MODIFIER", 172, 178], ["opacities", "OBSERVATION", 179, 188], ["long period", "OBSERVATION_MODIFIER", 203, 214], ["chronic", "OBSERVATION_MODIFIER", 373, 380], ["inflammation", "OBSERVATION", 381, 393], ["lung", "ANATOMY", 497, 501], ["injury", "OBSERVATION", 502, 508], ["different", "OBSERVATION_MODIFIER", 523, 532], ["viruses", "OBSERVATION", 533, 540]]], ["Although detailed reports on the pathological changes of COVID-19 are still insufficient, there have been reports describing the pathological changes on autopsy, and the pathological characteristics of COVID-19 are significantly similar to those of severe acute respiratory syndrome (SARS) andAtypical computed tomography presentation of COVID-19 and its pathological mechanismMiddle East respiratory syndrome (MERS), which mainly manifest as diffuse alveolar injury, shedding of alveolar epithelial cells, and hyaline membrane formation [11] .", [["alveolar", "ANATOMY", 451, 459], ["alveolar epithelial cells", "ANATOMY", 480, 505], ["hyaline membrane", "ANATOMY", 511, 527], ["acute respiratory syndrome", "DISEASE", 256, 282], ["SARS", "DISEASE", 284, 288], ["COVID-19", "CHEMICAL", 338, 346], ["Middle East respiratory syndrome", "DISEASE", 377, 409], ["alveolar injury", "DISEASE", 451, 466], ["COVID-19", "CHEMICAL", 57, 65], ["COVID-19", "GENE_OR_GENE_PRODUCT", 57, 65], ["COVID-19", "CELL", 202, 210], ["alveolar", "MULTI-TISSUE_STRUCTURE", 451, 459], ["alveolar epithelial cells", "CELL", 480, 505], ["hyaline membrane", "CELLULAR_COMPONENT", 511, 527], ["alveolar epithelial cells", "CELL_TYPE", 480, 505], ["COVID", "TEST", 57, 62], ["the pathological changes", "PROBLEM", 125, 149], ["autopsy", "TEST", 153, 160], ["COVID", "TEST", 202, 207], ["severe acute respiratory syndrome", "PROBLEM", 249, 282], ["Atypical computed tomography presentation", "TEST", 293, 334], ["COVID", "TEST", 338, 343], ["Middle East respiratory syndrome", "PROBLEM", 377, 409], ["diffuse alveolar injury", "PROBLEM", 443, 466], ["alveolar epithelial cells", "PROBLEM", 480, 505], ["hyaline membrane formation", "PROBLEM", 511, 537], ["severe", "OBSERVATION_MODIFIER", 249, 255], ["acute", "OBSERVATION_MODIFIER", 256, 261], ["respiratory syndrome", "OBSERVATION", 262, 282], ["respiratory syndrome", "OBSERVATION", 389, 409], ["diffuse", "OBSERVATION_MODIFIER", 443, 450], ["alveolar injury", "OBSERVATION", 451, 466], ["alveolar", "ANATOMY_MODIFIER", 480, 488], ["epithelial cells", "OBSERVATION", 489, 505], ["hyaline membrane formation", "OBSERVATION", 511, 537]]], ["The pathological changes of COVID-19 on autopsy, together with the pathological manifestations of SARS and MERS as a reference, are beneficial for understanding the mechanisms of atypical chest CT presentation of COVID-19.Atypical computed tomography presentation of COVID-19 and its pathological mechanismThe present study still has some limitations.", [["chest", "ANATOMY", 188, 193], ["SARS", "DISEASE", 98, 102], ["COVID-19", "CHEMICAL", 267, 275], ["chest", "ORGAN", 188, 193], ["COVID-19", "DNA", 28, 36], ["COVID", "TEST", 28, 33], ["autopsy", "TEST", 40, 47], ["SARS", "PROBLEM", 98, 102], ["atypical chest CT", "TEST", 179, 196], ["COVID", "TEST", 213, 218], ["Atypical computed tomography presentation", "TEST", 222, 263], ["COVID", "TEST", 267, 272], ["The present study", "TEST", 306, 323], ["pathological", "OBSERVATION", 4, 16], ["chest", "ANATOMY", 188, 193]]], ["Due to the limited number of case samples and the short study period, there is some research bias, and there are no imaging scores for clinical typing.", [["samples", "CANCER", 34, 41], ["the short study", "TEST", 46, 61], ["imaging scores", "TEST", 116, 130], ["clinical typing", "TEST", 135, 150], ["no", "UNCERTAINTY", 113, 115]]], ["Hence, further in-depth studies with large sample sizes are required.", [["further in-depth studies", "TEST", 7, 31], ["large sample sizes", "PROBLEM", 37, 55], ["large", "OBSERVATION_MODIFIER", 37, 42], ["sizes", "OBSERVATION_MODIFIER", 50, 55]]], ["In summary, COVID-19 has a variety of atypical presentations on J o u r n a l P r e -p r o o f chest CT, specifically significantly faint ground-glass opacities or small nodular opacities that are prone to missed diagnosis and misdiagnosis.", [["nodular opacities", "ANATOMY", 170, 187], ["opacities", "DISEASE", 178, 187], ["COVID", "TEST", 12, 17], ["chest CT", "TEST", 95, 103], ["significantly faint ground-glass opacities", "PROBLEM", 118, 160], ["small nodular opacities", "PROBLEM", 164, 187], ["misdiagnosis", "PROBLEM", 227, 239], ["chest", "ANATOMY", 95, 100], ["significantly", "OBSERVATION_MODIFIER", 118, 131], ["faint", "OBSERVATION_MODIFIER", 132, 137], ["ground-glass opacities", "OBSERVATION", 138, 160], ["small", "OBSERVATION_MODIFIER", 164, 169], ["nodular", "OBSERVATION_MODIFIER", 170, 177], ["opacities", "OBSERVATION", 178, 187]]], ["Familiarity with the atypical presentations of COVID-19 on CT examination has important reference value for the diagnosis and treatment of COVID-19 and is beneficial for disease screening and epidemic prevention and control when taken together with the patient's travel history, contact history, clinical symptoms, and laboratory examinations.", [["patient", "ORGANISM", 253, 260], ["patient", "SPECIES", 253, 260], ["COVID", "TEST", 47, 52], ["CT examination", "TEST", 59, 73], ["treatment", "TREATMENT", 126, 135], ["COVID", "TEST", 139, 144], ["disease screening", "TEST", 170, 187], ["epidemic prevention", "TREATMENT", 192, 211], ["clinical symptoms", "PROBLEM", 296, 313], ["laboratory examinations", "TEST", 319, 342]]]], "01e50b76a3812906c457b3a53c3e1d079f25a07d": [["Effects of inapparent virus infections of mice can compromise studies with other viruses, transplantable tumors and noninfectious agents.", [["transplantable tumors", "ANATOMY", 90, 111], ["inapparent virus infections", "DISEASE", 11, 38], ["tumors", "DISEASE", 105, 111], ["mice", "ORGANISM", 42, 46], ["transplantable tumors", "CANCER", 90, 111], ["mice", "SPECIES", 42, 46], ["mice", "SPECIES", 42, 46], ["inapparent virus infections", "PROBLEM", 11, 38], ["other viruses", "PROBLEM", 75, 88], ["transplantable tumors", "PROBLEM", 90, 111], ["noninfectious agents", "TREATMENT", 116, 136], ["inapparent", "OBSERVATION_MODIFIER", 11, 21], ["virus", "OBSERVATION", 22, 27], ["tumors", "OBSERVATION", 105, 111], ["noninfectious", "OBSERVATION", 116, 129]]], ["For example, inapparent infections by contaminating lactate dehydrogenase-elevating virus (LDV) causes various host effects that were erroneously attributed to transplantable tumors or other viruses (Riley et al., 1978; Rowson and Mahy, 1985; Plagemann and Moennig, 1992; Plagemann, 1996) .", [["transplantable tumors", "ANATOMY", 160, 181], ["infections", "DISEASE", 24, 34], ["lactate", "CHEMICAL", 52, 59], ["tumors", "DISEASE", 175, 181], ["lactate", "CHEMICAL", 52, 59], ["lactate dehydrogenase-elevating virus", "ORGANISM", 52, 89], ["LDV", "ORGANISM", 91, 94], ["transplantable tumors", "CANCER", 160, 181], ["lactate dehydrogenase", "PROTEIN", 52, 73], ["LDV", "SPECIES", 91, 94], ["inapparent infections", "PROBLEM", 13, 34], ["contaminating lactate dehydrogenase", "PROBLEM", 38, 73], ["elevating virus", "PROBLEM", 74, 89], ["various host effects", "PROBLEM", 103, 123], ["transplantable tumors", "PROBLEM", 160, 181], ["other viruses", "PROBLEM", 185, 198], ["inapparent", "OBSERVATION_MODIFIER", 13, 23], ["infections", "OBSERVATION", 24, 34], ["host effects", "OBSERVATION", 111, 123], ["transplantable", "OBSERVATION_MODIFIER", 160, 174], ["tumors", "OBSERVATION", 175, 181]]], ["A recent survey showed that 49/81 of transplantable mouse tumors maintained by mouse passage, 4/45 human tumors passaged in nude mice, and 2/58 monoclonal antibodies (mAbs) in ascites fluid were contaminated with LDV (Nicklas et al., 1993) .", [["tumors", "ANATOMY", 58, 64], ["tumors", "ANATOMY", 105, 111], ["ascites fluid", "ANATOMY", 176, 189], ["tumors", "DISEASE", 58, 64], ["tumors", "DISEASE", 105, 111], ["ascites", "DISEASE", 176, 183], ["mouse", "ORGANISM", 52, 57], ["tumors", "CANCER", 58, 64], ["mouse", "ORGANISM", 79, 84], ["human", "ORGANISM", 99, 104], ["tumors", "CANCER", 105, 111], ["nude mice", "ORGANISM", 124, 133], ["ascites fluid", "ORGANISM_SUBSTANCE", 176, 189], ["2/58 monoclonal antibodies", "PROTEIN", 139, 165], ["mAbs", "PROTEIN", 167, 171], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 79, 84], ["human", "SPECIES", 99, 104], ["mice", "SPECIES", 129, 133], ["mouse", "SPECIES", 52, 57], ["mouse", "SPECIES", 79, 84], ["human", "SPECIES", 99, 104], ["mice", "SPECIES", 129, 133], ["LDV", "SPECIES", 213, 216], ["A recent survey", "TEST", 0, 15], ["transplantable mouse tumors", "PROBLEM", 37, 64], ["human tumors", "PROBLEM", 99, 111], ["monoclonal antibodies (mAbs", "TREATMENT", 144, 171], ["ascites fluid", "PROBLEM", 176, 189], ["transplantable mouse tumors", "OBSERVATION", 37, 64], ["mouse passage", "OBSERVATION", 79, 92], ["tumors", "OBSERVATION", 105, 111], ["ascites", "ANATOMY", 176, 183]]], ["Similar situations hold for mouse hepatitis virus (MHV) (Barthold, 1986; Compton et al., 1993; Nicklas et al., 1993) .", [["mouse hepatitis virus", "DISEASE", 28, 49], ["mouse hepatitis virus", "ORGANISM", 28, 49], ["MHV", "ORGANISM", 51, 54], ["mouse", "SPECIES", 28, 33], ["hepatitis virus", "SPECIES", 34, 49], ["mouse hepatitis virus", "SPECIES", 28, 49], ["MHV", "SPECIES", 51, 54], ["mouse hepatitis virus", "TREATMENT", 28, 49]]], ["Furthermore, it has been estimated that a majority of mouse colonies might be infected with MHV (Lindsey et al., 1986) .", [["colonies", "ANATOMY", 60, 68], ["mouse", "ORGANISM", 54, 59], ["MHV", "ORGANISM", 92, 95], ["mouse colonies", "CELL_LINE", 54, 68], ["mouse", "SPECIES", 54, 59], ["mouse", "SPECIES", 54, 59], ["MHV", "SPECIES", 92, 95], ["mouse colonies", "PROBLEM", 54, 68], ["infected", "OBSERVATION", 78, 86]]], ["In a previous study we found that practically all mice raised in our animal facilities possessed significant titers of anti-MHV antibodies at 4-6 weeks of age without ever showing any clinical symptoms .", [["mice", "ORGANISM", 50, 54], ["anti-MHV antibodies", "GENE_OR_GENE_PRODUCT", 119, 138], ["anti-MHV antibodies", "PROTEIN", 119, 138], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 50, 54], ["anti-MHV", "SPECIES", 119, 127], ["a previous study", "TEST", 3, 19], ["anti-MHV antibodies", "TREATMENT", 119, 138], ["any clinical symptoms", "PROBLEM", 180, 201]]], ["Since LDV replication in mice is restricted to a subpopulation of macrophages (Plagemann and Moennig, 1992) and MHV also replicates in these cells (Smith et al., 1984) , we suspected that inapparent MHV infections may lead to a loss of LDV-permissive macrophages in mice and be responsible for the great variations (0-25%) in the proportion of LDV-permissive macrophages that have been observed in different populations of adult mice over the last 20 years (Plagemann and Moennig, 1992) .", [["macrophages", "ANATOMY", 66, 77], ["cells", "ANATOMY", 141, 146], ["macrophages", "ANATOMY", 251, 262], ["macrophages", "ANATOMY", 359, 370], ["MHV infections", "DISEASE", 199, 213], ["LDV", "ORGANISM", 6, 9], ["mice", "ORGANISM", 25, 29], ["macrophages", "CELL", 66, 77], ["Plagemann", "CELL", 79, 88], ["MHV", "ORGANISM", 112, 115], ["cells", "CELL", 141, 146], ["MHV", "ORGANISM", 199, 202], ["LDV", "ORGANISM", 236, 239], ["macrophages", "CELL", 251, 262], ["mice", "ORGANISM", 266, 270], ["LDV", "ORGANISM", 344, 347], ["macrophages", "CELL", 359, 370], ["mice", "ORGANISM", 429, 433], ["macrophages", "CELL_TYPE", 66, 77], ["LDV-permissive macrophages", "CELL_TYPE", 236, 262], ["LDV-permissive macrophages", "CELL_TYPE", 344, 370], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 266, 270], ["mice", "SPECIES", 429, 433], ["LDV", "SPECIES", 6, 9], ["mice", "SPECIES", 25, 29], ["MHV", "SPECIES", 112, 115], ["MHV", "SPECIES", 199, 202], ["mice", "SPECIES", 266, 270], ["LDV", "SPECIES", 344, 347], ["mice", "SPECIES", 429, 433], ["LDV replication", "TREATMENT", 6, 21], ["MHV", "TREATMENT", 112, 115], ["inapparent MHV infections", "PROBLEM", 188, 213], ["a loss of LDV", "PROBLEM", 226, 239], ["macrophages", "OBSERVATION", 66, 77], ["inapparent", "OBSERVATION_MODIFIER", 188, 198], ["MHV", "OBSERVATION_MODIFIER", 199, 202], ["infections", "OBSERVATION", 203, 213], ["macrophages", "OBSERVATION", 251, 262], ["permissive macrophages", "OBSERVATION", 348, 370], ["different", "OBSERVATION_MODIFIER", 398, 407], ["populations", "OBSERVATION_MODIFIER", 408, 419]]], ["This hypothesis seemed supported by our recent observation that the proportion of LDV-permissive macrophages in cultures of peritoneal cells from adult pathogen-free B10.A mice ranged from 25 to 50% (see bar at 0 time, Fig. 1 ), whereas it was only 6-10% for peritoneal macrophages from FVB mice that were raised in our facilities and possessed anti-MHV antibodies .A mice about 5 weeks of age was infected with about 105 PFU of MHV-A59.", [["macrophages", "ANATOMY", 97, 108], ["cultures", "ANATOMY", 112, 120], ["peritoneal cells", "ANATOMY", 124, 140], ["peritoneal macrophages", "ANATOMY", 259, 281], ["LDV", "ORGANISM", 82, 85], ["macrophages", "CELL", 97, 108], ["peritoneal cells", "CELL", 124, 140], ["B10", "CELL", 166, 169], ["mice", "ORGANISM", 172, 176], ["peritoneal macrophages", "CELL", 259, 281], ["FVB mice", "ORGANISM", 287, 295], ["anti-MHV antibodies", "GENE_OR_GENE_PRODUCT", 345, 364], ["mice", "ORGANISM", 368, 372], ["MHV-A59", "ORGANISM", 429, 436], ["LDV-permissive macrophages", "CELL_LINE", 82, 108], ["peritoneal cells", "CELL_TYPE", 124, 140], ["peritoneal macrophages", "CELL_TYPE", 259, 281], ["anti-MHV antibodies", "PROTEIN", 345, 364], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 291, 295], ["mice", "SPECIES", 368, 372], ["mice", "SPECIES", 172, 176], ["mice", "SPECIES", 291, 295], ["anti-MHV", "SPECIES", 345, 353], ["mice", "SPECIES", 368, 372], ["MHV-A59", "SPECIES", 429, 436], ["LDV", "PROBLEM", 82, 85], ["permissive macrophages", "PROBLEM", 86, 108], ["peritoneal cells", "PROBLEM", 124, 140], ["adult pathogen", "TEST", 146, 160], ["peritoneal macrophages", "PROBLEM", 259, 281], ["permissive macrophages", "OBSERVATION", 86, 108], ["peritoneal cells", "ANATOMY", 124, 140], ["peritoneal", "ANATOMY", 259, 269], ["macrophages", "OBSERVATION", 270, 281], ["infected", "OBSERVATION", 398, 406]]], ["At various times p.i. the mice were bled by the retroorbital method and their plasma titrated for anti-MHV antibodies (Abs) by an indirect fluorescent antibody staining assay as described previously .", [["plasma", "ANATOMY", 78, 84], ["mice", "ORGANISM", 26, 30], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["MHV antibodies", "PROTEIN", 103, 117], ["Abs", "PROTEIN", 119, 122], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 26, 30], ["MHV", "SPECIES", 103, 106], ["the retroorbital method", "TREATMENT", 44, 67], ["their plasma", "TEST", 72, 84], ["anti-MHV antibodies", "TEST", 98, 117], ["an indirect fluorescent antibody staining assay", "TEST", 127, 174]]], ["Peritoneal macrophages were harvested from mice before infection and at various times p.i. with MHV, enumerated, cultured for one day and then assayed for susceptibility to LDV infection (LDV permissiveness).", [["Peritoneal macrophages", "ANATOMY", 0, 22], ["infection", "DISEASE", 55, 64], ["LDV infection", "DISEASE", 173, 186], ["Peritoneal macrophages", "CELL", 0, 22], ["mice", "ORGANISM", 43, 47], ["MHV", "ORGANISM", 96, 99], ["LDV", "ORGANISM", 173, 176], ["Peritoneal macrophages", "CELL_TYPE", 0, 22], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["MHV", "SPECIES", 96, 99], ["LDV", "SPECIES", 173, 176], ["LDV", "SPECIES", 188, 191], ["Peritoneal macrophages", "PROBLEM", 0, 22], ["infection", "PROBLEM", 55, 64], ["MHV", "PROBLEM", 96, 99], ["LDV infection", "PROBLEM", 173, 186], ["macrophages", "OBSERVATION", 11, 22], ["infection", "OBSERVATION", 55, 64], ["MHV", "ANATOMY", 96, 99], ["LDV", "OBSERVATION_MODIFIER", 173, 176], ["infection", "OBSERVATION", 177, 186]]], ["The striped rectangle indicates a range of values observed in a number of experiments for the proportion of LDV-permissive peritoneal macrophages in B10.A mice before MHV infection; the values for mice p.i. with MHV are for peritoneal macrophages from one to three individual mice. .", [["peritoneal macrophages", "ANATOMY", 123, 145], ["peritoneal macrophages", "ANATOMY", 224, 246], ["MHV infection", "DISEASE", 167, 180], ["LDV", "ORGANISM", 108, 111], ["peritoneal macrophages", "CELL", 123, 145], ["B10", "CELL", 149, 152], ["mice", "ORGANISM", 155, 159], ["MHV", "ORGANISM", 167, 170], ["mice", "ORGANISM", 197, 201], ["MHV", "ORGANISM", 212, 215], ["peritoneal macrophages", "CELL", 224, 246], ["mice", "ORGANISM", 276, 280], ["LDV-permissive peritoneal macrophages", "CELL_TYPE", 108, 145], ["B10", "CELL_LINE", 149, 152], ["peritoneal macrophages", "CELL_TYPE", 224, 246], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 197, 201], ["mice", "SPECIES", 276, 280], ["mice", "SPECIES", 155, 159], ["MHV", "SPECIES", 167, 170], ["mice", "SPECIES", 197, 201], ["MHV", "SPECIES", 212, 215], ["mice", "SPECIES", 276, 280], ["permissive peritoneal macrophages in B10", "TREATMENT", 112, 152], ["MHV infection", "PROBLEM", 167, 180], ["the values", "TEST", 182, 192], ["MHV", "TREATMENT", 212, 215], ["peritoneal macrophages", "PROBLEM", 224, 246], ["striped", "OBSERVATION_MODIFIER", 4, 11], ["rectangle", "OBSERVATION_MODIFIER", 12, 21], ["permissive", "OBSERVATION_MODIFIER", 112, 122], ["peritoneal macrophages", "OBSERVATION", 123, 145], ["MHV", "OBSERVATION_MODIFIER", 167, 170], ["infection", "OBSERVATION", 171, 180], ["peritoneal", "ANATOMY", 224, 234], ["macrophages", "OBSERVATION", 235, 246]]], ["Our present results directly demonstrate that MHV infection of mice causes a long-term depletion of peritoneal macrophages that are permissive for LDV infection as well as an alteration in concanavalin A (ConA)-responsiveness of spleen T lymphocytes.", [["peritoneal macrophages", "ANATOMY", 100, 122], ["spleen T lymphocytes", "ANATOMY", 229, 249], ["MHV infection", "DISEASE", 46, 59], ["LDV infection", "DISEASE", 147, 160], ["MHV", "ORGANISM", 46, 49], ["mice", "ORGANISM", 63, 67], ["peritoneal macrophages", "CELL", 100, 122], ["LDV", "ORGANISM", 147, 150], ["concanavalin A", "SIMPLE_CHEMICAL", 189, 203], ["ConA", "SIMPLE_CHEMICAL", 205, 209], ["spleen T lymphocytes", "CELL", 229, 249], ["peritoneal macrophages", "CELL_TYPE", 100, 122], ["ConA", "PROTEIN", 205, 209], ["spleen T lymphocytes", "CELL_TYPE", 229, 249], ["mice", "SPECIES", 63, 67], ["MHV", "SPECIES", 46, 49], ["mice", "SPECIES", 63, 67], ["LDV", "SPECIES", 147, 150], ["MHV infection of mice", "PROBLEM", 46, 67], ["a long-term depletion of peritoneal macrophages", "PROBLEM", 75, 122], ["LDV infection", "PROBLEM", 147, 160], ["concanavalin A (ConA)", "TEST", 189, 210], ["MHV", "OBSERVATION_MODIFIER", 46, 49], ["infection", "OBSERVATION", 50, 59], ["long-term depletion", "OBSERVATION_MODIFIER", 77, 96], ["peritoneal", "ANATOMY", 100, 110], ["macrophages", "OBSERVATION", 111, 122], ["permissive for", "UNCERTAINTY", 132, 146], ["LDV", "OBSERVATION_MODIFIER", 147, 150], ["infection", "OBSERVATION", 151, 160], ["spleen", "ANATOMY", 229, 235], ["lymphocytes", "ANATOMY", 238, 249]]], ["These effects persist a long time after infectious MHV appears to have been cleared from the mice.", [["MHV", "ORGANISM", 51, 54], ["mice", "ORGANISM", 93, 97], ["mice", "SPECIES", 93, 97], ["MHV", "SPECIES", 51, 54], ["mice", "SPECIES", 93, 97], ["infectious MHV", "PROBLEM", 40, 54]]], ["A group of pathogen-free, 5-week-old B10.A mice (kindly supplied by Drs. Torseth and Gregerson) was injected intraperitoneally (i.p.) with 105 plaque-forming units (PFU) of MHV-A59 (provided by Dr. K. Holmes; Holmes, 1990) .", [["intraperitoneally", "ANATOMY", 109, 126], ["plaque", "ANATOMY", 143, 149], ["mice", "ORGANISM", 43, 47], ["MHV-A59", "ORGANISM", 173, 180], ["mice", "SPECIES", 43, 47], ["mice", "SPECIES", 43, 47], ["MHV-A59", "SPECIES", 173, 180], ["plaque", "OBSERVATION", 143, 149], ["MHV", "ANATOMY", 173, 176]]], ["The mice were bled at various times post-infection (p.i.) and their plasma assayed for infectious MHV and anti-MHV antibodies as described previously .", [["plasma", "ANATOMY", 68, 74], ["mice", "ORGANISM", 4, 8], ["plasma", "ORGANISM_SUBSTANCE", 68, 74], ["MHV", "ORGANISM", 98, 101], ["anti-MHV antibodies", "GENE_OR_GENE_PRODUCT", 106, 125], ["infectious MHV and anti-MHV antibodies", "PROTEIN", 87, 125], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["MHV", "SPECIES", 98, 101], ["anti-MHV", "SPECIES", 106, 114], ["their plasma", "TEST", 62, 74], ["infectious MHV and anti-MHV antibodies", "PROBLEM", 87, 125]]], ["Peritoneal cells were harvested from individual mice, counted, cultured and assayed for LDV permissiveness as described previously (Cafruny et al., 1986; Even and Plagemann, 1995) .", [["Peritoneal cells", "ANATOMY", 0, 16], ["Peritoneal cells", "CELL", 0, 16], ["mice", "ORGANISM", 48, 52], ["LDV", "ORGANISM", 88, 91], ["Peritoneal cells", "CELL_TYPE", 0, 16], ["mice", "SPECIES", 48, 52], ["mice", "SPECIES", 48, 52], ["LDV", "SPECIES", 88, 91], ["Peritoneal cells", "PROBLEM", 0, 16], ["LDV permissiveness", "PROBLEM", 88, 106]]], ["In brief, the ceils were cultured for one day and infected with about 500 50% infectious dose (IDs0) of LDV/cell.", [["ceils", "ANATOMY", 14, 19], ["cell", "ANATOMY", 108, 112], ["LDV", "ORGANISM", 104, 107], ["cell", "CELL", 108, 112], ["LDV", "SPECIES", 104, 107], ["LDV/cell", "PROBLEM", 104, 112], ["LDV", "ANATOMY", 104, 107], ["cell", "ANATOMY", 108, 112]]], ["At 8 h p.i. the cultures were fixed in acetone.", [["acetone", "CHEMICAL", 39, 46], ["acetone", "CHEMICAL", 39, 46], ["acetone", "SIMPLE_CHEMICAL", 39, 46], ["the cultures", "TEST", 12, 24]]], ["The fixed slides were incubated sequentially with mAb 159-12 which recognizes the envelope glycoprotein of LDV (Harry et al., 1990) or with polyclonal anti-LDV which consisted of plasma from 5-month LDV-infected mice and then with fluorescein-isothionate-conjugated goat F(ab')2 anti-mouse IgG.", [["plasma", "ANATOMY", 179, 185], ["fluorescein-isothionate", "CHEMICAL", 231, 254], ["fluorescein-isothionate", "CHEMICAL", 231, 254], ["LDV", "ORGANISM", 107, 110], ["plasma", "ORGANISM_SUBSTANCE", 179, 185], ["LDV", "ORGANISM", 199, 202], ["mice", "ORGANISM", 212, 216], ["fluorescein-isothionate", "SIMPLE_CHEMICAL", 231, 254], ["mAb 159-12", "PROTEIN", 50, 60], ["envelope glycoprotein", "PROTEIN", 82, 103], ["polyclonal anti-LDV", "PROTEIN", 140, 159], ["fluorescein-isothionate-conjugated goat F(ab')2 anti-mouse IgG", "PROTEIN", 231, 293], ["mice", "SPECIES", 212, 216], ["goat", "SPECIES", 266, 270], ["anti-mouse", "SPECIES", 279, 289], ["LDV", "SPECIES", 107, 110], ["anti-LDV", "SPECIES", 151, 159], ["mice", "SPECIES", 212, 216], ["The fixed slides", "TEST", 0, 16], ["mAb", "TEST", 50, 53], ["polyclonal anti-LDV", "TREATMENT", 140, 159], ["plasma", "TEST", 179, 185], ["fluorescein", "TEST", 231, 242], ["conjugated goat F(ab')", "TREATMENT", 255, 277]]], ["The cultures were examined with a fluorescence microscope and the proportion of stained cells estimated by counting about 500 cells.", [["cultures", "ANATOMY", 4, 12], ["cells", "ANATOMY", 88, 93], ["cells", "ANATOMY", 126, 131], ["cells", "CELL", 88, 93], ["cells", "CELL", 126, 131], ["stained cells", "CELL_TYPE", 80, 93], ["The cultures", "TEST", 0, 12], ["a fluorescence microscope", "TEST", 32, 57], ["stained cells", "PROBLEM", 80, 93], ["stained cells", "OBSERVATION", 80, 93]]]]}